

Final PROGRAM



CTAD **2026**
Clinical Trials on Alzheimer's Disease

**November
16-19, 2026
Boston, MA (USA)**

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
THE JOURNAL
OF PREVENTION
OF ALZHEIMER'S
DISEASE



TABLE OF CONTENTS

Organizing & Scientific Committees	03
Editorial	04
Lifetime Achievement Award	05
Keynotes	06
Scientific Sessions	07
Monday, November 16	07
Tuesday, November 17	09
Wednesday, November 18	13
Thursday, November 19	18
Poster List	22

CTAD Organizing Committee and Scientific Committee

Susan ABUSHAKRA (San Francisco, United States); **Paul AISEN** (San Diego, United States)*; **Rebecca E. AMARIGLIO** (Boston, United States); **Patricia ANDREWS** (Nashville, United States); **Sandrine ANDRIEU** (Toulouse, France)*; **Davide ANGIONI** (Toulouse, France); **Laura D. BAKER** (Winston-Salem, United States); **Randall J. BATEMAN** (St. Louis, United States); **Karim BENNY** (Montpellier, France); **Ram BISHNOI** (Tampa, United States); **Kaj BLENNOW** (Molndal, Sweden); **Merce BOADA** (Barcelona, Spain); **Marc CANTILLON** (Livingston, United States); **Maria CARRILLO** (Chicago, United States); **Mathieu CECCALDI** (Marseille, France); **Suzanne CRAFT** (Winston-Salem, United States); **Lucia CRIVELLI** (Buenos Aires, Argentina); **Jeffrey CUMMINGS** (Las Vegas, United States); **Steven DEKOSKY** (Gainesville, United States); **Michael C. DONOHUE** (San Diego, United States); **Rachelle DOODY** (Houston, United States); **Bruno DUBOIS** (Paris, France); **Howard FELDMAN** (San Diego, United States); **Howard FILLIT** (New York, United States); **Nick FOX** (London, UK); **Kristian Steen FREDERIKSEN** (Copenhagen, Denmark); **Giovanni B. FRISONI** (Brescia, Italy); **Serge GAUTHIER** (Montreal, Canada); **Joshua GRILL** (Los Angeles, United States); **Michael GRUNDMAN** (San Diego, United States); **Harald HAMPEL** (Nutley, United States); **Oskar HANSSON** (Lund, Sweden); **Tobias HARTMANN** (Homburg, Germany); **Jakub HORT** (Prague, Czech Republic); **Takeshi IWATSUBO** (Tokyo, Japan); **Frank JESSEN** (Cologne, Germany); **Ara KHACHATURIAN** (Washington DC, United States); **Zaven KHACHATURIAN** (Washington DC, United States); **Miia KIVIPELTO** (Stockholm, Sweden); **Yan LI** (St. Louis, United States); **Jorge J. LLIBRE GUERRA** (St. Louis, United States); **Constantine G. LYKETSOS** (Baltimore, United States); **Gad A. MARSHALL** (Boston, United States); **Adam MECCA** (New Haven, United States); **Lefkos T. MIDDLETON** (London, UK)*; **José Luis MOLINUEVO** (Valby, Denmark); **Kyra O'BRIEN** (Philadelphia, United States); **Claire PAQUET** (Paris, France); **Robert PERNECZKY** (Munich, Germany); **Ronald PETERSEN** (Rochester, United States); **Elif PINAR COSKUN** (Lexington, United States); **Michael S. RAFII** (San Diego, United States); **Rema RAMAN** (San Diego, United States); **Craig W. RITCHIE** (Edinburgh, UK); **Robert RISSMAN** (San Diego, United States); **Marwan SABBAGH** (Phoenix, United States); **Stephen SALLOWAY** (Providence, United States); **Pascual SANCHEZ-JUAN** (Madrid, Spain); **Nikolaos SCARMEAS** (New York, United States); **Rachel SCHINDLER** (New York, United States); **Philip SCHELTENS** (Amsterdam, NL); **Lon SCHNEIDER** (Los Angeles, United States); **Eric SIEMERS** (Indianapolis, United States); **Sietske SIKKES** (Amsterdam, The Netherlands); **Yong SHEN** (Hefei, China); **Jiong SHI** (Hefei, China); **Irina SKYLAR-SCOTT** (Stanford, United States); **Heather SNYDER** (Chicago, United States); **Maria SOTO** (Toulouse, France); **Reisa SPERLING** (Boston, United States)*; **Yaakov STERN** (New York, United States); **Duygu TOSUN** (San Francisco, United States); **Jacques TOUCHON** (Montpellier, France)*; **Maileen ULEP** (Las Vegas, United States); **Wiesje van Der FLIER** (Amsterdam, The Netherlands); **Christopher H. VAN DYCK** (New Haven, United States); **Bruno VELLAS*** (Toulouse, France); **Prashanthi VEMURI** (Rochester, United States); **Michael W. WEINER** (San Francisco, United States)* **Donna M. WILCOCK** (Indianapolis, United States); **Bengt WINBLAD** (Stockholm, Sweden); **Kirsten WRIGHT** (Portland, United States); **Jin-Tai YU** (Shanghai, China)

*Organizing Committee Member

Join Us at CTAD26: Advancing Alzheimer's Disease Clinical Research Together

The 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference will convene in Boston, USA, from November 16–19, 2026. For those of us who have watched our field transform over the past two decades, there is something fitting about returning to Boston — a city that has long been at the heart of Alzheimer's research — at what feels like a genuinely pivotal moment.

Since its founding in 2008, CTAD has grown into the premier global forum dedicated exclusively to Alzheimer's disease clinical research. What has always set CTAD apart is its format: all sessions take place in a single main ballroom, so that every investigator, clinician, industry scientist, and regulatory expert in attendance shares the same presentations and the same conversations. In a field where translation from bench to bedside depends on true interdisciplinary exchange, that shared experience matters. Some of the most consequential discussions I have witnessed in our field have happened in the hallways and roundtables during CTAD.

CTAD25 in San Diego offered a comprehensive picture of where the Alzheimer's clinical trials now stand. More than 2,850 international experts gathered to examine emerging data and evolving strategies across the full spectrum of Alzheimer's research. Sessions addressed disease-modifying therapies, gene- and cell-based approaches, vaccines, digital tools, and multimodal interventions, reflecting how far we have come but also how much remains to be done.

CTAD26 in Boston will carry that momentum forward. The questions we will be asking are more focused than even a few years ago: How do we define who needs to be treated with what and when? Who will benefit most from early intervention? How do we optimize combination approaches, not just tau and amyloid but including other emerging therapeutic mechanisms? What do biomarkers tell us about individualized disease trajectories that can inform more efficient trial design? These are the conversations that CTAD seeks to nurture and more...

I hope you will join us in Boston this November. We have made tremendous progress in Alzheimer's disease research due to the unwavering commitment of this community, and the open, cross-disciplinary collaborations that CTAD is designed to foster. There is no better place to continue that work than here in Boston, and we look forward to welcoming you all.




Reisa Sperling, MD

Harvard Medical School,
Brigham and Women's Hospital
Boston, MA (United States)

CTAD 2026

Lifetime Achievement Award

This year, the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research is awarded to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.



Jeffrey Cummings, MD, ScD

Joy Chambers-Grundy Professor of Brain Science

Director of the Chambers-Gundy Center for Transformative Neuroscience

Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV)

Biography

UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.

Dr. Cummings leads the UNLV Clinical Trials Observatory, the world's only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease.

Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las

Vegas, as well as two UCLA entities — the Mary S. Easton Center for Alzheimer's Disease Research, and the Deane F. Johnson Center for Neurotherapeutics.

Named a "Rock Star of Science" by Gentleman's Quarterly, Dr. Cummings — a fellow of the American Academy for the Advancement of Science — has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer's disease, and clinical trials.

His numerous recognitions for his scientific and leadership contributions include the American Association of Geriatric Psychiatry's Distinguished Scientist Award, Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, Society for Behavioral and Cognitive Neurology's Lifetime Achievement Award, and the national Alzheimer's Association's Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.

KEYNOTE

New Molecules in Phase 2b — Proof of Concept and Beyond

Monday, November 16 • 3:25 p.m. — 3:50 p.m.

CTAD 2026 Keynotes



A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)

Geoffrey A. Kerchner, MD, PhD is a neurologist and neuroscientist serving as Vice President and Global Head of Neurodegeneration at F. Hoffmann-La Roche, Ltd., in Basel, Switzerland, where he oversees all late-stage clinical development efforts in Alzheimer's, Parkinson's, and Huntington's diseases. Over his career, Dr. Kerchner has contributed to the fight against Alzheimer's disease as a basic scientist, a clinical neuroimaging scientist, a clinician, a patient advocate, and a clinical trial site investigator before moving to Genentech/Roche in 2015. There, he led clinical development teams for semorinemab and gantenerumab, among other programs, before moving into leadership positions, first as VP and Head of Early Development in Neuroscience and Rare Diseases and then in his current role. Dr. Kerchner studied at Harvard College (AB summa cum laude), Washington University School of Medicine (MD, PhD), and UCSF (residency and fellowships), and served on the faculty at Stanford University School of Medicine.



Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

Susan Landau, PhD, Research Neuroscientist, Helen Wills Neuroscience Institute, University of California, Berkeley, CA (United States)

Dr Landau's research focuses on brain changes that occur in healthy aging and Alzheimer's disease. She uses a variety of neuroimaging techniques, other biomarkers, and health information to understand the neurophysiological processes underlying cognitive decline in Alzheimer's disease and related dementias. Her research has a particular emphasis on the roles of amyloid and tau, measured with positron emission tomography (PET), and neurodegeneration, measured with magnetic resonance imaging (MRI).

She is the principal investigator of POINTER Imaging study, an ancillary study to the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) trial. This 2-year clinical trial is examining the influence of multidomain lifestyle interventions on brain changes in at-risk older individuals across the U.S. She also oversees PET pipeline development and analysis in multisite longitudinal studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ADNI Vietnam War Veterans study, the ADNI Late Life Depression study, and the Standardized Centralized Alzheimer's & Related Dementia Neuroimaging (SCAN) study. She has led curation and quantification of over 8000 PET images acquired with a variety of PET tracers and has made this data available to the scientific community for research, education, and clinical trial development. Dr. Landau received the Human Amyloid Imaging Christopher Clark Award in 2018.



Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials

Allan Levey, MD, PhD, Professor of Neurology, Emory University's School of Medicine, Director, Emory's Alzheimer's Disease Research Center, Emory University, Atlanta, GA (United States)

Allan Levey, MD, PhD, is a professor in the Department of Neurology at Emory University's School of Medicine, as well as the director of Emory's Alzheimer's Disease Research Center. He has secondary faculty appointments in the Departments of Pharmacology, Psychiatry and Behavioral Sciences.

Levey is an internationally recognized expert in neurodegenerative disorders. His work has contributed to understanding the brain systems and mechanisms involved in disorders such as Alzheimer's and Parkinson's diseases, as well as in identifying molecular targets for new therapeutic strategies. He has more than 250 research publications and has won several awards, including the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association, the Heikkila Research Scholar Award from the National Parkinson Foundation, the Health Advancement Research Award from Community Health Charities and the Team Hope Award for Medical Leadership from the Huntington's Disease Society of America. In addition, he was inducted into the Johns Hopkins Society of Scholars.

Levey consistently has been listed among one of the Best Doctors in America. His research interests include fundamental research into the cause of Alzheimer's disease and related neurodegenerative disorders, and development of new biomarkers and treatments.

Monday, November 16

2:15 p.m.
3:15 p.m.

POSTER WALKING TOUR

3:15 p.m.
3:25 p.m.

Welcome Ceremony & CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Jeffrey Cummings, MD, in recognition of his foundational contributions to clinical trial methodology, drug development frameworks, and his decades of leadership in advancing the field through the annual Alzheimer's disease drug development pipeline analyses.

Introduction by the CTAD Organizing Committee

Reisa Sperling, Brigham and Women's Hospital Harvard Medical School, Boston (United States)

Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA (United States)

Sandrine Andrieu, Toulouse University Hospital and INSERM 1295, Toulouse (France)

Rachelle Doody, Houston, TX (United States)

Lefkos Middleton, Imperial College, London (United Kingdom)

Jacques Touchon, Montpellier University, Montpellier (France)

Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)

Mike Weiner, UCSF, San Francisco, CA (United States)

3:25 p.m.
3:50 p.m.

KEYNOTE 1

New Molecules in Phase 2b – Proof of Concept and Beyond

Jeffrey Cummings University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

Introduction: Bruno Vellas, IHU HealthAge, Toulouse University, Toulouse (France)

3:50 p.m.
4:50 p.m.

ORAL COMMUNICATIONS

Chairs: Sharon Sha, Stanford - Palo Alto (United States) and Chris Chen, Dementia Research Centre (Singapore)

3:50 p.m.

OC1 Top-Line Results of SINGER: A Two-Year Randomized Controlled Trial of Multidomain Lifestyle Intervention to Prevent Cognitive Decline

Kwong Hsia Yap¹, Liang Shen², David Matchar^{3,4}, Helen Zhou^{5,6}, Mitchell Kim Peng Lai⁷, Xin Xu⁸, Cynthia Huijun Chen⁹, Laura Baker¹⁰, Miia Kivipelto^{11,12,13}, Nagaendran Kandiah¹⁴, Christopher Chen^{1,7}

¹Memory, Ageing and Cognition Centre (MACC), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ²Singapore Clinical Research Institute - Singapore (Singapore), ³Health Services and Systems Research Programme, Duke-NUS Medical School - Singapore (Singapore), ⁴Division of General Internal Medicine, Department of Medicine, Duke University, Durham - North Carolina (United States), ⁵Centre for Sleep and Cognition, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁶Department of Electrical and Computer Engineering, National University of Singapore, - Singapore (Singapore), ⁷Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁸School of Public Health and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, - Zhejiang (China), ⁹Saw Swee Hock School of Public Health, National University of Singapore - Singapore (Singapore), ¹⁰Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), ¹¹Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, - Stockholm (Sweden), ¹²Ageing Epidemiology Research Unit, School of Public Health, Imperial College London - London (United Kingdom), ¹³Institute of Public Health and Clinical Nutrition, University of Eastern Finland - Kuopio (Finland), ¹⁴Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University - Singapore (Singapore)

4:05 p.m.

OC2 POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase

Sharon Sha¹, Alireza Atri², Fernando Melgar-Somoza³, Marzena Zboch⁴, Do Hoon Kim⁵, Yi Tang⁶, Jennifer Lynch⁷, Howard Chertkow⁸, Sangyun Kim⁹, David Greeley¹⁰, James Rock¹¹, Fred Kim¹¹, Tianyang Xi¹¹, Jai Jun Choung¹¹

¹Stanford - Palo Alto (United States), ²Banner Sun Health Research and Banner Alzheimer's Institutes - Sun City (United States), ³Melgar-Caro MedCenter and Community Research - Miami (United States), ⁴Wroclawskie Centrum Alzheimerowski - Wroclaw (Poland), ⁵Chuncheon Sacred Heart Hospital - Chuncheon (Republic of Korea), ⁶Xuanwu Hospital Capital Medical University - Beijing (China), ⁷Glasgow NeuroClin - Motherwell (United Kingdom), ⁸Baycrest Centre for Geriatric Care - Ontario (Canada), ⁹Seoul National University College of Medicine - Seoul (Republic of Korea), ¹⁰Northwest Neurological - Spokane (United States), ¹¹Aribo Co., Ltd - San Diego (United States)

4:20 p.m.

OC3 Ultrasensitive Immunoassay for Plasma eMTBR-243 Quantification

Alpana Singh¹, Marisa Denkinger¹, Geidy E. Serrano¹, Thomas G. Beach¹, Eric M. Reiman², Shorena Janelidze³, Oskar Hansson³, Niklas Mattsson-Carlsson³, Pedro Rosa Neto⁴, Nicholas Ashton¹

¹Banner Sun Health Research Institute - Sun City (United States), ²Banner Alzheimer's Institute - Phoenix (United States), ³Lund University - Lund (Sweden), ⁴UT Southwestern Medical Center - Austin (United States)

4:35 p.m.

OC4 Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study

Colin Birkenbihl¹, Madison Cuppels¹, Diana Townsend¹, Gillian Coughlan¹, Mabel Seto¹, Jane Brown¹, Michael Properzi¹, Annie Li¹, Bryan James², Robert Rissman³, Melissa Petersen⁴, Tobey Betthausen⁵, Doreen Rentz¹, Reisa Sperling¹, Rachel Buckley¹

¹Mass General Brigham - Boston (United States), ²Rush Alzheimer's Disease Center - Chicago (United States), ³University of Southern California - Los Angeles (United States), ⁴University of North Texas - Fort Worth (United States), ⁵University of Wisconsin-Madison - Madison (United States)

4:50 p.m.

5:30 p.m.

SYMPOSIUM 1

Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab

Chair: Tammie L.S. Benzinger, Washington University in St. Louis -St. Louis, Missouri, (United States)

Presentation 1 Trontinemab in Alzheimer's disease – novel pharmacodynamic insights from the ongoing Phase Ib/IIa Brainshuttle™ AD study

Luka Kulic, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 2 Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer's disease

Gregory Klein, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

Presentation 3 Brain delivery and distribution of the novel Brainshuttle™ Aβ-targeting antibody trontinemab in participants with Alzheimer's disease measured with ⁸⁹Zr positron emission tomography

Elsmarieke Van De Giessen, Amsterdam UMC, Vrije Universiteit - Amsterdam (The Netherlands)

5:30 p.m.

6:15 p.m.

ORAL COMMUNICATIONS

Chairs: Eric McDade, Washington University in St Louis, St Louis, United States and Jacques Touchon, University of Montpellier – Montpellier (France)

5:30 p.m.

OC5 Agentic Artificial Intelligence in Alzheimer's Disease Clinical Trials: From Data-Driven Discovery to Adaptive Design Optimization and Statistical Validation

Randall BATEMAN, Eric MCDADE, Yan LI, Guoqiao WANG

Washington University in St Louis, St Louis, United States

5:45 p.m.

LB01 Spectris Treatment in Mild-to-Moderate Alzheimer's Disease: Topline Results and Secondary Analyses From the HOPE Pivotal Study

Roy HAMILTON¹, Ralph KERN², Robbert ZUSTERZEEL², Marwan SABBAGH³

¹Department of Neurology, University of Pennsylvania, Philadelphia, United States, ²Cognito Therapeutics Inc., Cambridge, United States, ³Barrow Neurological Institute, Phoenix, United States

6:00 p.m.

OC6 Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension

Christopher VAN DYCK¹, David LI², Michio KANEKIYO², Shobha DHADDA², Michelle GEE³, Steven HERSCH², Michael IRIZARRY², Lynn KRAMER²

¹Yale University School of Medicine, New Haven, United States, ²Eisai Inc., Nutley, United States, ³Eisai Ltd., Hatfield, United Kingdom

6:15 p.m.

7:15 p.m.

CTAD WELCOME RECEPTION with the Support of the Alzheimer's Association



● Tuesday, November 17

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 2

When Target Engagement Is Not Enough: Lessons from Posdinemab on Bridging Tau Biology to Clinical Outcomes

Chair: Fiona Elwood, Johnson & Johnson, Cambridge, MA, USA

Presentation 1 Spatial Determinants of Posdinemab's Effect on Tau PET

Ziad S. Saad, Johnson & Johnson, San Diego, CA (United States)

Presentation 2 CSF and Plasma Biomarker Changes After Anti-Tau Therapy: Fluid Biomarker Results from the Autonomy Phase 2 Clinical Trial

Gallen Triana-Baltzer, Johnson & Johnson, San Diego, CA (United States)

Presentation 3 Biomarker Associations with Cognition: Results from the Autonomy Phase 2 Clinical Trial

Gil D. Rabinovici, University of California, San Francisco (UCSF) - San Francisco, CA (United States)

9:10 a.m.
9:35 a.m.

KEYNOTE 2

A Glimpse of the Future: How Diagnostics, Therapies, Trials, and Concepts of Prevention Must Evolve

Geoffrey A. Kerchner, MD, Vice President and Global Head of Neurodegeneration, F. Hoffmann-La Roche, Ltd., Basel (Switzerland)

Introduction: Reisa Sperling, Brigham and Women's Hospital Harvard Medical School - Boston (United States)

9:35 a.m.
10:35 a.m.

ORAL COMMUNICATIONS

Chairs: Lon Schneider, USC Keck School of Medicine - Los Angeles (United States) and Sandrine Andrieu, IHU HealthAge/INSERM - Toulouse (France)

9:35 a.m.

OC7 Efficacy and Safety of Remlifanserin in Patients With Alzheimer's Disease Psychosis

Jeffrey Cummings¹, Wyllians Vendramini Borelli², Clive Ballard³, Maria E. Soto-Martin⁴, Samantha Friend⁴, Becky Howell⁵, Christine Murphy⁴, Peter Zhang⁵, Xiaoshu Feng⁵, Mona Darwish⁵, Bryan Dirks⁵, Sanjeev Pathak⁵

¹Kirk Kerkorian School of Medicine, University of Nevada - Las Vegas, Nevada (United States), ²Memory Center at the Hospital Moinhos de Vento - Porto Alegre, Rio Grande do Sul (Brazil), ³University of Exeter Medical School - Exeter (United Kingdom), ⁴Acadia Pharmaceuticals Inc. - San Diego, California (United States), ⁵Acadia Pharmaceuticals Inc. - Princeton, New Jersey (United States)

9:50 a.m.

OC8 Clinical Evidence for Disease Modification by Amyloid-Targeting Antibodies

Lon Schneider¹, Guoqiao Wang², Richard Kennedy³, Gary Cutter³, Robert Howard⁴

¹USC Keck School of Medicine - Los Angeles (United States), ²Washington University in St. Louis - St. Louis (United States), ³University of Alabama, Birmingham - Birmingham (United States), ⁴University College London - London (United Kingdom)

10:05 a.m.

OC9 Topline results from the Phase 2b PRIus-AD trial: Safety and efficacy of oral PRI-002 in early AD

Oliver Peters^{1,2}, Dagmar Jürgens^{2,3}, Gerhard Tischler³, Tina Bartsch³, Lorenzo Bulli³, Katja Lindner³, Julie-Anne Gabelich³, Julia Post-Schulz³, Gunther Kauselmann^{2,3}, Knut Adermann^{2,3}, Kathrin Zeiger³, Alexander Brener³, Dieter Willbold^{2,4}

¹Charité - Universitätsmedizin Berlin - Berlin (Germany), ²Priavoid - Düsseldorf (Germany), ³PRInnovation - Düsseldorf (Germany), ⁴Institut für Pysikalische Biologie, Heinrich-Heine Universität Düsseldorf - Düsseldorf (Germany)

10:20 a.m.

OC10 Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort

Gillian Coughlan¹, Madison Cuppels¹, Aaron Schultz¹, Keith Johnson¹, Robert Rissman², Doris Molina-Henry², Michael Donohue², Oliver Longford², Paul Aisen², Joel Braunstein³, Michael Irizarry⁴, Shobha Dhadda⁴, Rachel Buckley¹, Reisa Sperling¹, Ahead 3-45 Study Team⁵

¹Mass General Brigham, Department of Neurology - Boston (United States), ²University of Southern California Alzheimer Therapeutic Research Institute - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴EISAI - Nutley (United States), ⁵University of Southern California, Alzheimer Clinical Trials Consortium - San Diego (United States)

10:35 a.m.

11:05 a.m.

Coffee Break — Poster Session ([more info here](#)) and Rising Star Showcase in Gloucester, Level 3



Connor Dietz

University of British Columbia, Vancouver, (Canada)

Poster P289



Zahra Shirzadi

Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States)

Poster P108

11:05 a.m.

11:45 a.m.

SYMPOSIUM 3

Remote Digital Biomarkers in Alzheimer's Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment

Co-chairs: Gustavo A. Jimenez-Maggiore, Alzheimer's Therapeutic Research Institute (ATRI), Epstein Family Center for Alzheimer's Disease Research, Keck School of Medicine of USC, San Diego, CA – (United States)
Duygu Tosun, — University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 1 The voice Clinical Dementia Rating® (vCDR) to facilitate clinical assessment for dementia research and trials using a generative AI powered conversational agent

Rachel L. Nosheny, University of California, San Francisco (UCSF) - San Francisco, CA (United States)

Presentation 2 Using digital multi-day learning curves for scalable early detection and tracking of subtle cognitive decline in preclinical AD

Kathryn V. Papp, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Massachusetts General Hospital; Harvard Medical School - Boston, MA (United States)

Presentation 3 Real world feasibility, utility and generalizability of self-administered speech-based testing for scalable pre-screening for Mild Cognitive Impairment: results from the full ADNI4 digital cohort

Emil Fristed, Novoic Ltd.; Coagen Limited – London (United Kingdom)

11:45 a.m.

12:20 p.m.

BIOTECH SHOWCASE

Fueling Innovation: The Vital Role of Biotech in Alzheimer's Research

Panelists: Laura Nisenbaum, PhD (ADDF), Michael Weiner, MD (UCSF) and David Dolby, MBA (Dolby Family Ventures)

12:02 p.m.

BIOTECH SHOWCASE 1 Phase 2a AD Trial Results: NTRX-07 Reduces Neuroinflammation and Inhibits Neurodegeneration Following 28-days of Treatment

Joseph Foss¹, Marianna Kiraly¹, Peter Kovacs², Tony Giordano¹

¹NeuroTherapia, Inc. - Cleveland (United States), ²CRU Global - Budapest (Hungary)

12:08 p.m.

BIOTECH SHOWCASE 2 A Next-Generation circRNA Blood Biomarker Platform for Alzheimer's Disease Detection, Progression Prediction, and Clinical Deployment

Nikolaos Mellios¹, Bridget Phillips², Jessie Sanford², Vaibhav Janve³, Grigorios Papageorgiou³, John Morris², Joel Perlmutter², Paul Kotzbauer², Richard Perrin², Timothy Hohman³, Laura Ibanez², Carlos Cruchaga²

¹Circular Genomics - San Diego (United States), ²Washington University School of Medicine - St. Louis (United States), ³Vanderbilt University Medical Center - Nashville (United States)

12:14 p.m.

BIOTECH SHOWCASE 3 Sinaptica Therapeutics, Inc. ~ Precuneus-directed TMS-EEG precision-neuromodulation platform

Giacomo Koch^{1,2,3}

¹Sinaptica Therapeutics - Cambridge (United States), ²Santa Lucia Foundation IRCCS - Rome, Italy, ³University of Ferrara - Ferrara, Italy

12:20 p.m.

1:35 p.m.

Lunch and poster sessions

1:35 p.m.

2:35 p.m.

ORAL COMMUNICATIONS

Chairs: Susan Landau - Wills Neuroscience Institute University of California, Berkeley, CA (United States) and Lefkos Middleton - Imperial College London, London (United Kingdom)

1:35 p.m.

OC11 A Unified Timeline of Alzheimer's Disease: Linking Amyloid- β to Cognitive Decline

Rosita Shishegar¹, Timothy Cox², Marcela Cespedes³, Suzanne Schindler⁴, Tammie Benzinger⁵, Christopher C. Rowe⁶, Christopher J. Fowler⁷, Stephanie R. Rainey-Smith^{8,9,10}, Simon Laws¹¹, Mike Weiner¹², John Morris⁴, Colin L. Masters¹³, Hamid Sohrabi¹⁴, Paul Maruff¹⁵, James D. Doecke^{3,11}

¹The Australian e-Health Research Centre, CSIRO - Parkville (Australia), ²The Australian e-Health Research Centre, CSIRO - Canberra (Australia), ³The Australian e-Health Research Centre, CSIRO - Herston (Australia), ⁴Department of Neurology, Washington University School of Medicine - St Louis (United States), ⁵Washington University School of Medicine - St Louis (United States), ⁶Austin Health - Heidelberg (Australia), ⁷The Florey Institute, The University of Melbourne - Parkville (Australia), ⁸Australian Alzheimer's Research Foundation - Perth (Australia), ⁹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup, ¹⁰Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch, ¹¹Centre for Precision Health and Collaborative Genomics Group, School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ¹²University of California San Francisco, San Francisco, CA, USA; San Francisco Veterans Affairs Medical Center - San Francisco (United States), ¹³Alzheimer's Research Australia, University of Western Australia - Perth (Australia), ¹⁴Centre for Healthy Ageing, Health Future Institute, Murdoch University - Murdoch (Australia), ¹⁵Cogstate Ltd. - Parkville (Australia)

1:50 p.m.

OC12 When Plasma ptau217 and A β PET Disagree: Factors Associated With Biomarker Concordance and Discordance Across Ethnoracial Groups

Mahnaz Shekari¹, Tessa Harrison¹, Yishu Chao¹, Robert Rissman², Sid O'Bryant³, Petersen Melissa⁴, William J Jagust¹, Susan M. Landau¹

¹University of California - Berkeley (United States), ²University of California - San Diego (United States), ³University of North Texas Health Science Center - Texas (United States), ⁴Institute for Translational Research, University of North Texas Health Science Center - Texas (United States)

2:05 p.m.

OC13 Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice

Samuel Dickson¹, John Whetten¹, Chenge Zhang¹, Suzanne Hendrix¹, Katherine Youmans-Kidder², Daryl Jones²

¹Pentara Corporation - Salt Lake City (United States), ²Eisai Inc. - Nutley (United States)

2:20 p.m.

OC14 Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments

Hairin Kim¹, Mark Dubbelman¹, Lex Minto¹, Daniel Soberanes¹, Vivienne Lubbat¹, Dorene Rentz¹, Gad Marshall¹, Reisa Sperling¹, Laura Baker², Mark Espeland², Susan Landau³, Rebecca Amariglio¹, Kathryn Papp¹

¹Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Department of Internal Medicine, Wake Forest University School of Medicine - Winston-Salem (United States), ³Helen Wills Neuroscience Institute (SL), University of California - Berkeley (United States)

2:35 p.m.
3:15 p.m.

SYMPOSIUM 4

Neuroinflammation in Alzheimer's Disease: Targeting the NLRP3 Inflammasome and Neuroimmune Crosstalk

Chair: Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 1 Central-Peripheral Neuroimmune Crosstalk: Targeting Immune Dysfunction to Reduce Neurodegenerative Disease Progression

Malú Gámez Tansey, Neuroscience Research Institute, Indiana University School of Medicine – Indianapolis, IN (United States)

Presentation 2 NLRP3 regulates microglial immune and metabolic function in dementia

Róisín M. McManus, German Center for Neurodegenerative Diseases (DZNE), Venusberg Campus - Bonn (Germany)

Presentation 3 The NLRP3 inflammasome as a therapeutic target in Alzheimer's disease: biomarker, preclinical evidence and Phase I healthy participants' safety data of the oral inhibitor RG6434

Gennaro Pagano, F. Hoffmann-La Roche Ltd - Basel (Switzerland)

3:15 p.m.
4:15 p.m.

ORAL COMMUNICATIONS

Chairs: Rachelle Doody – Houston, TX (United States) and Pascal Geldsetzer, Stanford University - Stanford (United States)

3:15 p.m.

OC15 Treatment with Pepinemab, Anti-SEMA4D Blocking Antibody, Reduces a Unique Astrocyte Subset (Ast10) Correlated with Cognitive Decline and Associated Biomarkers of Synaptic Loss in People with Early-Stage AD

Elizabeth Evans¹, Terrence Fisher¹, Leslie Balch¹, Natacha Comandante-Lou², Vikas Mishra¹, John Leonard¹, Loretta Mueller¹, Alan Howell¹, Charlotte E. Teunissen³, Lisa Vermunt³, Anton Porsteinsson⁴, Hyun Keun Cho⁵, Howard H. Feldman⁵, Lon Scheider⁶, Maurice Zauderer¹

¹Vaccinex, Inc - Rochester (United States), ²Columbia University Irving Medical Center - New York (United States), ³Amsterdam UMC - Amsterdam (The Netherlands), ⁴University of Rochester, *on behalf of SIGNAL-AD investigators - Rochester (United States), ⁵University of California, San Diego - San Diego (United States), ⁶University of Southern California, Keck School of Medicine - Los Angeles (United States)

3:30 p.m.

OC16 Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer's Disease

Nicolas R. Barthelemy¹, Soumya Mukherjee¹, Yingxin He¹, Vitaliy Ovod¹, Kanta Horie¹, Rama Koppiseti¹, Ani Eloyan², Dustin B. Hammers³, Kelly N. Nudelman³, Maria C. Carrillo⁴, Bradford C. Dickerson⁵, Gil D. Rabinovici⁶, Liana G. Apostolova³, Randall J. Bateman¹, Jeffrey L. Dage¹

¹Washington University - St. Louis (United States), ²Brown University - Providence (United States), ³Indiana University - Indianapolis (United States), ⁴Alzheimer's Association - Chicago (United States), ⁵Harvard Medical School - Charlestown (United States), ⁶UCSF - San Francisco (United States)

3:45 p.m.

OC17 Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts

Richard Haarbarger¹, James Mbinta², Siu Yuat Wong¹, Alex Wang², Colin Simpson³, Noah Stegehuis¹, Till Baernighausen⁴, Greg Martin⁵, Yoram Barak⁶, Andrew Sporle³, Aliitasi Su'a-Tavalla², Pascal Geldsetzer¹

¹Stanford University - Stanford (United States), ²Victoria University - Wellington (New Zealand), ³University of Auckland - Auckland (New Zealand), ⁴Heidelberg University - Heidelberg (Germany), ⁵New Zealand Ministry of Health - Wellington (New Zealand), ⁶Dunedin School of Medicine - Dunedin (New Zealand)

4:00 p.m.

OC18 Metabolic-Inflammatory Burden Identifies Attenuated Responders to Lifestyle Intervention and Supports GLP-1RA Combination-Trial Design: Evidence from the FINGER study

Adrian Noriega De La Colina^{1,2,3}, Arvid Gollwitzer^{1,2}, Anna Matton^{4,5,6}, Francesca Mangialasche^{7,5,6}, Li-Huei Tsai^{1,8}, Alina Solomon^{6,4,9}, Tiia Ngandu^{6,9}, Giovanni Traverso^{1,2,3,10}, Miia Kivipelto^{4,5,11}


¹Broad Institute of MIT and Harvard - Cambridge (United States), ²Massachusetts Institute of Technology - Cambridge (United States), ³Brigham and Women's Hospital - Boston (United States), ⁴Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁵Division of Neurogeriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁶FINGERS Brain Health Institute - Stockholm (Sweden), ⁷Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Solna (Sweden), ⁸The Picower Institute for Learning and Memory - Cambridge (United States), ⁹Institute of Clinical Medicine/Neurology, University of Eastern Finland - Kuopio (Finland), ¹⁰Koch Institute for Integrative Cancer Research, MIT - Cambridge (United States), ¹¹FINGERS Brain Health Institute - Stockholm (Sweden)

4:15 p.m.
4:45 p.m.

Coffee Break — Poster Session and Rising Star Showcase



Yuta Katsumin
Massachusetts General Hospital, Harvard Medical School, Boston, MA (United States)
Poster P107



Dorothy MacFarlane
Adams Clinical, Watertown (United States)
Poster P389

4:45 p.m.
5:25 p.m.

LATE BREAKING SYMPOSIUM 1

Additional biomarker and clinical findings from the Phase 2 CELIA study of diranersen in early Alzheimer's disease

Adrian COLES, Jessica COLLINS, Gioacchino CURIALE, Amanda EDWARDS, Ellen HUANG, Melanie SHULMAN
Biogen, Cambridge, United States

● Wednesday, November 18

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:30 a.m.

ORAL COMMUNICATIONS

Chairs: [Rema Raman](#), *University of Southern California, San Diego (United States)* and [Jeffrey Cummings](#), *University of Nevada at Las Vegas, Las Vegas (United States)*

8:30 a.m.

OC19 Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies

[Robert RISSMAN](#)¹, [Michael DONOHUE](#)¹, [Joanne BEER](#)², [Clare PATERSON](#)², [Rema RAMAN](#)¹, [Sara ABDEL-LATIF](#)¹, [James BARLOW](#)¹, [Sahar SALEHI](#)¹, [Gustavo JIMENEZ-MAGGIORA](#)¹, [Richard GALLARDO](#)¹, [Keith JOHNSON](#)³, [Paul AISEN](#)¹, [Reisa SPERLING](#)³

¹University of Southern California, San Diego, United States, ²Alamar Biosciences, Fremont, United States, ³Mass General Research Institute, Boston, United States

8:45 a.m.

OC20 Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer's disease

[Aram ASLANYAN](#)¹, [Nicolas BARTHÉLEMY](#)², [Chihiro SATO](#)², [Don ELBERT](#)³, [Catherine MUMMERY](#)¹, [Lisa FRENCH](#)¹, [Guoqiao WANG](#)², [Nupur GHOSHAL](#)², [Eric MCDADE](#)², [Randall BATEMAN](#)², [Ross PATERSON](#)¹

¹UCL, London, United Kingdom, ²Washington University St Louis, St Louis, United States, ³University of Washington, Seattle, United States

9:00 a.m.

OC21 Psychosis symptoms associated with AD improve with short- and long-term open-label KarXT treatment

[Jeffrey CUMMINGS](#)¹, [Ninoslav MIMICA](#)², [Ashish SHAH](#)³, [Janette GARNER](#)³, [Codrin LUNGU](#)³, [Antonio OLIVEROS-CID](#)⁴, [George GROSSBERG](#)⁵

¹Kirk Kerkorian School of Medicine, University of Nevada at Las Vegas, Las Vegas, United States, ²University Psychiatric Hospital Vrapče and University of Zagreb School of Medicine, Zagreb, Croatia, ³Bristol Myers Squibb, Princeton, United States, ⁴Hospital Reina Sofia, Tudela, Spain, ⁵Saint Louis University School of Medicine, St. Louis, United States

9:15 a.m.

OC22 Estimating 15-Year absolute risk of cognitive impairment in cognitively unimpaired older adults with Alzheimer disease biomarkers based on amyloid PET or plasma %p-tau217

[Sarah HARTZ](#), [Lisa HAYIBOR](#), [Shinjini KUNDU](#), [Randall BATEMAN](#), [Tammie BENZINGER](#), [Brian GORDON](#), [John MORRIS](#), [Krista MOULDER](#), [Jessica MOZERSKY](#), [Kellen PETERSEN](#), [Guoqiao WANG](#), [Suzanne SCHINDLER](#), [Walter KUKULL](#), [Chengjie XIONG](#)

Washington University, St. Louis, United States

9:30 a.m.
9:55 a.m.

KEYNOTE 3

Integration of Fluid Imaging and other Multimodal Biomarkers towards Optimizing Disease Understanding and New Therapeutics

[Susan Landau](#), PhD, Research Neuroscientist, Helen Wills Neuroscience Institute University of California, Berkeley, CA (United States)

Introduction: [Michael Weiner](#), University of California, San Francisco – San Francisco, CA (United States)

9:55 a.m.
10:25 a.m.

ORAL COMMUNICATIONS

Chairs: [Reisa Sperling](#), *Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States)* and [Mike Weiner](#), *University of California at San Francisco (UCSF) – San Francisco (United States)*

9:55 a.m.

OC23 PreventRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer's disease at high risk of clinical decline

[Reisa Sperling](#)¹, Catherine Mummery², Jeffrey L. Cummings³, Gil Rabinovici⁴, Stephen Salloway⁵, Henrik Zetterberg⁶, Juan Fortea⁷, Frank G. Boess⁸, Christopher Lane⁹, Marion Monchalin⁸, Paul Delmar⁸, Luka Kulic⁸, Hanno Svoboda⁸, Geoffrey A. Kerchner⁸, Janice Smith⁹

¹Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Queen Square Institute of Neurology, University College London - London (United Kingdom), ³Chambers-Grundy Center for Transformative Neuroscience, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas - Las Vegas (United States), ⁴Weill Institute for Neurosciences, Department of Radiology and Biomedical Imaging, University of California San Francisco - San Francisco (United States), ⁵Warren Alpert Medical School, Brown University - Providence (United States), ⁶Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg - Mölndal (Sweden), ⁷Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Antoni Maria Claret - Barcelona (Spain), ⁸F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁹Roche Products Ltd - Welwyn Garden City (United Kingdom)

10:05 a.m.

OC24 Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer's Disease; a First-in-Human Study

[Christopher Duma](#)¹, Jessica Buxton², Hans Keirstead³, Gabriel Nistor², Robert Lynn², Sawyer Farmer², Ashley Harris², Karlyssa Chung², Nathaniel Cho², Zoe Hareng², Jason Bock², Benjamin Rapaport², Gustavo Alva¹

¹Hoag Memorial Hospital - Newport Beach, CA (United States), ²Regeneration Biomedical, Inc. - Newport Beach, CA (United States), ³Aivita Biomedical, Inc. - Irvine, CA (United States)

10:15 a.m.

OC25 A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer's disease: Study rationale and design

[W. Joseph Herring](#)¹, Yuchuan Wang¹, Li He¹, Yuki Mukai¹, Christine Furtak¹, Angela Gee¹, Andrei Popescu¹, Seth Robey¹, Michael F. Egan¹

¹Merck & Co., Inc. - Rahway, NJ (United States)

Coffee Break — Poster Session and Rising Star Showcase

10:25 a.m.
11:00 a.m.



Dhruv Kapadia

Stanford University, Stanford, CA (United States)

Poster P426



Casey Vanderlip

University of California, Irvine, CA (United States)

Poster P433

11:00 a.m.
11:40 a.m.

SYMPOSIUM 5

Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings

Chair: [Marwan Sabbagh](#), *Barrow Neurological Institute - Phoenix, AZ (United States)*

Presentation 1 Real-World Lecanemab Utilization and Outcomes from Initiation Through Maintenance Therapy in Early Alzheimer's Disease: A Multicenter Retrospective Study (LEADER)

[Jose Soria](#), *The Neuron Clinic - Chula Vista, CA (United States)*

Presentation 2 Sex-Based Outcomes of Lecanemab in Early Alzheimer's Disease: A Multicenter, Real-World, Retrospective Study (LEADER)

[Tinatin Chabrashvili](#), *SUNY Upstate Medical University - New York, NY (United States)*

Presentation 3 At-Home Subcutaneous Lecanemab Administration: A Multicenter, Real-World, Retrospective Study (LEADER)

[Brent Berry](#), *Minneapolis Clinic of Neurology - Minneapolis, MN (United States)*

11:40 a.m.
12:25 p.m.

ORAL COMMUNICATIONS

Chairs: [Karim Bennys](#), *Montpellier University Hospital – Montpellier (France)* and [Laura Nisenbaum](#), *The Alzheimer's Drug Discovery Foundation – New York City (United States)*

11:40 a.m.

OC26 Using Plasma P-tau217 and APOE Genotype to Predict Onset of Symptoms of Alzheimer's Disease

Yuexuan Xu¹, Tamil Gunasekaran¹, Yian Gu¹, Lawrence Honig¹, Jennifer Manly¹, Adam Brickman¹, Corinne Engelman², Sterling Johnson², David Bennett³, Sid O'Bryant⁴, Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Columbia University - New York (United States), ²University of Wisconsin-Madison - Madison (United States), ³Rush University - Chicago (United States), ⁴University of North Texas Health Science Center - Fort Worth (United States)

11:55 a.m.

OC27 AAV2-BDNF Gene Therapy in Alzheimer's Disease and Mild Cognitive Improvement Improves FDG-PET in Memory Circuitry

Yilong Ma¹, Gabriel Leger², Douglas Scharre³, Andrea Davis³, Kai Christman², Sara Rahman², Russell Lonser³, Krystof Bankiewicz³, David Eidelberg¹, Bradley Elder³, Mark Tuszynski²

¹Feinstein Institute for Medical Research – Manhasset, NY (United States), ²UC San Diego – La Jolla, CA (United States), ³Ohio State University – Columbus, OH (United States)

12:10 p.m.

OC28 Leveraging the Global Neurodegeneration Proteomics Consortium Dataset to Identify Plasma Proteomic Profiles Associated with Alzheimer's Disease Progression and Biological Endotypes

[Jennifer Panlilio](#)¹, Lydia Wu², Olga Kahn¹, Jennifer Hsiao-Nakamoto¹, Varsha Krish², Farhad Imam², Ilya Barshai³, Sergey Feldman³, Laura Nisenbaum⁴, Aishwarya Sukumar²

¹Diagnostics Accelerator, Alzheimer's Drug Discovery Foundation - New York (United States), ²Gates Ventures - Seattle (United States), ³Data Cowboys - Seattle (United States), ⁴Alzheimer's Drug Discovery Foundation - New York (United States)

12:25 p.m.
1:40 p.m.

Lunch and Poster Sessions

1:40 p.m.
3:25 p.m.

ORAL COMMUNICATIONS

Chairs: [Marissa Denking](#), *Banner Sun Health Research Institute, Sun City, (United States)* and [Frank Longo](#), *Stanford University, Palo Alto, (United States)*

1:40 p.m.

OC29 Prognostic value of plasma p-tau217 for short- and long-term risk of cognitive impairment

Marisa N. DENKINGER¹, Valentina GHISAYS^{1,2}, Wagner S. BRUM¹, Geidy E. SERRANO¹, Adam MECCA³, Sylvia VILLENEUVE⁴, Pedro ROSA NETO⁵, Alexa PICHET BINETTE⁶, Rhoda AU⁷, Michael ALOSCO⁸, Elizabeth HEAD⁹, Sterling C. JOHNSON¹⁰, Eric M. REIMAN², Jessica B. LANGBAUM², Nicholas J. ASHTON^{1,2}

¹Banner Sun Health Research Institute, Sun City, United States, ²Banner Alzheimer's Institute, Phoenix, United States, ³Department of Psychiatry, Yale School of Medicine, New Haven, United States, ⁴Douglas Research Centre, McGill University, Montreal, United States, ⁵Translational Neuroimaging Laboratory, Douglas Hospital, The McGill University Research Centre for Studies in Aging, McGill University, Montreal, United States, ⁶Institut Universitaire de Gériatrie de Montréal Research Center, Montreal, United States, ⁷Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study Framingham, Boston, United States, ⁸Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, ⁹University of California, Irvine School of Medicine, Irvine, United States, ¹⁰Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, United States

1:55 p.m.

OC30 LM11A-31 reduces CSF levels of eMTBR-tau243: a retrospective analysis of a phase 2a safety and exploratory biomarker trial in mild-moderate Alzheimer's disease

[Frank LONGO](#)¹, Stephen MASSA², Taylor SCHMITZ³, Mark ADAMS⁴, Shin-Cheng TZENG⁴, Philip VERGHESE⁴, Hayley SHANKS³

¹Stanford University, Palo Alto, United States, ²SFVAHCS/UCSF, San Francisco, United States, ³Western University, London, Canada, ⁴CN Dignostics LLC, St Louis, United States

2:10 p.m.

OC31 Relative Impact of Multidomain Lifestyle Interventions on Cardiovascular Risk Factor Change and Cognition over 24 months in the U.S. POINTER TRIAL

Rachel A WHITMER¹, Iris LENG², Laura BAKER², Maria C CARRILLO³, Heather SNYDER³, Rema RAMAN⁴, Sarah FARIAS TOMASZEWSKI⁵, Mark ESPELAND²

¹University of California, Davis, United States, ²Wake Forest University, Winston Salem, United States, ³Medical and Scientific Relations, Alzheimer's Association, Chicago, United States, ⁴University of Southern California, Los Angeles, United States, ⁵University of California Davis, Davis, United States

2:25 p.m.

OC32 Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson's paradox

[Chengjie XIONG](#)¹, Ruijin LU¹, Jingqin LUO¹, Suzanne SCHINDLER¹, Tammie BENZINGER¹, David WOLK², Leslie SHAW², Carey GLEASON³, James LAH⁴, Reisa SPERLING⁵, Keith JOHNSON⁵, Erik ROBERSON⁶, Krista MOULDER¹, David HOLTZMAN¹, John MORRIS¹

¹Washington University, St. Louis, United States, ²University of Pennsylvania, Philadelphia, United States, ³University of Wisconsin, Madison, United States, ⁴Emory University, Atlanta, United States, ⁵Harvard University, Boston, United States, ⁶University of Alabama, Birmingham, United States

2:40 p.m.

OC33 Harmonizing plasma pTau217 across immunoassay platforms: the Unified pTau217 Score (Units)

Wagner S. Brum¹, Marisa N. Denkinger², Alpana Singh², Tainá Marques², Lennessa Mazo³, Rachael E. Wilson⁴, Ramiro Eduardo Rea Reyes⁴, Henrik Zetterberg⁵, Antoine Leuzy¹, Valentina Ghisays⁶, Reisa A. Sperling⁷, Eric M. Reiman⁶, Jessica B. Langbaum⁶, Sterling C. Johnson⁴, Nicholas J. Ashton⁶

¹ZRO Imaging - Santiago De Compostela (Spain), ²Banner Sun Health Research Institute - Sun City (United States), ³Arizona State University - Phoenix (United States), ⁴University of Wisconsin-Madison - Madison (United States), ⁵University of Gothenburg - Gothenburg (Sweden), ⁶Banner Alzheimer's Institute - Phoenix (United States), ⁷Harvard Medical School - Boston (United States)

2:55 p.m.

OC34 Rapamycin modulates disease-relevant processes in the central nervous system of patients with early Alzheimer's disease: data from PET, MRI and CSF with long-term follow-up

Jonas E. Svensson¹, Ruben Dörfel¹, Martin Schain², Martin Bolin¹, Simona Sacuiu¹, Göran Hagman¹, Anton Forsberg Morén¹, Miia Kivipelto¹, Sangram Nag¹, Pontus Plavén-Sigra¹

¹Karolinska Institutet - Stockholm (Sweden), ²Antaros Medical - Mölndal (Sweden)

3:10 p.m.

OC35 Longitudinal characterization of tau PET accumulation and spread anchored to amyloid and tau positivity timelines

Samira Maboudian¹, Karly Cody², William Coath¹, Julie Oomens¹, Jacob Morse¹, Hailey Bruzzone¹, Ramiro Rea Reyes¹, Matthew Zammit¹, Bradley Christian¹, Sanjay Asthana¹, Nathaniel Chin¹, Jessica Caldwell¹, Sterling Johnson¹, Tobey Betthausen¹

¹University of Wisconsin - Madison - Madison (United States), ²University of California San Francisco - San Francisco (United States)

3:25 p.m.
4:00 p.m.

Coffee break — Poster session (Gloucester Level 3)

4:00 p.m.
5:00 p.m.

ORAL COMMUNICATIONS

Chairs: Ann Hartry, *Eli Lilly and Company - Indianapolis (United States)*, and Mike Rafii, *University of Southern California - San Diego (United States)*

4:00 p.m.

OC36 Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort

Benjamin Zide¹, Aaron Schultz¹, Michael Properzi¹, Michael Rafii², Gustavo Jimenez-Maggiora², Michael Donohue², Oliver Langford², Paul Aisen², Jin Zhou³, Michael Irizzary³, Shobha Dhadda³, Keith Johnson¹, Rachel Buckley¹, Reisa Sperling¹, On Behalf Of The Ahead 3-45 Study Team⁴

¹Center for Alzheimer Research and Treatment, Mass General Brigham, Harvard Medical School - Boston, Ma (United States), ²Epstein Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), ³Eisai Inc. - Nutley, Nj (United States), ⁴AHEAD ³⁻⁴⁵ Study Team, Alzheimer Clinical Trials Consortium (United States)

4:15 p.m.

OC37 Comparison of MK6240, Flortaucipir, PI2620 and R0948 tau PET tracers and plasma pTau217 across the Alzheimer's disease continuum

Guilherme Povala¹, Bruna Bellaver¹, Pamela C. L. Ferreira¹, Firoza Z. Lussier¹, Livia Amaral¹, Juan Fortea², Thomas K. Karikari¹, David N. Soleimani-Meigooni³, Val J. Lowe⁴, Hwamee Oh⁵, Brian A. Gordon⁶, Belen Pascual⁷, Pedro Rosa-Neto⁸, Suzanne Baker⁹, Tharick A. Pascoal¹

¹University of Pittsburgh, Department of Psychiatry - Pittsburgh (United States), ²Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ³University of California San Francisco, Edward and Pearl Fein Memory and Aging Center - San Francisco (United States), ⁴Mayo Clinic, Department of Radiology - Rochester (United States), ⁵Brown University, Department of Psychiatry and Human Behavior - Providence (United States), ⁶Washington University in St. Louis, Department of Radiology - St. Louis (United States), ⁷Houston Methodist Research Institute and Weill Cornell Medicine, Department of Neurology - Houston (United States), ⁸Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montréal (Canada), ⁹Lawrence Berkeley National Laboratory - Berkeley (United States)

4:30 p.m.

OC38 Characterization of US Real-World Patients Receiving Donanemab with Modified Titration Using the NeuroDiscovery AI Database and the ALZ-NET Registry

Armen Moughamian¹, Paul Schulz², Drew Spargo³, Erin Gautier Doty³, J. Scott Andrews³, Krista M. Schroeder³, Chuanjie Deng³, Ju Ji³, Xueqing Huang³, Vamsi Chandra Kasivajjala⁴, Akash Bhushan⁵, Anand K Srirampurapu⁵, Ann Hartry³

¹Ray Dolby Brain Health Center, Sutter Health, San Francisco, CA, United States ²McGovern Medical School, UTHealth, Houston, TX, United States ³Eli Lilly and Company, Indianapolis, IN, USA ⁴NeuroDiscovery AI, Alpharetta, GA, USA ⁵NeuroDiscovery AI, Bangalore, Karnataka, India

4:45 p.m.

OC39 Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer's Disease Progression

Menghan Liu¹, Katherine Gong¹, Yike Chen¹, Ying Xu¹, Jigyasha Timsina¹, John Budde¹, John Morris¹, Marco Giorgetti², David Holtzman¹, Jeremiah Hinson², Scott Levin², Suzanne Schindler¹, Kausik Das², Muhammad Ali¹, Carlos Cruchaga¹

¹Washington University School of Medicine - St. Louis, MO (United States), ²Danaher Diagnostics - Washington DC (United States)

5:00 p.m.	BIOTECH SHOWCASE Chairs: <u>Melissa Lee</u> , Alzheimer's Drug Discovery Foundation – New York City (United States) and <u>Andrea Pfeifer</u> , Global BHP Braintrust, Lausanne (Switzerland)
5:20 p.m.	
5:02 p.m.	BIOTECH SHOWCASE 4 A First-in-Class CNS-Penetrant Small Molecule Targeting APOE4-mediated Neurovascular Dysfunction in Alzheimer's Disease <u>Caghan Kizil</u> ¹ , Badri Vardarajan ¹ , Richard Mayeux ¹ ¹ Department of Neurology, Columbia University Irving Medical Center - New York City (United States) Late breaking Biotech Showcase sessions
5:08 p.m.	BIOTECH SHOWCASE 5 Temporal Biodynamics: An AI Platform for Identification of Stage-Relevant Targets and Biomarkers <u>Sandra J. ENGLE</u> ¹ , Joseph ZULLO ¹ , Joseph J. RAYMOND ¹ , Tanya JAIN ¹ , Michelle CHEN ¹ , Parth NATEKAR ¹ , Baixue YAO ¹ , Anna RUSNAK ¹ , Sachit SAKSENA ² , Artem SOKOLOV ¹ ¹ Etiome, Cambridge, United States, ² Flagship Pioneering, Cambridge, United States
5:14 p.m.	BIOTECH SHOWCASE 6 Multimodal AI for early prediction and precision stratification in AD RD <u>Zoe KOURTZI</u> ¹ , Felix BREACH ¹ , Tino PETER ² , Welchman ANDREW ³ ¹ Univ Cambridge, Prodromic, Cambridge, United Kingdom, ² Univ of Birmingham, Birmingham, United Kingdom, ³ Prodromic, Cambridge, United Kingdom
5:20 p.m.	End of the conference day

● Thursday, November 19

7:30 a.m.
8:30 a.m.

POSTER WALKING TOUR

8:30 a.m.
9:10 a.m.

SYMPOSIUM 6

Lessons from The Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia

Chairs: Olga Brawman-Mintzer, Medical University of South Carolina and Ralph H. Johnson, VA Health Care System - Charleston, SC (United States)

Presentation 1 Domain-Specific Effects of THC/CBD on Agitation in Advanced Dementia: Cohen-Mansfield Agitation Inventory Analyses from the LiBBY Study Presentation

Jacobo Mintzer, Medical University of South Carolina, Charleston, South Carolina (United States)

Presentation 2 Effects of THC/CBD on NPI-Q Agitated Symptoms in Advanced Dementia: Results from the Double-Blind, Placebo-Controlled LiBBY Study

Brigid Reynolds, Georgetown University, Washington, DC, United States

Presentation 3 Advancing Trials in Dementia: Lessons from LiBBY and a Future Research Agenda for the Alzheimer's Clinical Trial Consortium (ACTC)

Paul Aisen, University of Southern California, La Jolla, California (United States)

9:10 a.m.
10:10 a.m.

ORAL COMMUNICATIONS

Chairs: Thomas Karikari University of Pittsburgh - Pittsburgh (United States) and Heather Snyder, Alzheimer's Association - Chicago (United States)

9:10 a.m.

OC40 Early versus delayed cognitive effects of donanemab and lecanemab in early Alzheimer's disease: 24-month real-world trajectories and drug-specific baseline predictors of response

Yuki Kujuro¹

¹Tachikawa Hospital - Tokyo (Japan)

9:25 a.m.

OC41 CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression

Xuemei Zeng¹, Marissa F. Farinas¹, Michel N. Nafash¹, Neelesh Nadkarni¹, C. Elizabeth Shaaban¹, Tharick A. Pascoal¹, Victor L. Villemagne¹, Beth E. Snitz¹, Milos D. Ikonovic¹, Julia K. Kofler¹, M. Ilyas Kamboh¹, Annie D. Cohen¹, Oscar L. Lopez¹, Thomas K. Karikari¹

¹University of Pittsburgh - Pittsburgh (United States)

9:40 a.m.

OC42 Understanding intermediate values in two-point thresholds for PET, CSF, and plasma biomarkers across cohorts and p-tau217 assays

Jacob Zientz¹, Ganna Blazhenets¹, Zoe Lin¹, John Kornack¹, Susan Landau², Leslie Shaw³, Jeffrey Dage⁴, Dustin Hammers⁴, Ani Eloyan⁵, Robert Koeppe⁶, Maria Carrillo⁷, Bradford Dickerson⁸, Liana Apostolova⁴, Gil Rabinovici¹, Renaud La Joie¹

¹University of California, San Francisco - San Francisco, CA (United States), ²University of California, Berkeley - Berkeley, CA (United States), ³University of Pennsylvania - Philadelphia, PA (United States), ⁴Indiana University - Bloomington, IN (United States), ⁵Brown University - Providence, RI (United States), ⁶University of Michigan - Ann Arbor, MI (United States), ⁷Alzheimer's Association - Chicago, IL (United States), ⁸Massachusetts General Hospital - Boston, MA (United States)

9:55 a.m.

OC43 Diagnostic Performance of the Fujirebio Lumipulse Plasma p-tau217 and p-tau217/Aβ42 Assays for Detection of Amyloid Pathology in Cognitively Unimpaired Individuals

Daniel Figdore¹, Jeremy Syrjanen¹, Joshua Bornhorst¹, Jonathan Graff-Radford¹, Prashanthi Vemuri¹, David Knopman¹, Clifford Jack¹, Ronald Petersen¹, Alicia Algeciras-Schimmich¹

¹Mayo Clinic - Rochester (United States)

10:10 a.m. 10:40 a.m.	Coffee Break — Poster Session (Gloucester - Level 3)
10:40 a.m. 11:05 a.m.	KEYNOTE 4 Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials <i>Allan Levey, Professor of Neurology, Emory University's School of Medicine, Emory's Alzheimer's Disease Research Center, Emory University - Atlanta, GA (United States)</i> Introduction: <u>Paul Aisen</u> , <i>ATRI-USC – La Jolla, CA (United States)</i>
11:05 a.m. 12:05 p.m.	ORAL COMMUNICATIONS Chairs: <u>Lucia Crivelli</u> , <i>FLENI, Buenos Aires (Argentina)</i> and <u>Renaud LaJoie</u> , <i>UCSF, San Francisco (United States)</i>
11:05 a.m.	OC44 The relationship between P-tau217 blood tests and neuropathology at autopsy in cognitively unimpaired individuals <u>Samantha BURNHAM</u> ¹ , Amanda MORRIS ¹ , Marisa DENKINGER ² , Taina M. MARQUES ² , Alpana SINGH ² , Geidy SERRANO ² , Brandy R. MATTHEWS ¹ , Thomas BEACH ² , Mark MINTUN ¹ , Nicholas J. ASHTON ² ¹Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, United States, ²Banner Sun Health Research Institute, Sun City, AZ, USA, Sun City, United States
11:20 a.m.	OC45 When Is Amyloid Really Cleared? Discordance Between Centiloid Quantification and Visual Reads after Treatment <u>Renaud LA JOIE</u> , Marlene LIN, Yingbing WANG, David SOLEIMANI-MEIGOONI, Tara ELLINGSON, Hong NGUYEN, Ganna BLAZHENETS, Corrina FONSECA, Jake LEVY, Julio ROJAS-MARTINEZ, Melanie STEPHENS, Nhat BUI, Peter LJUBENKOV, Lawren VANDEVREDE, Gil RABINOVICI UCSF, San Francisco, United States
11:35 a.m.	OC46 Cognitive change across the healthy adult lifespan, ages 36 to 108: Associations with modifiable risk factors and ADRD plasma biomarkers <u>Steven ARNOLD</u> ¹ , Pia KIVISÄKK ¹ , Chao-Yi WU ¹ , Edmarie GUZMAN-VELEZ ² , Brandon YATES ¹ , Yue HONG ¹ , Hrioko DODGE ¹ , David SALAT ¹ ¹Massachusetts General Hospital / Harvard Medical School, Boston, United States, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, United States
11:50 a.m.	OC47 PROTECT-Cog: A Large, Global Randomized Phase 3 Trial of Combined Multidomain Lifestyle Intervention With and Without a Metabolic Targeting Drug to Benefit Cognitive Performance and Mitigate Decline in At-Risk Older Adults <u>Alireza ATRI</u> ¹ , Laura D BAKER ² , Lucia CRIVELLI ³ , Mark ESPELAND ² , Miia KIVIPELTO ⁴ , Markku PELTONEN ⁵ , Rema RAMAN ⁶ , Heather M SNYDER ⁷ , Ari SOLOMAN ⁸ , Rachel A WHITMER ⁹ , Maria C CARRILLO ⁷ ¹Banner Research, Director of Banner Sun Health Research Institute, Sun City, United States, ²Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, United States, ³Department of Cognitive Neurology, FLENI, Buenos Aires, Argentina, ⁴Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden, ⁵Finnish Institute for Health and Welfare, Helsinki, Finland, ⁶Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ⁷Medical and Scientific Relations and Medical Affairs Division, Alzheimer's Association, Chicago, United States, ⁸Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, ⁹Department of Public Health Sciences and Neurology, University of California, Davis, Davis, United States
12:05 p.m. 1:05 p.m.	Lunch and Poster Sessions
1:05 p.m. 3:50 p.m.	ORAL COMMUNICATIONS Chairs: <u>Miranda Orr</u> , <i>Washington University School of Medicine - Saint Louis, MO, (United States)</i> and <u>Gad Marshall</u> , <i>Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States)</i>

- 1:05 p.m. **OC48 Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study**
Rui MU , Anna HOFMANN, Katherine GONG, Menghan LIU, Alex ROUSSAK, Madeline PACZYNSKI, Zachary POSEY, Aditi GUPTA, Tammie BENZINGER, David HOLTZMAN, John MORRIS, B.Joy SNIDER, Randall BATEMANN, Suzanne SCHINDLER, Carlos CRUCHAGA
 Washington University School of Medicine, Saint Louis, United States
- 1:20 p.m. **OC49 ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers**
Catherine MUMMERY¹, Rohit KATIAL², Saffron CALMAN-O'DONNELL², Roger CHANG³, Dylon CHEN³, Ian COHEN⁴, David JAKABEK⁵, Bruce BREW⁵, Emma DEVENNEY⁶, Richard BERGERON⁷, Ran FU³, Grigoriy SHEKHTMAN³, James HAMILTON³, Sharon COHEN⁴
¹University College London, London, United Kingdom, ²New Zealand Clinical Research, Auckland, New Zealand, ³Arrowhead pharmaceuticals, Pasadena, United States, ⁴Toronto Memory Programme, Toronto, Canada, ⁵St. Vincent's Hospital Sydney, Sydney, Australia, ⁶NeuRA, Randwick, Australia, ⁷The Memory Clinic, Montreal, Canada
- 1:35 p.m. **OC50 Lecanemab Treatment and α -Synuclein Co-Pathology in the Clarity AD CSF Substudy**
 Kanta HORIE , Pallavi SACHDEV, Han YIN, Steven HERSCH, Lynn KRAMER, Shobha DHADDA, Michael IRIZARRY
 Eisai Inc., Nutley, United States
- 1:50 p.m. **OC51 Plasma eMTBR-tau as a biomarker for chronic traumatic encephalopathy tau tangle neuropathology**
Annalise E. MINER¹, Thor D. STEIN¹, Ann C. MCKEE¹, Jesse MEZ¹, Breton M. ASKEN², Henrik ZETTERBERG³, Christopher J. NOWINSKI⁴, Jeremy A. TANNER⁵, Martha E. SHENTON⁶, Jeffrey L. CUMMINGS⁷, Eric M. REIMAN⁸, Robert A. STERN¹, Gil D. RABINOVIC⁹, Nicholas J. ASHTON⁸, Michael L. ALOSCO¹
¹Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, United States, ²Department of Clinical and Health Psychology, University of Florida, Gainesville, United States, ³Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ⁴Concussion & CTE Foundation, Boston, United States, ⁵Department of Neurology, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, United States, ⁶Psychiatry Neuroimaging Laboratory, Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Somerville, United States, ⁷Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, United States, ⁸Banner Alzheimer's Institute, Phoenix, United States, ⁹Edward & Pearl Fein Memory and Aging Center, Department of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, United States
- 2:05 p.m. **OC52 A proof of concept trial of MIB-626, a sirtuin-NAD⁺ activator, in mild Alzheimer's disease dementia**
Gad Marshall¹, Karol Pencina², Valentine Shang², Daniel Press³, Scott McGinnis⁴, Seth Gale⁴, Pamela Friedman⁴, Soyoung Lee⁴, Ricardo Salazar⁵, Brahyan Galindo Mendez⁴, Kirsten Glennon⁴, Danielle Lavey⁴, Alexander Lin¹, Shalender Bhasin²
¹Center for Clinical Spectroscopy, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ²Section on Men's Health, Aging and Metabolism, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ³Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School – Boston, MA (United States), ⁴Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States), ⁵Division of Geriatric Psychiatry, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School – Boston, MA (United States)
- 2:20 p.m. **OC53 Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD**
Stephanie Doering^{1,2}, Praveen Honhar^{1,2}, Amal Tiss², Charles Chen^{1,2}, Elliott Slade², Emma Thibault², Jackson Thompson², Eva Pintucci², Alex Becker², Michelle Farrell², Reisa Sperling², Julie Price^{1,2}, Keith Johnson², Jessie Fanglu Fu^{1,2}
¹Athinoula A. Martinos Center for Biomedical Imaging - Charlestown, MA (United States), ²Massachusetts General Hospital, Harvard Medical School - Boston, MA (United States)

ORAL COMMUNICATIONS

Chairs: Doris Molina-Henry, USC Keck School of Medicine ATRI San Diego, CA (United States) and Mike Donohue, USC Epstein Family Alzheimer's Therapeutic Research Institute, USC, San Diego, CA (United States)

- 2:35 p.m. **OC54 Amyloid and Tau PET Biological Staging Across Ethnoracial Groups in a Multi-Cohort Alzheimer's Disease Study**
Andrzej Sokolowski¹, Karly Cody^{1,2}, Lucah Medina Guerra¹, Isha Sai¹, Emily Johns¹, Alaina Durant³, Derek Archer³, Raul Vintimilla⁴, Sid O'Bryant⁴, Timothy Hohman³, Christina Young^{5,6}, Elizabeth Mormino⁴
¹Department of Neurology and Neurological Sciences, Stanford University – Stanford, CA (United States), ²Department of Neurology, University of California San Francisco - San Francisco, CA (United States), ³Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center – Nashville, TN (United States), ⁴Institute for Translational Research University of North Texas Health Science Center, - Fort Worth, TX (United States), ⁵Department of Radiology, UC Davis – Davis, CA (United States), ⁶Department of Neurology, UC Davis, - Davis, CA (United States)

2:50 p.m.

OC55 Biomarker Associations and Outcome Performance in Preclinical Alzheimer Disease Trials

Michael DONOHUE¹, Oliver LANGFORD¹, Philip INSEL², Rema RAMAN¹, Michael RAFII³, Reisa SPERLING⁴, Paul AISEN¹

¹USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, Ca, United States, ²Department of Psychiatry, University of California, San Francisco, San Francisco, Ca, United States, ³USC Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego, Ca (United States), San Diego, Ca, United States, ⁴Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Ma, United States

3:05 p.m.

OC56 [¹⁸F]MODAG-009 PET imaging of alpha-synuclein pathology in the presence of amyloid-beta and tau co-pathology across the AD-DLB spectrum

Armin GIESE¹, Daniel BLEHER², Ann-Kathrin GROTEGERD², Felix SCHMIDT¹, Daniel WECKBECKER¹, Andrei LEONOV¹, Sergey RYAZANOV¹, Viktoria RUF³, Andreas MAURER⁴, Christian GRIESINGER⁵, Ken MAREK⁶, Roger GUNN⁷, Johannes LEVIN¹, Matthias BRENDDEL⁸, Kristina HERFERT²

¹MODAG GmbH, Wendelsheim, Germany, ²University of Tübingen, Tübingen, Germany, ³Ludwig-Maximilians-University, München, Germany, ⁴HZDR, Dresden, Germany, ⁵MPI Multidisciplinary Sciences, Göttingen, Germany, ⁶Institute for Neurodegenerative Disorders, New Haven, United States, ⁷XingImaging, New Haven, United States, ⁸Klinikum der Universität München, München, Germany

3:20 p.m.

OC57 Cross-platform performance of plasma p-tau217 assays for predicting amyloid PET positivity across cohorts

Sonal SUKREET¹, Jennifer NGOLAB¹, Michael C. DONOHUE¹, Oliver LANGFORD¹, Rema RAMAN¹, Sara ABDEL-LATIF¹, Gustavo A. JIMENEZ-MAGGIORA¹, Michael S. RAFII¹, Hartmuth C. KOLB², Sterling C. JOHNSON³, Jasmeer CHATWAL⁴, Keith A. JOHNSON⁴, Paul S. AISEN¹, Reisa A. SPERLING⁴, Robert A. RISSMAN¹

¹Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, ²Enigma Biomedical Group, San Diego, United States, ³University of Wisconsin, Wisconsin, United States, ⁴Harvard Medical School, Boston, United States

3:35 p.m.

OC58 Plasma %p-tau217 and Aβ42/Aβ40 provide complementary information about amyloid PET below 20 Centiloids: Baseline findings from the Alzheimer's Plasma Extension Study

Doris MOLINA-HENRY¹, Andy LIU¹, Oliver LANGFORD¹, Michael DONOHUE¹, Rema RAMAN¹, Joel BRAUNSTEIN², Gustavo JIMENEZ-MAGGIORA¹, Robert RISSMAN¹, Keith JOHNSON², Paul AISEN¹, Reisa SPERLING²

¹USC Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States, ²Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, United States

3:50 p.m.
4:10 p.m.

BIOTECH SHOWCASE

Biotech Showcase and introductory panel

3:52 p.m.

BIOTECH SHOWCASE 7 Restoring Proteostasis in Alzheimer's Disease with Buntanetap, a Small-Molecule Translational Inhibitor of Neurotoxic Proteins

Alexander MORIN, Maria MACCECCHINI

Annovis Bio, Malvern, United States

3:58 p.m.

BIOTECH SHOWCASE 8 In silico simulation of clinical trials for Alzheimer's disease and related dementias

Min Gyeong KIM¹, Yeong-Hun SONG^{1,2}, Yeon-Jeong LEE¹, Jeong-Yeon SONG¹, Junseo LEE^{1,3}, Euijeong SONG¹, Soohyun PARK¹, Seok HONG^{1,2}, Ahyun CHOI^{1,2}, Joon-Kyung SEONG^{1,2,3}, Wha Jin LEE¹

¹Neuroxt, Inc., Seoul, Korea, Republic of, ²Department of Artificial Intelligence, Korea University, Seoul, Korea, Republic of, ³School of Biomedical Engineering, Korea University, Seoul, Korea, Republic of

4:04 p.m.

BIOTECH SHOWCASE 9 iMediSync Inc. — iSB-M: AI-based QEEG Biomarker Platform for Alzheimer's Disease and Lewy Body Comorbidity

Seung Wan KANG¹, Nam Heon KIM¹, Jun Yeop KIM¹, Daekeun KIM¹, Dong Won YANG², Seong Hye CHOI³, Young Chul YOUN⁴, Byoung Seok YE⁵, Joon-Kyung SEONG⁶

¹iMediSync, Inc., Seoul, Korea, Republic of, ²The Catholic University of Korea, Seoul, Korea, Republic of, ³Inha University School of Medicine, Incheon, Korea, Republic of, ⁴Chung-Ang University College of Medicine, Seoul, Korea, Republic of, ⁵Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁶NeuroXT, Inc. / Korea University, Seoul, Republic of Korea

4:10 p.m.

End of the conference

● Posters List

CLINICAL TRIALS – PHASE IIB & III	P.23
CLINICAL TRIALS – PHASE I & IIA	P.28
IMAGING (MRI & PET)	P.32
ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS	P.38
EPIDEMIOLOGY	P.40
NEW HYPOTHESES – NEW THERAPEUTIC APPROACHES FOR AD	P.44
NON-PHARMACOLOGIC INTERVENTIONS	P.47
BIOMARKERS (CSF & PLASMA)	P.51
PRE-CLINICAL, EARLY DISCOVERY AND MECHANISTIC RESEARCH	P.64
TRIAL DESIGN, STATISTICAL INNOVATION, AND ANALYTICAL FRAMEWORKS	P.68
COGNITIVE AND FUNCTIONAL OUTCOMES	P.73
DIGITAL ENDPOINTS, REMOTE MONITORING, AND CONNECTED HEALTH TOOLS	P.77
REAL-WORLD DATA, REGISTRIES & IMPLEMENTATION SCIENCE	P.81
BIOTECH SHOWCASE	P.87

CLINICAL TRIALS – PHASE IIB & III

P001 Continuous vs. Finite Dosing Until Amyloid Plaque Clearance in Early Alzheimer's Disease: A Horizontal Matching Analysis of Long-Term Clinical Trajectories for Lecanemab and Donanemab

Presenteur : Suzanne Hendrix

Suzanne Hendrix¹, John Whetten¹, Samuel Dickson¹, Kent Hendrix¹, Alireza Atri², Mary Sano³, Chris Van Dyck⁴

¹Pentara Corporation, Millcreek, United States, ²Banner Health, Sun City, United States, ³Mount Sinai School of Medicine, New York, United States, ⁴Yale School of Medicine, New Haven, United States

P002 Updated Projections Confirm Long-Term Benefits of Continuous Lecanemab: 10 Years of Treatment Could Delay Moderate Disease by 18.7 Years

Presenteur : Suzanne Hendrix

Suzanne Hendrix¹, John Whetten¹, Garrett Duncan¹, Samuel Dickson¹, Katherine Youmans-Kidder², Daryl Jones²

¹Pentara Corporation, Millcreek, United States, ²Eisai Inc., Nutley, United States

P003 Utility of Clinically Scalable Biomarkers for Prescreening in Preclinical Alzheimer's Disease: Insights from RETAIN

Presenteur : Anahita Kyani

Anahita Kyani¹, Federico Parisi², Adria Mallol-Ragolta³, Casey Vanderlip¹, Macarena Garcia Valdecasas Colell², Stephanie Slania⁴, Charmaine Demanuele², Nicklas Linz⁵, Johannes Tröger⁵, Gayle Wittenberg⁶, Arthur Simen⁷, Fiona Elwood⁷, Rachel Kolster⁷, Ziad Saad⁸, Tricia Thornton-Wells⁷

¹Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, La Jolla, United States, ²Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Cambridge, United States, ³Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Beerse, Belgium, ⁴Johnson & Johnson Innovative Medicine, Neuroscience Data Science, Digital Health & Artificial Intelligence (DDSAI), United States, Pennsylvania, United States, ⁵ki:elements GmbH, Germany, ⁶Johnson & Johnson Innovative Medicine, Neuroscience, United States, New Jersey, United States, ⁷Johnson & Johnson Innovative Medicine, Neuroscience, United States, Cambridge, United States, ⁸Johnson & Johnson Innovative Medicine, Neuroscience, United States, La Jolla, United States

P005 SPINOZA: Rationale and Design of a Phase 2b Trial of Obicetrapib in APOE-Stratified Preclinical Alzheimer's Disease

Presenteur : Andrew Hsieh

Michael Davidson, Marc Ditmarsch, Andrew Hsieh, Ashley Walker, Adam Johnson, John Kastelein

NewAmsterdam Pharma, Naarden, The Netherlands

P006 Plasma Biomarker Screening for Amyloid Status in the BenfoTeam randomized controlled trial in Early Alzheimer's Disease

Presenteur : Jose Luchsinger

Jose Luchsinger¹, Howard Feldman², Hyun Cho², Adam Tran², Andrew Mackelfresh², Bryce Truver², Jody-Lynn Lupo², Carolyn Revta², Tim West³, Philip Verghese³, Gary Gibson⁴

¹Columbia University Irving Medical Center, New York, United States, ²University of California-San Diego, La Jolla, United States, ³C2N Diagnostics LLC, St. Louis, United States, ⁴Weill Cornell Medicine, New York, United States

P007 Beyond Amyloid Clearance: CSF Proteomics Reveals Proteome-Wide CNS Remodeling Following Lecanemab Treatment

Presenteur : Pallavi Sachdev

Pallavi Sachdev¹, Taeko Kamakura², Yuanqing Ye¹, Kazuhiro Tahara², Kenji Kita³, Kristin Wildsmith¹, Hongmei Niu¹, Michael Irizarry¹, Lynn Kramer¹, Shobha Dhadda¹, Kanta Horie¹

¹Eisai Inc., Nutley, United States, ²Eisai Co., Ltd., Tsukuba, Japan, ³Sunplanet Co., Ltd., Tsukuba, Japan

P009 Exploratory Clinical Cognition and Biomarker Outcomes of RY01 in Patients with Alzheimer's Disease: An Investigator-Initiated Trial

Presenteur : Hong Ye

Hong Ye¹, Tao Jiang², Qingwei Tian¹, Xiumei Wang², Caimeng Qin³, Ningmao Jiang³

¹Ruiyi Pharmaceutical, Shenzhen, China, ²Institute of Biophysics, Chinese Academy of Sciences, Beijing, China, ³Brain Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China

P010 Effect of Intensive vs Standard Blood Pressure Control According to APOE ε4 Genotype: A Secondary Analysis of SPRINT

Presenteur : Yizhe Xu

Yizhe Xu¹, Jeremy Pruzin², Tom Greene³, Jeff Williamson⁴, David Reboussin⁵, Nicholas Pajewski⁵, Michael Klein⁶, Wai-Yingwendy Yau^{7, 8}, Eric Reiman², Mark Supiano⁹, Nicholas Ashton¹⁰, Jasmeer Chhatwal^{7, 8}, Adam Bress^{3, 11}

¹Division of Epidemiology, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, United States, ²Banner Alzheimer's Institute, Phoenix, United States, ³Divisions of Health System Innovation and Research, and Biostatistics, Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, United States, ⁴Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, and Sticht Center for Healthy Aging and Alzheimer's Prevention, Wake Forest University School of Medicine, Winston-Salem, United States, ⁵Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, United States, ⁶Genomics Core, Health Sciences Center Core Research Facility, University of Utah, Salt Lake City, United States, ⁷Department of Neurology, Harvard Medical School, Boston, United States, ⁸Department of Neurology, Mass General Brigham, Boston, United States, ⁹Division of Geriatrics, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, United States, ¹⁰Banner Sun Health Research Institute, Sun City, United States, ¹¹George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, United States

P011 The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clinical and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD

Presenteur : John Hey

John Hey¹, Susan Abushakra¹, Fanny Elahi², Earvin Liang¹, Patrick Kesslak¹, Jeremy Yu¹, Brian Roth¹, Susan Flint¹, Adem Albayrak¹, Elitza Hristova¹, Aidan Power¹, Martin Tolar¹

¹Alzheon, Framingham, United States, ²Icahn School of Medicine at Mt. Sinai, New York, United States

P012 The Oral Anti-Amyloid Agent Valiltramiprosate Reduces Spontaneous ARIA Rates in APOE4/4 Early AD Subjects: Results of the Phase 3 Placebo-Controlled APOLLOE4 Trial

Presenteur : S. Abushakra

S. Abushakra¹, E. Liang¹, M. Sabbagh², S. Cohen³, D. Watson⁴, E. Macsweeney⁵, J. Sampalis⁶, J. Barakos⁷, J. Kesslak¹, J. Hey¹, S. Flint¹, R. McLaine¹, A. Albayrak¹, A. Power¹, M. Tolar¹

¹Alzheon, Inc., Framingham, Ma, United States, ²Barrow Neurological Institute, Phoenix, Az, United States, ³Toronto Memory Clinic, Toronto, On, Canada, ⁴Alzheimer's Research and Treatment Center, Wellington, Fl, United States, ⁵Re:Cognition Health, London, United Kingdom, ⁶McGill University and Université de Montréal, Canada, ⁷Clario Inc. & Pacific Medical Center, San Francisco, Ca, United States

P013 Effects of Valiltramiprosate on Plasma P-tau217 and Select Pro-Inflammatory and Vascular Injury Biomarkers with the NULISA CNS Panel: Exploratory Analyses from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD

Presenteur : Susan Abushakra

Susan Abushakra¹, John A Hey¹, F. Elahi², David Watson³, Aidan Power¹, Marwan Sabbagh⁴, Sharon Cohen⁵, Earvin Liang⁶, E. Hristova⁶, J. Patrick Kesslak⁶, Susan Flint⁶, Adem Albayrak⁶, Martin Tolar⁶

¹Alzheon, Inc., Framingham, Ma, United States, ²Mt. Icahn School of Medicine, Mt. Sinai, New York, Ny, United States, ³Alzheimer's Research and Treatment Center, Wellington, Fl, United States, ⁴Barrow Neurological Institute, Phoenix, Az, United States, ⁵Toronto Memory Program, Toronto, On, Canada, ⁶Alzheon, Inc., Framingham, Ma, United States

P014 PUFA Trial Ancillary Biomarker Study: n-3 polyunsaturated fatty acids lower plasma soluble ICAM-1 and NfL in older adults with cerebral small vessel disease

Presenteur : Gene Bowman

Yan Gao¹, Lynne Shinto², Charles Murchison³, Hiroko Dodge¹, Pia Kivisakk¹, Steven Aronold¹, Jeffrey Kaye², Joseph Quinn², Lisa Silbert², Rudolph Tanzi¹, Gene Bowman¹

¹Harvard-MGB, Boston, United States, ²OHSU, Portland, United States, ³UAB, Birmingham, United States

P015 ALTITUDE-AD: Baseline characteristics of participants randomized in a phase 2 trial of sabirnetug in early Alzheimer's disease

Presenteur : Linda Pao

Linda Pao¹, Todd Feaster², Maddelyn Hyland², Gopalan Sethuraman², Eric Siemers²

¹Jem Research Institute, Atlantis, Fl, United States, ²Acumen Pharmaceuticals, Newton, Ma, United States

P016 Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease

Presenteur : Loes Rutten-Jacobs

Loes Rutten-Jacobs¹, Venissa Machado¹, Paul Edison², Catherine Mummery³, Alessandro Padovani⁴, Malu G. Tansey⁵, Silke Simon¹, Celine Adessi¹, Nikhat Parkar⁶, Nima Shariati¹, Bastian Zinnhardt¹, Gabriel Schnetzler¹, Geoffrey A. Kerchner¹, Luka Kulic¹, Gennaro Pagano¹

¹F. Hoffmann-La Roche Ltd, Basel, Switzerland, ²Faculty of Medicine, Imperial College London, London, United Kingdom, ³Queen Square Institute of Neurology, University College London, London, United Kingdom, ⁴Institute of Neurology, University Hospital ASST Spedali Civili of Brescia, Brescia, Italy, ⁵Department of Neurology, Indiana University School of Medicine, Stark Neuroscience Research Institute - Indianapolis, Indianapolis, United States, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom

P017 The unique mode of action of the orally applied PRI-002 and its confirmed target engagement in the phase 2b study PRIMus-AD

Presenteur : Dieter Willbold

Dieter Willbold^{1,2}, Dagmar Jürgens^{1,3}, Gerhard Tischler³, Tina Bartsch³, Gunther Kauselmann^{3,1}, Knur Adermann^{3,1}, Lorenzo Bulli³, Katja Lindner³, Julia Post-Schulz³, Julie-Anne Gabelich³, Alexander Brener³, Kathrin Zeiger³, Oliver Peters^{1,4}

¹Priavoid GmbH, Düsseldorf, Germany, ²Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, ³PRInnovation GmbH, Düsseldorf, Germany, ⁴Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P018 PRIMus-AD: Biomarker Profile Data of the phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenteur : Alexander Brener

Alexander Brener¹, Julia Post-Schulz¹, Dagmar Jürgens², Gerhard Tischler¹, Tina Bartsch¹, Gunther Kauselmann², Knut Adermann², Kathrin Zeiger¹, Katja Lindner¹, Lorenzo Bulli¹, Julie-Anne Gabelich¹, Dieter Willbold², Oliver Peters²

¹PRInnovation GmbH, Düsseldorf, Germany, ²Priavoid GmbH, Düsseldorf, Germany

P019 Design of a phase 3 clinical trial of the oral p38 α kinase inhibitor neflamapimod in patients with dementia with Lewy bodies (DLB)

Presenteur : James Galvin

James Galvin¹, John-Paul Taylor², Nathalie Adda³, Amanda Gardner³, Shannon Bradley³, Kelly Blackburn³, John J Alam³

¹U. of Miami Miller School of Medicine, Boca Raton, United States, ²Newcastle University, Newcastle Upon Tyne, United Kingdom, ³CervoMed Inc, Boston, United States

P020 PRIImus-AD: Safety data of the Phase 2b study treating early AD patients with the novel drug candidate PRI-002

Presenteur : Gerhard Tischler

Gerhard Tischler¹, Dagmar Jürgens², Alexander Brener¹, Tina Bartsch¹, Gunther Kauselmann¹, Knut Adermann², Kathrin Zeiger², Katja Linder¹, Julie-Anne Gabelich¹, Lorenzo Bulli¹, Julia Post-Schulz¹, Dieter Willbold², Oliver Peters²

¹PRInnovation GmbH, Düsseldorf, Germany, ²Priavoid GmbH, Düsseldorf, Germany

P021 PRIImus-AD: Design, Recruitment and Baseline Data of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002

Presenteur : Dagmar Jürgens

Dagmar Jürgens^{1,2}, Gerhard Tischler², Alexander Brener², Tina Bartsch², Gunther Kauselmann^{1,2}, Knut Adermann^{1,2}, Kathrin Zeiger², Katja Lindner², Julie-Anne Gabelich², Dieter Willbold^{1,3}, Oliver Peters^{1,4}

¹Priavoid GmbH, Düsseldorf, Germany, ²PRInnovation GmbH, Düsseldorf, Germany, ³Institut für Physikalische Biologie, Heinrich Heine University, Düsseldorf, Germany, ⁴Department of Psychiatry and Neuroscience, Charité - Universitätsmedizin Berlin, Berlin, Germany

P022 Effect of the P. gingivalis (Pg) gingipain inhibitor atuzaginstat on neuropsychiatric symptoms in Pg-positive mild-moderate AD patients and distress in their caregivers: Analysis of the NPI-12 in the Phase 2/3 GAIN trial

Presenteur : Michael Detke

Michael Detke¹, Marwan Sabbagh², Joanna Bolger¹, Tyler Duke³, Florian Ermini¹, Casey Lynch¹, Stephen Dominy¹

¹Lighthouse Pharma, Novato, United States, ²Barrow Neurological Institute, Phoenix, United States, ³Pentara Corp, Millcreek, United States

P023 ALTITUDE-AD: Qualitative interviews assessing treatment expectations and motivations for clinical trial participation in early Alzheimer's disease

Presenteur : Stephanie Cline

Elizabeth Merikle¹, Todd Feaster², Eric Siemers², Diana Kerwin³, Stephanie Cline²

¹Clinical Outcomes Assessment Consultant, Parksville, Bc, Canada, ²Acumen Pharmaceuticals, Newton, Ma, United States, ³Kerwin Medical Center, Dallas, Tx, United States

P024 Perspectives on the care experience in early Alzheimer's: Narratives from study partners in the ALTITUDE-AD clinical trial

Presenteur : Stephanie Cline

Elizabeth Merikle¹, Todd Feaster², Robyn Moxon², Eric Siemers², Dung Trinh³, Stephanie Cline²

¹Clinical Outcomes Assessment Consultant, Parksville, Bc, United States, ²Acumen Pharmaceuticals, Newton, Ma, United States, ³Healthy Brain Research, Long Beach, Ca, United States

P025 Clinical trial design and baseline characteristics of buntanetap's pivotal study in treating early Alzheimer's patients

Presenteur : Cheng Fang

Cheng Fang¹, Sarah Maccalum¹, Hui Liu¹, David Feng², Maria Maccacchini¹

¹Annovis Bio, Malvern, United States, ²TCM, Princeton, United States

P026 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclnx Glasgow.

Presenteur : Jennifer Lynch

Kanwal Aadil, Lewis Cowan, Jennifer Lynch, Fraser Inglis

Neuroclnx Glasgow, Motherwell, United Kingdom

P027 BenfoTeam Phase 2 RCT in Early Alzheimer's Disease: Report of Completed Enrollment and Recruitment

Presenteur : Howard Feldman

Andrea Lacroix¹, Howard Feldman^{2,3}, José Luchsinger⁴, Hyun Keun Cho^{2,3}, Adam Tran^{2,3}, Diane Jacobs^{2,3}, David Salmon^{2,3}, Donna Tan^{2,3}, Andrew Mackelfresh^{2,3}, Bryce Truver^{2,3}, Jody-Lynn Lupo^{2,3}, Carolyn Revta^{2,3}, Gary Gibson⁵

¹Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, United States, ²Department of Neurosciences, University of California San Diego, La Jolla, United States, ³Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, United States, ⁴Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, United States, ⁵Brain and Mind Research Institute, Weill Cornell Medicine, New York, United States

P029 Safety and Efficacy of Mevidalen in Alzheimer's Disease: A Phase 2, Randomized, Double-Blinded Trial

Presenteur : Adam Fleisher

Adam Fleisher¹, Nicole Mehdiyou¹, Hu Haoyan¹, Tronchin Giulia², Hansson Oskar³

¹Eli Lilly, Indianapolis, United States, ²Eli Lilly, Cork, Ireland, ³Eli Lilly, Boston, United States

P030 Brain-Gut Photobiomodulation in Mild-to-Moderate Alzheimer's Disease: Progress Update from the Light4Life Pivotal Trial

Presenteur : Guillaume Blivet

Julien Delrieu¹, Marie-Noëlle Cufi², Claire Paquet³, Hermine Lenoir^{4, 5}, Louise Naccache⁶, Antoine Garnier-Crussard^{7, 8}, Maud Jourdain⁹, Mélodie Fouillen¹⁰, Guillaume Blivet¹¹, Jacques Touchon¹²

¹Toulouse University Hospital, Toulouse, France, ²CHIC Castres-Mazamet, Castres, France, ³Université Paris Cité, GHU APHP Nord, Hôpital Lariboisière, IHU ReConnect, Paris, France, ⁴Services de gériatrie 1 & 2, Centre Mémoire de Ressources et de Recherche Île-de-France Sud - site Broca, AP-HP, Hôpital Broca, Paris, France, ⁵Université Paris Cité, INSERM UMR-S 1144, Paris, France, ⁶Lavaur Hospital, Lavaur, France, ⁷Clinical Research Center Ageing-Brain-Frailty, Clinical and Research Memory Centre of Lyon, Lyon Institute For Aging, Charpennes Hospital, Hospices Civils de Lyon, Lyon, France, ⁸Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, Bron, France, ⁹Biofortis, Nantes, France, ¹⁰ORCTs, Lyon, France, ¹¹REGEnLIFE, Paris, France, ¹²Montpellier University, Montpellier, France

P031 Episodic Memory Testing in TRAVELLER and TRONTIER: Evaluating the Relationship Between the International Shopping List Test (ISLT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Presenteur : Ralph Lee

Yu-Jay Huoh¹, Ralph Lee¹, Elly Lee¹, Tara Parnitvithikul¹, T. Richard Parenteau¹, Dung Trinh², My-Linh Tong¹, Edward Zamrini¹, Maricor Grio¹

¹Irvine Clinical Research, Irvine, United States, ²Healthy Brain Clinic, Long Beach, United States

P032 Oral Blarcamesine Clinical Effect In a Phase 2b/3 Early AD Population For SIGMAR1 And Col24a1 Genotypes

Presenteur : Marwan Sabbagh

Marwan Sabbagh¹, Audrey Gabelle², Timo Grimmer³

¹Barrow Neurological Institute, Phoenix, United States, ²University of Montpellier, Montpellier, France, ³Technical University of Munich, Munich, Germany

P033 Masupirdine (a pure 5-HT₆ receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer's type

Presenteur : Pradeep Jayarajan

Ramakrishna Nirogi, Satish Jetta, Vinod Kumar Goyal, Vijay Benade, Anil Shinde, Santosh Kumar Pandey, Ramkumar Subramanian, Abdul Rasheed Mohammed, Dhanunjay Dogiparti, Pradeep Jayarajan, Venkat Jasti

Suven Life Sciences Ltd, Hyderabad, India

P034 Evaluation of Sex and APOE4-Related Differences in Baseline Characteristics and Disease Progression Among Placebo-Treated Patients in Anti-Amyloid Alzheimer's Clinical Trials

Presenteur : Kevin Krudys

Athanasios Chamzas, Gopichand Gottipati, Ananth Ram Nookala, Venkatesh Atul Bhattaram, Mehul Mehta, Ramana Uppoor, Kevin Krudys, Sreedharan Sabarinath

Center for Drug Evaluation and Research, FDA, Silver Spring, United States

P035 Evolution of Late-Stage Alzheimer's Disease Clinical Trial Design: Toward Biomarker-Driven, Precision Development

Presenteur : Laurentiu Gutiu

Laurentiu Gutiu¹, Abby Fuller², Todorova Antoniya³

¹Fortrea Germany GmbH, Munich, Germany, ²Fortrea Inc., Durham, United States, ³Fortrea Belgium SRL, Brussels, Belgium

P037 A Phase 2 Randomized, Controlled Trial of MK-1167, a Positive Allosteric Modulator of the $\alpha 7$ nAChR, as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease Dementia

Presenteur : **Eva Kohegyi**

Eva Kohegyi, Beatriz Caballero, James Kost, Yi Mo, Yuki Mukai, Aristide Merola, Michael F. Egan

Merck & Co., Inc., Rahway, United States

P038 Repeated Theta Burst Stimulation to Brain Area 8AV Transiently Improves Memory Retention in Early-Stage Alzheimer's Disease

Presenteur : **Michael Rosenbloom**

Ian Coulter, Michael Rosenbloom, John Yi, Andrea Stocco

University of Washington, Seattle, United States

P039 A Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Phase Ia, First in Human Study of the Safety, Tolerability and Pharmacokinetics of OLX-07010, a Novel Tau Self-Association Inhibitor, in Healthy Adult and Older Volunteers.

Presenteur : **William Erhardt**

William Erhardt¹, John Ieni¹, Uma Kuruganti¹, Eliot Davidowitz¹, James Moe¹, Hakop Gevorkian²

¹Oligomerix, Inc, Bronx, NY, United States, ²California Clinical Trials Medical Group, Glendale, CA, United States

P040 Phase 1 Study Results of the Novel TREM2 Small Molecule Agonist MNA-001: Safety, Pharmacokinetics And Pharmacodynamics In Healthy Young And Elderly Volunteers

Presenteur : **Niels Plath**

Manuela Polydoro, Tamara Agajanov, Peter Flagstad, Angeliki Kallia Spentza, Laura Sans-Comerma, Jin Zheng, Ashley Comer, Ashley Lu, Joachim Vilstrup, Morten Andersen S, Ninna Frederiksen, Maria Dalby, Rita Balice-Gordon, David Howe, Niels Plath

Muna Therapeutics, Frederiksberg, Denmark

P042 Five-year phase II BCG immunotherapy trial for Alzheimer's disease prevention in diabetes: Impact of APOE $\epsilon 4$ status on p-tau217 and A β 42/40

Presenteur : **Denise Faustman**

Shiho Hashiguchi^{1,2}, James Reilly¹, Nicholas Kartsounis¹, Emily Naughton¹, Thora McIsaac¹, Zachary Lucchini¹, Joan Braley¹, Hui Zheng¹, Willem K  h  treiber^{1,2}, Denise Faustman^{1,2}

¹Massachusetts General Hospital, Charlestown, United States, ²Harvard Medical School, Boston, United States

P043 Effectiveness and safety of electroconvulsive therapy for severe, treatment-resistant agitation and aggression in dementia: Results from the ECT-AD study

Presenteur : **Brent Forester**

Brent Forester

Tufts Medical Center, Boston, United States

P044 A next-generation septin molecular glue, REM392, advancing to confirm proof of concept in mild-to-moderate Alzheimer's disease patients

Presenteur : **Floor Stam**

Floor Stam, Mieke Nuytten, Eveline Dubroux, Marieke Voets, Jessika Meuviss, Gerard Griffioen

remynd N.V., Leuven, Belgium

P045 Initial neurodegeneration biomarker results from a Phase 2a clinical trial of neflamapimod in patients with non-fluent variant primary progressive aphasia

Presenteur : **Ian M Grant**

Ian M Grant¹, Hugo Botha², Lawerance S Honig³, Douglas W Scharre⁴, Gardner Amanda⁵, Kelly Blackburn⁵, Bradley F Boeve², John J Alam⁶, David J Irwin⁷

¹Northwestern University, Chicago, United States, ²Mayo Clinic, Rochester, United States, ³Columbia University, New York, United States, ⁴Ohio State University, Columbus, United States, ⁵CervoMed, Boston, United States, ⁶Mayo Clinic, Boston, United States, ⁷University of Pennsylvania, Philadelphia, United States

P046 Safety, tolerability, pharmacokinetics and changes in CSF α -synuclein seeding activity and the CSF proteome in a first-in-patient trial of the oligomer modulator anle138b

Presenteur : Johannes Levin

Johannes Levin¹, Jonathan Evans², Nand Singh³, Sue Melbourne³, Amber Morgan³, Camille Carroll⁴, Olivia Wagemann⁵, Matteo Vestrucci⁶, Scott Berry⁶, Sebastian Longen⁷, Svenja Trossbach¹, Felix Schmidt¹, Daniel Weckbecker¹, Torsten Matthias¹, Armin Giese¹

¹MODAG GmbH, Wendelsheim, Germany, ²Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ³Quotient Sciences, Nottingham, United Kingdom, ⁴Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom, ⁵Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁶Berry Consultants, Austin, United States, ⁷AESKU.Diagnostics GmbH, Wendelsheim, Germany

P047 Interim Safety and Biomarker Analysis of PRECISE-AD

Presenteur : William Mantyh

William Mantyh¹, Wendy Luca², Misty Lamendola², Heidi Pavia², Lindsay Moody², Neil Warma², Max Milbury², Johanne Kaplan², Suzanne Hendrix³, Neil Cashman^{4,2}, Larry Altstiel²

¹University of Minnesota, Minneapolis, United States, ²ProMIS Neurosciences, Cambridge, MA, United States, ³Pentara, Millcreek, United States, ⁴University of British Columbia, Vancouver, Canada

P048 Phase 2a clinical trial of the oral p38 α kinase inhibitor neflamapimod in patients with non-fluent variant primary progressive aphasia

Presenteur : Ian M. Grant

Ian M. Grant¹, Hugo Botha², Lawerance S. Honig³, Douglas W. Scharre⁴, Amanda Gardner⁵, Kelly Blackburn⁵, Bradley F. Boeve², John J. Alam⁶, David J. Irwin⁷

¹Northwestern University, Chicago, United States, ²Mayo Clinic, Rochester, United States, ³Columbia University, New York, United States, ⁴Ohio State University, Columbus, United States, ⁵CervoMed, Inc., Boston, United States, ⁶CervoMed Inc., Boston, United States, ⁷University of Pennsylvania, Philadelphia, United States

P049 Results from 2 phase 1 studies evaluating the dual FAAH/MAGL inhibitor irafamdistat in healthy adults (including Japanese and elderly)

Presenteur : Kimberley Lentz

Thomas Lodewyckx¹, Jan De Hoon¹, Amina Haggag², Alice Wang³, Min Chen⁴, Kevin Dines⁴, Joel Schwartz⁴, Michael Thomas⁴, Mark Thomas⁴, Anthony Krakovich⁴, Yanying Wang⁴, Sumit Bansal⁴, Richard Hargreaves⁴, Marc Gleichmann³, Kimberley Lentz⁴

¹Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, Leuven, Belgium, ²CenExel, Anaheim, United States, ³Bristol Myers Squibb (affiliation at time of study), Princeton, United States, ⁴Bristol Myers Squibb, Princeton, United States

P050 Safety and Modulation of ABCC9 pathways by nicorandil for the Treatment of Hippocampal Sclerosis of aging: The SMaRT-HS Study primary outcome results

Presenteur : Gregory Jicha

Gregory Jicha, Erin Abner, Ahmed Bahrani, Maria Carrillo, Elif Coskun, Danica Coy, Alexandra Curtis, Brian Gold, Molly Harper, Emily Smith, Heather Snyder, Peter Nelson

University of Kentucky, Lexington, United States

P051 The ABCA1 agonist CS6253 in humans increases plasma apoE and amyloid in plasma and cerebrospinal fluid.

Presenteur : Jan Johansson

Jan Johansson¹, Bengt Winblad², Henrik Zetterberg³, Jeffrey Cummings⁴, Hussein Yassine⁴

¹Artery Therapeutics, Inc., San Ramon, United States, ²Karolinska Institute, Stockholm, Sweden, ³Sahlgrenska, Gothenburg, Sweden, ⁴UoNevada, Las Vegas, United States

P052 SAPHARY Phase 1b/2a study to investigate the safety, efficacy, and pharmacokinetics of GAL-101 salt as oral treatment for patients with mild to moderate Alzheimer's disease

Presenteur : Katrin Riemann

Katrin Riemann¹, Bernhard Katgely¹, Alexander Gebauer¹, Luciana Summo¹, John Harrison², Charlotte Teunissen³, Willem De Haan⁴, Andreas Busjahn⁵, Manfred Windisch⁶, Hermann Russ¹

¹Galimedix Therapeutics Inc., Kensington, United States, ²Alzheimercentrum, AUMC, Amsterdam, The Netherlands, ³Neurochemistry Laboratory, Alzheimer Center Amsterdam UMC, Amsterdam, The Netherlands, ⁴Alzheimer Center, Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands, ⁵HealthTwist GmbH, Berlin, Germany, ⁶NeuroScios GmbH, St. Radegund/graz, Austria

P053 Low-dose levetiracetam to treat cortical hyperexcitability in early Alzheimer's disease: a randomized, double-blind phase 2a crossover trial

Presenteur : Stephanie Buss

Stephanie Buss, Brice Passera, Recep Ozdemir, Emma Ferry, Martina Upton, Carol Abedelnor, Grace Desmond, Brenna Hagan, Peter Fried, Tom Travison, Daniel Press, Mouhsin Shafi

Beth Israel Deaconess Medical Center, Boston, United States

P054 Baseline Characteristics of Participants Enrolled in a Multiple Ascending Dose Study of the C-Terminal Targeting Anti-Tau Antibody VY7523 in Early Alzheimer's Disease

Presenteur : Monroe Butler

Monroe Butler, Charlotte Chung, Joydeep Ghosh, Jennifer Morgan, Joydip Kundu, Krishanu Mathur, Vik Arora, Wencheng Liu, Craig Mallinckrodt, Maurice Emery, Tina Olsson, Dinah Sah, Alfred Sandroock, Raj Rajagovindan, Elena Ratti

Voyager Therapeutics, Lexington, United States

P055 First-in-Human Study Design of VY1706, a Systemically Administered Blood-Brain Barrier (BBB)-Penetrant Tau Lowering Gene Therapy in Early Alzheimer's Disease

Presenteur : Monroe Butler

Monroe Butler, Charlotte Chung, Joydeep Ghosh, Vik Arora, Wencheng Liu, Thrusha Chauhan, Ivan Nestorov, Tina Olsson, Craig Mallinckrodt, Rajeev Sivasankaran, Todd Carter, Dinah Sah, Alfred Sandrock, Raj Rajagovindan, Elena Ratti
Voyager Therapeutics, Lexington, United States

P056 Lithium Orotate for Early Stages of Alzheimer Disease and Related Dementias: Design and Methods of a Placebo-Controlled Dose-Ranging Pilot Trial

Presenteur : Olivia Okereke

Olivia Okereke¹, Joann Manson², Pamela Rist², Howard Sesso², Jennifer Gatchel¹, Chirag Vyas¹, David Mischoulon¹, David Bennett³, Bruce Yankner⁴
¹Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, United States, ²Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, United States, ³Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, United States, ⁴Department of Genetics, Harvard Medical School, Boston, United States

P058 NSC001 in Alzheimers's disease: Phase 2a proof of concept of the best in class biased selectove M1 muscarinic agonist

Presenteur : Manfred Windisch

Manfred Windisch¹, Abraham Fischer²
¹NSC-Therapeutics GmbH, St. Radegund, Austria, ²ADPD, Holon, Israel

P059 TREMHANCE: A Phase 2 study to evaluate the efficacy and safety of TREM2 agonist SAR448851 in early Alzheimer's disease

Presenteur : Jeffrey Cummings

Jeffrey Cummings¹, Catherine Mummery², David Watson³, Christopher Rowe⁴, Charlotte Teunissen⁵, Sebastian Palmqvist⁶, Jeffrey Norton⁷, Sneha Narasimhan⁸, Stephane Hourcade⁹, Xiaodong Luo¹⁰, Bing Zhu¹⁰, Erik Wallstroem¹⁰, Marco Colonna¹¹
¹University of Nevada Las Vegas, Las Vegas, Nevada, United States, ²Dementia Research Centre, University College London, London, United Kingdom, ³Alzheimer's Research and Treatment Center, Wellington, Florida, United States, ⁴Austin Health, Heidelberg, Australia, ⁵Amsterdam University Medical Center, Amsterdam, The Netherlands, ⁶Lund University, Lund, Sweden, ⁷Charter Research, The Villages, Florida, United States, ⁸Sanofi, Morristown, New Jersey, United States, ⁹Sanofi, Vitry-Sur-Seine, France, ¹⁰Sanofi, Cambridge, Massachusetts, United States, ¹¹Washington University in St. Louis, St. Louis, Missouri, United States

P061 Caring for Behavioral Symptoms of Dementia (CBD): Pilot Trial of Cannabidiol for Anxiety in Patients with Mild Cognitive Impairment and Alzheimer's Dementia

Presenteur : Ipsit Vahia

Rosemary Smith¹, Emily Kim², Kimaya Reddy², Edward De La Cruz², Rosain Ozonsi², Julia Merrill², Andre Nguyen², Regan Patrick^{2,3}, David Harper^{2,3}, Ipsit Vahia^{2,3}, Brent Forester⁴, Staci Gruber^{1,3}
¹Marijuana Investigations for Neuroscientific Discovery (MIND) Program, McLean Hospital, Belmont, United States, ²Geriatric Psychiatry Research Program (GPRP), McLean Hospital, Belmont, United States, ³Department of Psychiatry, Harvard Medical School, Boston, United States, ⁴Department of Psychiatry, Tufts Medical Center, Boston, United States

P062 Long-term Cognitive Benefit of troculeucel NK Cell Therapy in a Patient With Moderate Alzheimer's Disease: A Single-Subject Analysis

Presenteur : Paul Song

Paul Song¹, Hui Lucia¹, Hong Sean¹, Kang Yoonmi¹, Lee Hank¹, Mata Juan¹, Chung Harry², Carr Jesse², Betito Katia²
¹NKGen Biotech, Santa Ana, United States, ²Behavioral Research Specialists, LLC, Glendale, United States

P063 ADVANCE: A Randomised, Double-Blind, Placebo-Controlled Phase 2a Trial of ALZ-101 Active Immunotherapy in Early Alzheimer's Disease

Presenteur : Stefan Pierrou

Stefan Pierrou¹, Anders Sandberg¹, Arnesson Karin¹, Sjögren Niclas², Sabbagh Marwan³
¹Alzinova AB, Mölndal, Sweden, ²Cytel Inc., Stockholm, Sweden, ³Barrow Neurological Institute, Phoenix, United States

P064 Phase 1b Proof-of-Mechanism Trial of EC5026, a Soluble Epoxide Hydrolase Inhibitor, in Biomarker-Confirmed Early Alzheimer's Disease

Presenteur : Myuri Ruthirakuhan

Myuri Ruthirakuhan¹, Cindy McReynolds², William Schmidt², Heather Hsu², Mario Masellis¹, Sandra Black¹, Walter Swardfager¹
¹Sunnybrook Research Institute, Toronto, On, Canada, ²Eicosis Human Health Inc., Davis, Ca, United States

P065 Operational Strategies for Executing Complex, Dose-Escalation Phase 1 Alzheimer's Disease Clinical Trials

Presenteur : Bob Dagher

Bob Dagher
Clinilabs, Eatontown, United States

P066 First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects

Presenteur : Anil Shinde

Anil Shinde, Vinod Kumar Goyal, Veera Raghava Chowdary Palacharla, Ramkumar Subramanian, Satish Jetta, Pradeep Jayarajan, Vijay Benade, Santosh Kumar Pandey, Dhanunjay Dogiparti, Ilayaraja Kalaikadhiban, Abdul Rasheed Mohammed, Ramakrishna Nirogi, Venkat Jasti
Suven Life Sciences, Hyderabad, India

P067 THN391 – A First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: Update of an Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease

Presenteur : Aaron B. Kantor

Nuno Mendonca¹, Aaron B. Kantor¹, Tanja A.M. Hoffman¹, Sarah Kavanagh¹, Henk J.M.M. Mutsaerts², Frederik Barkhof², Khalid Abd-Elaziz³, E. Jort G.B. Vijverberg², Catherine Mummery⁴, Craig Ritchie⁵
¹Therini Bio, Sacramento, Ca, United States, ²Amsterdam UMC, Amsterdam, The Netherlands, ³CTC Groningen, Groningen, The Netherlands, ⁴University College London Hospitals, London, United Kingdom, ⁵Scottish Brain Sciences, Edinburgh, United Kingdom

P068 Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH): Update on progress in a phase 2a proof-of-concept trial of a novel anti-neuroinflammatory small molecule drug candidate

Presenteur : Linda Van Eldik

Linda Van Eldik¹, Wendy Ziai², Lauren Sansing³, D. Martin Watterson⁴, Saktimayee Roy⁴, Daniel Hanley²
¹University of Kentucky, Lexington, United States, ²Johns Hopkins Univ, Baltimore, United States, ³Yale University, New Haven, United States, ⁴Northwestern University, Chicago, United States

P069 Global Exploratory Phase 2 Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of TML-6, a Synthetic Curcumin Analog Targeting the Autolysosomal Pathway in Early Alzheimer's Disease: Study Design and Rationale

Presenteur : Hiep Nguyen

Ih Jen Su^{1,2}, Chien-Hong Lin², Chia-Yu Hsu², Hui-Chen Wang², Hiep Nguyen³, Feng-Shiun Shie⁴
¹Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, Tainan City, Taiwan, ²Merry Life Biomedical Company, Tainan City, Taiwan, ³Nguyen Scientific, Encinitas, United States, ⁴Center for Neuropsychiatric Research National Health Research Institutes, Zhunan Town, Taiwan

P070 Clinical and Biomarker Characteristics of Persons with Tau PET Deposits in the Medial Temporal Lobe Only

Presenteur : Lynne Hughes

Douglas Beauregard¹, Richard Mohs¹, Robin Wolz², Lynne Hughes¹, Amanda Ng¹, John Dwyer¹

¹Global Alzheimer's Platform Foundation, Washington, DC, United States; ²IXICO, London, United Kingdom

P071 Baseline probable CAA phenotype, lobar microbleeds, and multispot white matter hyperintensities predict clinically consequential ARIA during anti-amyloid therapy

Presenteur : Wai-Ying Wendy Yau

Wai-Ying Wendy Yau¹, Elizabeth Moore¹, Era Laho², Ron Danziger¹, Bradford Dickerson¹, Sheena Baratono¹, Kirk Daffner¹, Teresa Gomez-Isla¹, Nathan Praschan¹, Sokratis Charisis¹, John Dickson¹, Michael Erkinen³, Mariel Kozberg¹, Liliana Ramirez-Gomez¹, Jeremy Ford⁴

¹Mass General Brigham Department of Neurology, Harvard Medical School, BOSTON, United States; ²Mass General Brigham Department of Neurology, BOSTON, United States; ³Department of Neurology, University of California Davis, Sacramento, United States; ⁴Mass General Brigham Department of Radiology, Harvard Medical School, BOSTON, United States

P072 Comparison of NeuroEXPLORER PET system and conventional PET/CT in measuring regional tau burden in Alzheimer's disease

Presenteur : Christopher van Dyck

Alexandra Difilippo, Ryan O'Dell, Daniel Camacho, William Wakefield, Katerina Allanson, Natalie Baer, Yannis Cavrel, Richard Carson, Adam Mecca, Christopher Van Dyck

Yale University, New Haven, United States

P073 Automated FLAIR volumetry of ARIA-E under lecanemab and donanemab: agreement with clinical grading, interval change, and an audit of the manual reference

Presenteur : Zahra Khodakarami

Zahra Khodakarami, Sandhitsu Das, David Wolk, Christopher Brown, Paul Yushkevich

University of Pennsylvania, Philadelphia, United States

P074 Laromestrol preserves brain volume and cognitive function in Alzheimer's disease by inhibiting neuroinflammation

Presenteur : Brian Rash

Brian Rash¹, Sofya Levitina¹, Jeffrey Botbyl², Chris Conklin³, Madhura Ingahalikar³, Joshua Hare¹

¹Longeveron Inc, Miami, United States; ²Provonix Inc, Sewell, United States; ³Clario Inc, Philadelphia, United States

P075 Nicotinamide Riboside Supplementation in Mild Cognitive Impairment and Mild Alzheimer's Disease: Target Engagement and Downstream Effects of Mitochondrial Function and Oxidative Stress

Presenteur : Fei Du

Fei Du¹, Chao Wang¹, Abigail Stein¹, Boyu Ren¹, Edward De La Cruz¹, Kimaya Alysa Reddy¹, Ellis Reardon², Regan Eric Partirck¹, Lpsit Vahia¹, Dost Öngür¹, Brent P. Forester²

¹McLean Hospital, Mass-General Brigham Department of Psychiatry, Harvard Medical School, Belmont, United States; ²Tufts Medical Center and Tufts University School of Medicine, Boston, United States

P076 Longitudinal amyloid-PET trajectories in subjects with early compared to late onset Alzheimer's disease: results from LEADS and ADNI study

Presenteur : Ganna Blazhenets

Ganna Blazhenets¹, Marlene Lin¹, Ani Eloyan², Kala Kirby³, Maryanne Thangarajah², Dustin Hammers³, Robert A Koeppe⁴, David N Soleimani-Meigooni¹, Susan M Landau⁵, William J Jagust⁵, Maria C Carrillo⁶, Bradford C Dickerson⁷, Liana G Apostolova³, Gil D Rabinovici¹, Renaud La Joie¹

¹Edward and Pearl Fein Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, United States; ²Department of Biostatistics, Center for Biostatistics and Health Data Science, Brown University School of Public Health, Providence, United States; ³Department of Neurology, Indiana University School of Medicine, Indianapolis, United States; ⁴Department of Radiology, University of Michigan, Ann Arbor, United States; ⁵Department of Neuroscience, University of California, Berkeley, United States; ⁶Medical and Scientific Relations, Alzheimer's Association, Chicago, United States; ⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States

P078 Early Cerebrovascular MRI Abnormalities in Diabetes: Non-Amyloid Pathway to Cognitive Impairment

Presenteur : Maria Vassilaki

Maria Vassilaki¹, Ekaterina Hofrenning¹, Angela Fought¹, Clifford Jack JR.¹, David Knopman¹, Jonathan Graff-Radford¹, Ronald Petersen¹, Zoe Arvanitakis^{2,3}, Prashanthi Vemuri¹

P077 Detection of tau pathology in patients with early Alzheimer's disease: Diagnostic performance of florquinital F 18 PET in pivotal phase 3 studies

Presenteur : Christopher C. Rowe

Christopher C. Rowe¹, Serge Gauthier², Kenji Ishii³, Keith Johnson⁴, Sterling C. Johnson⁵, Susan Landau⁶, Eric Reiman⁷, Koen Van Laere⁸, Luca Passamonti⁹, David Scott¹⁰, Alison Long¹¹, Sulantha S. Mathotaarachchi¹¹, Hartmuth C. Kolb¹¹, Antoine Leuzy¹¹, Samantha Budd-Haeberlein¹¹

¹Austin Health, Melbourne, Australia, ²McGill University, Montreal, Canada, ³Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁴Harvard Medical School, Boston, United States, ⁵University of Wisconsin-Madison, Madison, United States, ⁶University of California Wisconsin-Madison, Berkeley, United States, ⁷Banner Alzheimer's Institute, Phoenix, United States, ⁸University Hospitals Leuven, Leuven, Belgium, ⁹Lantheus, Bedford, United States, ¹⁰Clario, Philadelphia, United States, ¹¹Enigma Biomedical Group, Knoxville, United States

P079 DELTA-SVD: A Diffusion MRI Framework for Cerebrovascular Injury Relevant to Alzheimer's Disease Clinical Trials

Presenteur : Marco Duering

Anna Dewenter¹, Benno Gesierich², Julie Rutten³, Daniel Tozer⁴, Pauline Maillard⁵, Frank-Erik De Leeuw⁶, Prashanthi Vemuri⁷, Nicolai Franzmeier¹, Karl G. Helmer⁸, Steven M. Greenberg⁹, Anand Viswanathan⁹, Saskia Lesnik Oberstein³, Hugh S. Markus⁴, Martin Dichgans¹, Marco Duering²

¹Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Medizin, LMU Munich, Munich, Germany, ²Antaros Medical AB, Mölndal, Sweden, ³Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, ⁴Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, ⁵Department of Neurology, University of California, Davis, Davis, United States, ⁶Radboud University Medical Center, Department of Neurology, Research Institute for medical research and Innovation, Nijmegen, The Netherlands, ⁷Department of Radiology, Mayo Clinic, Rochester, United States, ⁸Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, United States, ⁹Department of Neurology, J. Philip Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, United States

P080 Robustness of Amyloid PET on a Brain-Dedicated PET Scanner in Real-World Neurology Practice: Quantification Stability and Visual-Read Agreement

Presenteur : Camilia Hoorvash

Camilia Hoorvash¹, Matthias Brendel², Dario Dhoqina², Johannes Sebastian Gnoerich², Alvaro Carpio Chicote¹, Jannis Fischer¹, Michael Shriver³

¹Positron AG, Zurich, Switzerland, ²Ludwig-Maximilians-Universität München, Germany, Munich, Germany, ³Proscan Imaging, Naples, United States

P081 Contribution of the automated MRI segmentation of the brain trophicity in the diagnosis of Lewy Body Disease in a clinical center

Presenteur : Claire Paquet

Christine Delmaire¹, Julien Savatovsky², Claire Hourregue³, Esteban Munoz³, Emmanuel Morain³, Fabien Hauw³, Agathe Vrillon³, Claire Paquet³

¹Fondation Rothschild, Radiology, Paris, France, ²Fondation Rothschild, Radiology - Paris (France), Paris, France, ³Hôpital Fernand Widal, Assistance Publique Hôpitaux de Paris, Centre de Neurologie Cognitive - Paris (France), Paris, France

P082 Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer's disease spectrum

Presenteur : Gerard Nisal Bischof

Gerard Nisal Bischof^{1, 2}, Lukas Frontzkowski³, Marianthi Zeinaki³, Boris-Stephan Rauchmann³, Johannes Gnörich³, Dario Dhoqina³, Günther Höglinger^{4, 5, 6}, Rudolf.A Werner³, Gemma Salvado^{7, 8}, David Vallez-Garcia⁷, Robert Perneczky^{9, 10}, Norman Koglin¹¹, Nicolai Franzmeier¹², Andrew Stephens¹¹, Matthias Brendel^{13, 14, 15}

¹Lantheus GmbH Germany, Berlin, Germany, ²University Hospital Cologne, Germany, Cologne, Germany, ³University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, Germany, Munich, Germany, ⁴German Center for Neurodegenerative Diseases, DZNE, Munich, Germany, Munich, Germany, ⁵Munich Cluster for Systems Neurology, SyNergy, Munich, Germany, Munich, Germany, ⁶University Hospital, LMU Munich Department of Neurology, Munich, Germany, ⁷BarcelonaBeta Brain Research Center (BBRC), Barcelona, Spain, ⁸University Hospital, LMU Munich, Institute for Stroke and Dementia Research (ISD), Munich, Spain, ⁹University Hospital, LMU Munich, Department of Psychiatry and Psychotherapy, Munich, Germany, ¹⁰Germany; German Center for Neurodegenerative Diseases, DZNE, Munich, Germany, Munich, Germany, ¹¹Lantheus Germany GmbH, Berlin, Germany, ¹²Munich Cluster for Systems Neurology, SyNergy, Munich, Germany, Munich, Germany, ¹³University Hospital, LMU Munich, Department of Nuclear Medicine, Munich, Germany, Munich, Germany, ¹⁴German Center for Neurodegenerative Diseases, DZNE, Munich, Munich, Germany, ¹⁵Munich Cluster for Systems Neurology, SyNergy, Munich, Germany, Munich, Germany

P084 Alzheimer disease in Down syndrome: A decade of biomarker discovery and a pathway to clinical trials.

Presenteur : Elizabeth Head

Elizabeth Head¹, Mark Mapstone¹, Bradley Christian², Benjamin Handen³, Michael Rafii⁴

¹University of California Irvine, Irvine, United States, ²University of Wisconsin, Madison, Madison, United States, ³University of Pittsburgh, Pittsburgh, United States, ⁴University of Southern California, Los Angeles, United States

P085 Spatiotemporal Emergence and Longitudinal Progression of Tau-PET Pathology in Autosomal Dominant Alzheimer Disease: Implications for Prevention Trial Design

Presenteur : Savannah Tiemann Powles

Savannah Tiemann Powles¹, Nicole McKay¹, Shaney Flores¹, Julie Wisch¹, Edita Sabaredzovic¹, Sarah Keefe¹, Guoqiao Wang¹, Jalen Scott¹, T. Hunter Smith¹, Stephanie Doering², Eric McDade¹, Randall Bateman¹, Brian Gordon¹, . Dominantly Inherited Alzheimer Network³, Tammie Benzinger¹

¹Washington University in St. Louis School of Medicine, St. Louis, United States, ²Massachusetts General Hospital, Boston, United States, ³Observational Study and Trials Unit

P086 Do superagers in various cognitive domains show resistance to imaging-based neuropathologies? The Lifeafter90 Study

Presenteur : Batool Rizvi

Batool Rizvi¹, Hilary Colbeth¹, Rifat Alam¹, Alexander Posis¹, Katherine Colcord², Charles Decarli¹, Dan Mungas¹, Paola Gilsanz³, Maria Corrada², Rachel Whitmer⁴

¹UC Davis, Davis, United States, ²UC Irvine, Irvine, United States, ³Kaiser Permanente Northern California Division of Research, Pleasanton, United States, ⁴UC Davis, Irvine, United States

P087 Point-of-Care Low-Field MRI for Monitoring ARIA-E and Pseudoatrophy During Anti-Amyloid Therapy

Presenteur : Annabel Sorby-Adams

Annabel Sorby-Adams¹, Ava Farnan¹, Shenghua Zhu¹, John R. Dickson¹, Liliana Ramirez-Gomez², Alberto Serrano-Pozo¹, Arman Fesharaki-Zadeh³, Matthew S. Rosen⁴, Jeremy Ford⁵, Kevin N. Sheth³, Adam De Havenon³, J. Eugenio Iglesias⁴, Teresa Gomez-Isla¹, W. Taylor Kimberly¹

¹Department of Neurology, Mass General Brigham and Harvard Medical School, Boston, United States, ²Department of Neurology, Mass General Brigham and Harvard Medical School - Boston, Boston, United States, ³Yale Center for Brain & Mind Health, Yale New Haven Hospital and Yale Medical School, New Haven, United States, ⁴Athinoula A. Martinos Center for Biomedical Imaging, Mass General Brigham and Harvard Medical School, Boston, United States, ⁵Department of Radiology, Mass General Brigham and Harvard Medical School, Boston, United States

P088 A practical correction for non-specific [18F]MK-6240 uptake to improve tau PET quantification for early detection

Presenteur : Praveen Honhar

Praveen Honhar¹, Jessie Fanglu Fu¹, Amal Tiss², Michael Properzi³, Aaron Schultz¹, Julie Price¹, Keith Johnson¹

¹Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, United States, ²Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, United States, ³Massachusetts General Hospital, Boston, United States

P089 Tau PET spatial patterns for trial-relevant measurement of tau progression in preclinical AD: AHEAD-3/45 and HABS

Presenteur : Stephanie Doering

Jessie Fanglu Fu¹, Stephanie Doering¹, Praveen Honhar¹, Amal Tiss¹, Emma Thibault¹, Eva Pintucci¹, Elliott Slade¹, Alex Becker¹, Michelle Farrell¹, Michael Properzi¹, Aaron Schultz¹, Reisa Sperling¹, Julie Price¹, Keith Johnson¹, Actc Ahead 3-45 Study Team²

¹Massachusetts General Hospital, Boston, United States, ²Alzheimer Clinical Trials Consortium, , United States

P090 Predicting Amyloid PET Positivity from a Brief Digital Cognitive Assessment in Memory Clinic Patients

Presenteur : Ali Jannati

David Libon¹, Mitchel Kling¹, Ali Jannati², Kallie Sweetman¹, Jacqueline Nguyen¹, Ileana De Anda-Duran³, Rod Swenson⁴, Sean Tobbyne², Alvaro Pascual-Leone^{2,5}

¹Rowan University, Glassboro, United States, ²Linus Health, Boston, United States, ³Tulane University, New Orleans, United States, ⁴University of North Dakota, Grand Forks, United States, ⁵2Hebrew SeniorLife - Harvard Medical School, Boston, United States

P091 Radiology Inferred CAA as a Potential Biomarker: Links to Pathology Timing, Cognition, and Proteomics

Presenteur : Julie Oomens

Julie Oomens¹, Ramiro Eduardo Rea Reyes¹, Leonardo Rivera-Rivera¹, Mai Abdelmoaty², Rachael Wilson², Sterling Johnson¹

¹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, ²Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P092 AIND: A Validated AI-Derived Neurodegeneration Marker for Alzheimer's Disease Clinical Trials

Presenteur : David Vaillancourt

David Vaillancourt¹, Jesse Desimone², Robin Chen¹, Shannon Chiu³, Wei-En Wang¹, Freydel Espinoza-Urbina¹, Angelos Barmoutis¹

¹University of Florida, Gainesville, United States, ²Neuropacs, Gainesville, United States, ³Mayo Clinic, Phoenix, United States

P093 Baseline Radiologic Predictors of ARIA-E and ARIA-H: A Quantitative AI-Supported MRI Analysis of a US Real-World Cohort

Presenteur : Mark Pippenger

Mark Pippenger¹, Nuno Pedrosa De Barros², Dirk Smeets², Arno Liseune², Ricardo Magalhaes², Diana Sima², Thibo Billiet², Wim Van Hecke², Aaron Ritter³, Bela Ajtai⁴, Keith Schluterman⁵, Kinyee Fong⁶, Boyang Bian⁶, Nick Belviso⁶, Lydia Wood⁶

¹Baptist Health Medical Center, North Little Rock, United States, ²icomatrix, Leuven, Belgium, ³Hoag Medical Center, Newport Beach, United States, ⁴DENT Neurologic Institute, Amherst, United States, ⁵Conway Regional Neuroscience Center, Conway, United States, ⁶Biogen, Cambridge, United States

P094 Incidence of Aβ-PET-positivity and tau-PET-positivity in individuals without dementia

Presenteur : Emma Coomans

Emma Coomans^{1,2}, Colin Groot^{1,2}, Rik Ossenkoppele^{1,2}

¹Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands, ²Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands

P095 Sex, education and race/ethnicity have distinct effects on amyloid and tau-PET status

Presenteur : Colin Groot

Colin Groot, Emma Coomans, Rik Ossenkoppele

Amsterdam UMC, Amsterdam, The Netherlands

P096 Burden-dependent bias of cerebellar reference regions in amyloid PET monitoring of disease-modifying therapy: eroded white matter as a calibratable anchor

Presenteur : Sang Won Seo

Sang Won Seo¹, Soo Hyun Cho², Seongmi Kim¹, Duk L Na³, Seongbeom Park⁴, Kichang Kwak⁴, Hee Jin Kim¹, Jun Pyo Kim¹, Seunghwan Moon¹

¹Samsung medical center, Seoul, Korea, Republic of, ²Chonnam National University Hospital, Gwangju, Korea, Republic of, ³HappyMind Clinic, Seoul, Korea, Republic of, ⁴BeauBrain Healthcare, Seoul, Korea, Republic of

P097 Amyloid load in the precuneus is associated with lack of response to anti-amyloid treatment in preclinical Alzheimer's disease.

Presenteur : Annalena Venneri

Annalena Venneri, Matilde Grilli, Riccardo Manca
University of Parma, Parma, Italy

P098 Outpatient Medications and Risk of Amyloid-Related Imaging Abnormalities in a Memory Clinic Population Receiving Anti-Amyloid Therapy

Presenteur : Sokratis Charisis

Sokratis Charisis, John Dickson, Yingnan He, Cinthya Aguero Murillo, Jeremy N Ford, Michael G Erkkinen, Liliana A Ramirez Gomez, Katelyn Mary Horan, Wedgina Norelus, Sheena R Baratonio, Elmira Hassanzadeh, Nathan C Praschan, Sudeshna Das, Kirk R Daffner, Teresa Gomez-Isla
Mass General Brigham, Boston, United States

P099 Towards clinical CMB detection: a two-stage deep learning approach utilising synthetic data

Presenteur : Robin Wolz

Anita Karsa¹, Richard Joules¹, Jane Waugh¹, Luigi Lorenzini², Frederik Barkhof^{2,3}, Robin Wolz¹
¹IXICO, London, United Kingdom, ²Amsterdam UMC, Amsterdam, The Netherlands, ³University College London, London, United Kingdom

P100 Integration of neuroimaging signatures of aging and Alzheimer's disease with plasma biomarkers for the detection and prediction of cognitive impairment

Presenteur : Mitzi Gonzales

Mitzi Gonzales¹, Ngoc Huynh Ho², David Wang², Sachintha Brandigampala², Tanweer Rashid², Mengjin Dong², Sokratis Charisis², Timothy Hohman³, Sudha Seshadri², Christos Davatzikos⁴, Kristine Yaffe⁵, Jon Toledo⁶, Mohamad Habes²
¹Cedars-Sinai, Los Angeles, United States, ²UT Health San Antonio, San Antonio, United States, ³Vanderbilt, Nashville, United States, ⁴University of Pennsylvania, Philadelphia, United States, ⁵University of California San Francisco, San Francisco, United States, ⁶Houston Methodist, Houston, United States

P101 Rapid tau proliferation at different amyloid stages based on initial tauopathy

Presenteur : Michelle Farrell

Michelle Farrell¹, Emma Thibault¹, Elliott Slade¹, Fanglu Fu¹, Julie Price¹, Brian Healy¹, Heidi Jacobs¹, Rachel Buckley², Reisa Sperling², Keith Johnson²
¹Massachusetts General Hospital, Harvard Medical School, Boston, United States, ²Massachusetts General Hospital, Brigham & Women's Hospital, Harvard Medical School, Boston, United States

P102 Regional Amyloid PET Quantification for Re-review of Global Centiloid-Negative Scans in ADNI and IDEAS

Presenteur : Regina Ey Kim

Yeong Sim Choe¹, Hyunjae Yu¹, Mijung Park¹, Renaud La Joie², Gil Rabinovici², Regina Ey Kim¹, Donghyeon Kim¹
¹Research Institute, Neurophat Inc, Seoul, Korea, Republic of, ²Department of Neurology, Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, United States

P103 Predicting Regional Tau-PET SUVR using Plasma and Structural MRI Biomarkers

Presenteur : Thomas Kirk

Sofiia Tatosh¹, Armen Bodossian¹, Logan Zhang¹, Thomas Kirk¹, Martin Craig¹, Michael Chappell^{1,2}
¹Quantified Imaging, London, United Kingdom, ²School of Medicine, University of Nottingham, Nottingham, United Kingdom

P105 Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium

Presenteur : Timothy Hohman

Timothy Hohman
Vanderbilt University Medical Center, Nashville, United States

P107 Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort

Presenteur : Yuta Katsumi

Yuta Katsumi¹, Neguine Rezaii¹, Kirk Daffner², John Dickson¹, Jeremy Ford¹, Seth Gale², Teresa Gomez-Isla¹, Gad Marshall², Liliana Ramirez Gomez¹, Dennis Selkoe², Hyun-Sik Yang², Wai-Ying Yau¹, Mark Eldaief¹, Scott McGinnis², Bradford Dickerson¹
¹Massachusetts General Hospital, Boston, United States, ²Brigham and Women's Hospital, Boston, United States

P108 Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE 4 selectively influence lobar microhemorrhages

Presenteur : Zahra Shirzadi

Zahra Shirzadi¹, Nazila Loghmani², Aaron Schultz¹, Wai-Ying Yau¹, Hyun-Sik Yang¹, Roy Yaari³, Michael Properzi¹, Michael S. Rafii⁴, Clifford R. Jack Jr⁵, Steven M. Greenberg¹, Paul Aisen⁴, Reisa A. Sperling¹, Jasmeer P. Chhatwal¹
¹Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, ²Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, , United States, ³Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States, ⁴Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ⁵Mayo Clinic, Radiology, Rochester, United States

P109 Comparison of test-retest variability and longitudinal stability of total intracranial volume measurement between atlas-based and segmentation-based MRI methods

Presenteur : **Luc Bracoud**

Thomas Cajgfinger¹, Alessandro Delmonte¹, Madhura Ingahalikar², Chris Conklin², Joel Schaerer³, Meredith Burke⁴, David Scott⁴, Luc Bracoud¹

¹Clario, part of Thermo Fisher Scientific, Lyon, France, ²Clario, part of Thermo Fisher Scientific, Philadelphia, United States minor outlying islands, ³Clario, part of Thermo Fisher Scientific, Geneva, Switzerland, ⁴Clario, part of Thermo Fisher Scientific, Philadelphia, United States

P110 Longitudinal evolution of enlarged perivascular spaces across the AD continuum

Presenteur : **Luc Bracoud**

Luc Bracoud¹, Alessandro Delmonte¹, Thomas Cajgfinger¹, Madhura Ingahalikar², Chris Conklin², Joel Schaerer³, Meredith Burke², David Scott²

¹Clario, part of Thermo Fisher Scientific, Lyon, France, ²Clario, part of Thermo Fisher Scientific, Philadelphia, United States, ³Clario, part of Thermo Fisher Scientific, Geneva, Switzerland

P111 Retinal layer thickness predicts cerebral amyloid burden in preclinical Alzheimer's disease

Presenteur : **Jordan Sergio**

Jordan Sergio^{1, 2, 3}, Cyrus Raji⁴, Ashley Bernardo^{1, 2}, Megan Stradtman⁵, Savannah A. Doster^{2, 3}, Rachel Lacroix^{3, 5}, Emma T. Larracey^{2, 3}, Mahshid Naghashzadeh⁴, Mobina Amanollahi⁴, Soheil Mohammadi⁴, Mona Mirbeyk⁴, Mahsa Dolatshahi⁴, Peter Snyder^{1, 2, 6}, Jessica Alber^{1, 2, 3, 6}

¹Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, United States, ²Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, United States, ³Butler Hospital Memory & Aging Program, Providence, United States, ⁴Neuroimaging Labs Research Center at Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, United States, ⁵Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United States, ⁶George & Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, United States

P112 – Remote MRI-based enrichment for pathology-targeted progressive supranuclear palsy trials in non-fluent variant primary progressive aphasia

Presenteur : **Jesús García-Castro**

Jesús García-Castro¹, Maria Luisa Mandelli², Alexandre Bejanin¹, Oriol Dols-Icardo¹, Juan Fortea¹, Daniel Alcolea¹, Alberto Lleó¹, Kejal Kantarci³, Hilary W. Heuer², Howard Rosen², Brad Boeve³, Adam Boxer², Zachary Miller², Maria Luisa Gorno-Tempini², Ignacio Illán-Gala¹

¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²Memory and Aging Center, UCSF, San Francisco, United States, ³Mayo Clinic, Rochester, United States

P113 Evaluation of atrophy-defined subtypes in early symptomatic Alzheimer's disease

Presenteur : **Vikas Kotari**

Mintao Liu, Vikas Kotari, Jiaying Guo, Adam S. Fleisher, Rik Ossenkoppele, Sergey Shcherbinin

Eli Lilly and Company, , United States

P114 Distinct Associations Between Hippocampal Subfield Volumes and Episodic Memory in Alzheimer's Disease

Presenteur : **Giulia Tronchin**

Giulia Tronchin, Mintao Liu, Tina Wang, Alette Maria Wessels, Ming Lu, Vikas Kotari, Sergey Shcherbinin

Eli Lilly and Company, Indianapolis, United States

P115 Therapeutic Amyloid Reduction and Cortical Excitability in Alzheimer's Disease (TRACE-AD) Study Protocol and Early-Stage Findings.

Presenteur : **Basma Gomaa**

Basma Gomaa^{1, 2}, Stephanie Buss^{1, 2}

¹Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Boston, United States, ²Department of Neurology, Harvard Medical School, Boston, United States

P116 – Remote Advanced Arterial Compliance Impairment Is Associated with Tau Accumulation and Progressive Neurodegeneration

Presenteur : **Young Noh**

Young Noh¹, Jaelim Cho², Yeo Jin Kim³, Ha-Eun Seo⁴, Daegyeom Kim⁴, Jihyun Bae⁴, Sang-Yoon Lee⁵, Kee Hyung Park⁶, Geert Jan Biessels⁷, Jae-Hong Lee⁸, Keun-Hwa Jung⁹

¹Department of Neurology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of, ²Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Department of Neurology, Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of, ⁴Neuroscience Research Institute, Gachon University, Incheon, Korea, Republic of, ⁵Department of Neuroscience, College of Medicine, Gachon University, Incheon, Korea, Republic of, ⁶Department of Neurology, Gachon University Gil Medical Center, Incheon, Korea, Republic of, ⁷Department of Neurology, UMC Utrecht, Utrecht, The Netherlands, ⁸Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of, ⁹Department of Neurology, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of

P117 The Pronghorn Sign: Hunting for a Radiologic Biomarker in LBD

Presenteur : **Preston Roche**

Preston Roche¹, Samy Abdullah¹, James Rini², Leila Saadatpour^{1, 3}, Alicia Parker^{1, 3}, Tanvi Kosuri¹

¹UT San Antonio, San Antonio, United States, ²OCHSNER Health, New Orleans, United States, ³Biggs Institute, United States

P118 Tau PET signature of amyloid PET visual-positive/quantitative-negative discordance despite low global amyloid burden in ADNI

Presenteur : **Saki Nakashima**

Saki Nakashima¹, Kenichiro Sato², Yoshiaki Niimi², Wataru Satake¹, Takeshi Iwatsubo³

¹Department of Neurology, Graduate School of Medicine, The University of Tokyo - Tokyo (Japan), Tokyo, Japan, ²Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan, Tokyo, Japan, ³National Center of Neurology and Psychiatry, Tokyo, Japan

ARTIFICIAL INTELLIGENCE-DRIVEN INNOVATION IN ALZHEIMER'S THERAPEUTICS

P120 Causal modeling using Gemini Digital Twins identifies SPI1 as a potential modifier of neurodegenerative disease progression

Presenteur : [Apoorva Bharthur Sanjay](#)

Apoorva Bharthur Sanjay, So-Youn Shin, Li Sun, Jean-Michel Gries, Jeanne Latourelle
Aitia, Cambridge, United States

P121 Predicting blood-brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer's disease using artificial intelligence

Presenteur : [Alexander Morin](#)

Alexander Morin¹, Rick Fontenot², Panna Sharma², Maria Maccocchi¹
¹Annovis Bio, Malvern, United States, ²Lantern Pharma, Dallas, United States

P122 Improved Performance and Fairness of Dementia Risk Stratification from Claims Data with Machine Learning

Presenteur : [Daniel Schulman](#)

Daniel Schulman¹, Ali Jannati^{1,2}, Sean Tobyne¹
¹Linus Health Inc, Boston, MA, United States, ²Harvard Medical School, Boston, MA, United States

P123 GPND-AI Treatment: A Trajectory Monitor for Treatment Responses

Presenteur : [Ying Xu](#)

Ying Xu¹, Rui Mu¹, Alex Roussak¹, Menghan Liu¹, Yike Chen¹, John Budde¹, Steven Funk¹, Tammie L. S. Benzinger², John C. Morris³, David M. Holtzman³, B Joy Snider³, Randall J. Bateman³, Suzanne E. Schindler³, Carlos Cruchaga¹
¹Department of Psychiatry, Washington University School of Medicine, St Louis, United States, ²Department of Radiology, Washington University School of Medicine, St Louis, United States, ³Department of Neurology, Washington University School of Medicine, St Louis, United States

P124 FINGERS-7B: A Multi-Omic Foundation Model for Precision Biomarker Discovery

Presenteur : [Arvid Gollwitzer](#)

Arvid Gollwitzer^{1,2}, Adrian Noriega De La Colina^{1,2,3}, Li-Huei Tsai^{1,4}, Miia Kivipelto^{5,6}, Giovanni Traverso^{1,2,7}
¹Broad Institute of MIT and Harvard, Cambridge, United States, ²Massachusetts Institute of Technology, Cambridge, United States, ³Brigham and Women's Hospital, Boston, United States, ⁴The Picower Institute for Learning and Memory, Cambridge, United States, ⁵FINGERS Brain Health Institute, Stockholm, Sweden, ⁶Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁷Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States

P125 AI-based prognostic stratification accurately predicts future clinical decline and increases observed decline in symptomatic and preclinical AD placebo arms

Presenteur : [Luca Villa](#)

Luca Villa, Zi Hui Su, Ayoub Gueddou, Mathilde Borrot, Nicolas Guizard, Elizabeth Gordon
Gynapse, 2-10 rue d'Oradour-sur-Glane, 75015 Paris, France, Paris, France

P126 Characteristics, trajectories, and Alzheimer's disease biomarkers in subjective cognitive decline: a proposal for a management framework in clinical and research settings

Presenteur : [Salvatore Mazzeo](#)

Salvatore Mazzeo^{1,2}, Michael Lassi³, Sonia Padiglioni^{4,5}, Alberto Arturo Vergani^{3,6}, Valentina Moschini⁴, Giulia Giacomucci⁴, Carmen Morinelli⁴, Silvia Bagnoli⁷, Assunta Ingannato⁷, Maria Salzone^{1,2}, Massimo Filippi⁸, Benedetta Nacmias^{7,9}, Antonello Grippo^{10,9}, Alberto Mazzoni³, Valentina Bessi^{10,7}
¹Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³The BioRobotics Institute and Department of Excellence in Robotics and AI, Scuola Superiore Sant'Anna, Pisa, Italy, ⁴SOD Neurologia, Dipartimento Neuromuscolo-Scheletrico e degli Organi di Senso, AOU Careggi, Florence, Italy, ⁵Regional Referral Centre for Relational Criticalities - Tuscany Region, Florence, Italy, ⁶Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy, ⁷Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, ⁸Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, "Vita-Salute" San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy, ⁹IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy, ¹⁰SODC Neurofisiopatologia, Azienda Ospedaliero-universitaria Careggi, Florence, Italy

P127 Artificial Intelligence-Guided Drug Repurposing for Alzheimer's Disease Based on the Unified Theory of Neurodegenerative, Metabolic, and Cardiovascular Diseases

Presenteur : [Lloyd Tran](#)

Lloyd Tran, Michael Willis, Zung Tran
Biomed AI, Inc., San Jose, United States

P128 AI-Enabled Analysis of Anti-A β Clinical Trial Outcomes Supports Investigation of the Neurogenesis-Based Therapeutic Candidate NA-831 for Alzheimer's Disease

Presenteur : [Lloyd Tran](#)

Lloyd Tran, Michael Willis, Zung Tran
Biomed AI, Inc., San Jose

P129 AI-designed disulfide-cyclized peptides targeting transferrin receptor 1: a computational-to-experimental pipeline for blood-brain barrier shuttle development

Presenteur : Weiwei Ma

Weiwei Ma¹, Dapeng Jiang², Bowen Gao², Yanyan Lan²

¹Aipher (beijing) Technology, beijing, China, ²Tsinghua Univ., beijing, China

P130 Feasibility of Automated ARIA-E Assessment on Data Collected From Portable MR Imaging Systems: A Case Series

Presenteur : Yoselyn Garcia

Yoselyn Garcia¹, Kayla Tran¹, Somphanh Khousakoun¹, Simon Eyndhoven², Rafay Khan²

¹Tampa Bay Neurocognitive Institute, Clearwater, United States, ²GE HealthCare, Leuven, Belgium

P131 Machine Learning Improves Error Detection for the CDR through Precision Endpoint Protection.

Presenteur : Selam Negash

Selam Negash, Matt Welch, Danielle Di Gregorio, Dorothee Schoemaker, Shelly Steele, Briana Webber-Lind, Barbara Echevarria, David Ju, Chris Randolph

Clario, part of Thermo Fisher Scientific, Philadelphia, United States

P132 Radiomics Classification of Amyloid Status on Florbetapir PET

Presenteur : Elif Sikoglu

Elham Yousef Kalafi¹, Samuel Lockhart^{1,2}, Victoria Hegedus¹, Ryan Petrulli¹, David Cash^{1,3}, Elif Sikoglu¹

¹Perceptive, Burlington, United States, ²Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, ³UCL Queen Square Institute of Neurology, London, United Kingdom

P133 Automated visual assessment of amyloid PET images through deep-learning classification

Presenteur : Elif Sikoglu

Anand Kadumberi¹, Samuel Lockhart^{1,2}, David Cash^{1,3}, Elif Sikoglu¹

¹Perceptive, Burlington, United States, ²Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, ³UCL Queen Square Institute of Neurology, London, United Kingdom

P134 Application of Data Mining and AI LLM Tools to enhance recruitment for an MCI clinical trial

Presenteur : Gloria Xie

Murali Doraiswamy, Gloria Xie

Duke University Medical Center, Durham, United States

P135 — Remote AI-Assisted Review Support Tool for Clinical Operations and Data Reconciliation in a Global Phase 3 Alzheimer's Disease Trial

Presenteur : Phil Kang

Phil Kang, Lisa Vaden, Ja Yeon Shin, Fred Kim, Jai Jun Choung

AriBio Co., Ltd., San Diego, United States

P136 Cross-sectional and longitudinal factor analysis of everyday activity and cognition in cognitively unimpaired older adults: the Stanford Aging and Memory Study 7-Year Follow-Up

Presenteur : Irina Skylar-Scott

Olivia Lu¹, Kenyon Weis¹, Zihai He¹, Valerie Carr², Alexandra Trelle¹, Christina Young¹, Joseph Winer¹, America Romero¹, Hillary Vossler¹, Jennifer Park¹, Sharon Sha¹, Deutch Gayle¹, Wilson Edward¹, Anthony Wagner¹, Irina Skylar-Scott¹

¹Stanford University, Palo Alto, United States, ²San Jose State University, . United States

P137 Blood Pressure and Amyloid-Related Imaging Abnormalities During Anti-Amyloid Therapy: An Exploratory Meta-Analysis

Presenteur : Sarah Ackley

Sirui Zhang, Michelle Caunca, Michael Flanders, Kaleen Hayes, Sarah Ackley
Brown University, Providence, United States

P138 Frailty is associated with faster clinical progression in early symptomatic Alzheimer's disease: implications for anti-amyloid therapy

Presenteur : Nicholas Vogt

Nicholas Vogt^{1,2,3}, Heidi Jacobs^{4,5}, Wai-Ying Wendy Yau^{6,7}, Alvaro Pascual-Leone^{1,2,7}, Daniel Press^{8,3}, Dae Hyun Kim^{1,9,3}

¹Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, United States, ²Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States, ³Department of Medicine, Harvard Medical School, Boston, United States, ⁴Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, United States, ⁵Department of Radiology, Harvard Medical School, Boston, United States, ⁶Department of Neurology, Massachusetts General Hospital, Boston, United States, ⁷Department of Neurology, Harvard Medical School, Boston, United States, ⁸Beth Israel Deaconess Medical Center, Boston, United States, ⁹Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, United States

P139 Variability in mild cognitive impairment incidence rates across study populations

Presenteur : Emmanuel Papadakis

Emmanuel Papadakis, Jeremiah Aakre, Jonathan Graff-Radford, Mary Machulda, Prashanthi Vemuri, Sophia Graff-Radford, Clifford Jack Jr, David Knopman, Maria Vassilaki, Ronald Petersen
Mayo Clinic, Rochester, United States

P140 Reciprocal Associations Between Alzheimer's Disease and Colorectal Cancer in Older Adults: A Real-World Cohort Analysis With Evaluation of Competing Mortality

Presenteur : Yuji Zhang

Yuji Zhang, Kathryn Barry, Sally Adebamovo, Michelle Shardell
University of Maryland Baltimore, Baltimore, United States

P141 Roles of coagulation factors targeted by existing or potential anticoagulants in Alzheimer's disease: Mendelian randomization study

Presenteur : Man Ki Kwok

Man Ki Kwok¹, Ian Chi Kei Wong², Stephen Burgess³, Pak Chung Sham²

¹Hong Kong Metropolitan University, Hong Kong, ²The University of Hong Kong, Hong Kong, ³University of Cambridge, United Kingdom

P142 Physical Activity and Domain-Specific Cognitive Function in Older Adults by Hypertension Status: A Longitudinal Analysis of the Health and Retirement Study Harmonized Cognitive Assessment Protocol

Presenteur : Mohammad Moniruzzaman

Mohammad Moniruzzaman, Kelvin Choi
National Institute on Minority Health and Health Disparities, Bethesda, United States

P143 – Remote A Bayesian Data-Integration Framework for Estimating Diagnosed and Undiagnosed Dementia Burden at the County and State Level

Presenteur : Carolina Franco

Carolina Franco, Gianattasio Kan, Rein David
NORC at the University of Chicago, Dunkirk, United States

P144 Systemic inflammation and longitudinal trajectory of cognition and blood-based biomarkers of Alzheimer's Disease in a multiethnic community-based cohort

Presenteur : Yian Gu

Yian Gu, Lawrence Honig, Kang Min Suk, Sanchez Danurys, Reyes-Dumeyer Dolly, Manly Jennifer, Brickman Adam, Mayeux Richard
Columbia University, New York, United States

P145 Population-Adjusted Alzheimer's Clinical Trial Capacity in the United States: Reassessing the Perception of Site Saturation in High-Burden States

Presenteur : Sean Stanton

Sean Stanton, Sameer Saddiqui, Taylor Rice, Brandon Lenox, Craig Curtis
K2 Medical Research, Orlando, United States

P146 Pathology-Informed Polygenic Scores Identify Distinct Genetic Contributors to Alzheimer's and Non-Alzheimer's Dementia Across Ancestries

Presenteur : Yuexuan Xu

Yuexuan Xu¹, Tamil Gunasekaran¹, Yian Gu¹, Lawrence Honig¹, Jennifer Manly¹, Adam Brickman¹, Corinne Engelman², Sterling Johnson², Sid O'Bryan³, Caghan Kizil¹, Badri Vardarajan¹, Richard Mayeux¹

¹Columbia University, New York, United States, ²University of Wisconsin-Madison, Madison, United States, ³University of North Texas Health Science Center, Fort Worth, United States

P147 The effect of herpes zoster vaccination on full-time care use in people with and without cognitive complaints: a causal inference study using Swedish record-linkage data

Presenteur : Pieter Van Der Veere

Pieter Van Der Veere¹, Emil Aho¹, Johansson Naimi¹, Lövheim Hugo², Jönsson Linus¹

¹Karolinska Institutet, Stockholm, Sweden, ²Umeå University, Umeå, Sweden

P148 Characterization of Serious ARIA Events from Approved Amyloid Antibodies: Real World Analysis of Spontaneous Reports FDA Adverse Event Monitoring System (AEMS)

Presenteur : Soeren Mattke

Soeren Mattke¹, Tabasa Ozawa¹, Susan Abu-Shakra², John Hey²

¹University of Southern California, , United States, ²Alzheon, , United States

P149 Time Savings and Patient Preference for Subcutaneous Injection Versus Intravenous Infusion of Lecanemab

Presenteur : Cara Leahy

Cara Leahy¹, Victor Faradji², Lara Marcel², Feride Frech³, Hideki Toyosaki³, Dean Smith⁴

¹Memorial Healthcare Institute for Neuroscience, Owosso, United States, ²First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States, ³Eisai Inc., Nutley, United States, ⁴School of Public Health, University of Michigan, Ann Arbor, United States

P150 Peri-infusion Blood Pressure Reactivity as a Non-Invasive Marker of Cerebrovascular Amyloid Burden during Lecanemab Treatment in Early Alzheimer's Disease

Presenteur : So Yeon Jeon

So Yeon Jeon¹, Byung-Hyug Choi¹, Jung Hwan Kim², Yu Kyeong Kim¹, Jun-Young Lee¹

¹SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of, ²Seoul National University College of Medicine, Seoul, Korea, Republic of

P151 The population-level impact of herpes zoster vaccination on dementia-related and all-cause mortality: Evidence from country-wide death certificate data for England

Presenteur : Pascal Geldsetzer

Felix Michalik¹, Disser Michelle¹, Seunghun Chung¹, Min Xie¹, Markus Eyting¹, Mark Joy², Simon De Lusignan², Aziz Sheikh², Pascal Geldsetzer¹

¹Stanford University, Stanford, United States, ²Oxford University, Oxford, United Kingdom

P152 Clinical Practice Outcomes with Lecanemab for Alzheimer's Disease

Presenteur : Andy Liu

Andy Liu

Duke University, Durham, North Carolina, United States

P153 Updated Results from a Post-Marketing Observational Study of Lecanemab in Japan

Presenteur : Atsushi Iwata

Atsushi Iwata¹, Sakata Yukinori², Koizumi Kinuyo², Kanekiyo Michio³, Dhadda Shobha³, Endo Akira², Kuang Weijie², Sakamoto Yusuke², Sumitomo Kenta², Ishii Mika², Iwatsubo Takeshi⁴

¹Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ²Eisai Co., Ltd., Tokyo, Japan, ³Eisai Inc., New Jersey, United States, ⁴National Center of Neurology and Psychiatry, The University of Tokyo Hospital, Tokyo, Japan

P154 Ambient fine particulate matter and the incidence of Alzheimer's disease dementia in a nationwide time-varying cohort of 150,836 Korean dementia care center registrants: the association reverses after adjustment for nitrogen dioxide

Presenteur : Sun Min Lee

Sun Min Lee^{1,2}, Areum Kim², Gaeun Kim², Jiwon Ju², Im Seok Koh^{1,2}

¹Department of Neurology, National Medical Center, Seoul, Korea, Republic of, ²National Institute of Dementia, National Medical Center, Seoul, Korea, Republic of

P155 Burden Profiles by Caregiver Sex Among Hospice-Eligible Persons Living with Dementia: A Secondary Analysis of the LiBBY Phase II Trial

Presenteur : Leah Pulinat

Ava Wagner¹, Leah Pulinat¹, Brenda Armenta², Rema Raman², Kelly McCann¹, Jacobo Mintzer³, Brigid Reynolds¹

¹Georgetown University, Washington, DC, United States, ²University of Southern California, San Diego, United States, ³The Medical University of South Carolina, Charleston, SC, United States

P157 Undetected Diabetes, Glycemic Status and Cognitive Outcomes in Hispanic/Latino Adults in Southern California: Baseline Findings from SERVE OC

Presenteur : Alissa Kurzman-Wecht

Alissa Kurzman-Wecht¹, Jeffrey Wing², Aryanna Chavez¹, Xueting Ding¹, Megan Castro¹, Desiree Gutierrez¹, Cassandra Cardenas¹, Stephania Tovar Vargas¹, Matthew Landry³, Bernadette Boden-Albala^{1,4,5}

¹Department of Health, Society, and Behavior, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States, ²Division of Epidemiology, College of Public Health, Ohio State University, Columbus, United States, ³Department of Global Health and Biobehavioral Sciences, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States, ⁴Department of Neurology, School of Medicine, University of California, Irvine, Irvine, United States, ⁵Department of Epidemiology & Biostatistics, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, United States

P158 Limited social connection and dementia risk: candidate biological processes with therapeutic implications

Presenteur : Chao-Yi Wu

Chao-Yi Wu, Pia Kivisäkk, Hiroko Dodge, Steven Arnold

Massachusetts General Hospital, Harvard Medical School, Charlestown, United States

P159 Age-Specific Probabilities of Amyloid-PET Positivity Across Racial and Ethnic Groups: Results from HABS-HD

Presenteur : Michael Flanders

Michael Flanders¹, Michelle Caunca², Sarah Ackley¹

¹Brown University, Providence, United States, ²UCSF, San Francisco, United States

P160 — Remote Combined slow gait and subjective cognitive decline and long-term adverse health outcomes in adults aged 66 years: A nationwide cohort study

Presenteur : Seon Young Ryu

Seon Young Ryu¹, Sojeong Park², Jiwoo Yun²

¹The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, Korea, Republic of, ²Hanmi Pharm. Co., Ltd, Seoul, Korea, Republic of

P161 Non-Melanoma Skin Cancer, but Not Systemic Cancer History, Is Associated with Faster Plasma P-tau217 Accumulation and Cognitive Decline in Cognitively Unimpaired Older Adults: A Longitudinal ADNI Analysis

Presenteur : Micah Tratt

Micah Tratt, Daniel Gillen, Joshua Grill

Institute for Memory Impairments and Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, Irvine, United States

P162 Stronger Association of PM2.5 Exposure with Early-Onset Alzheimer's Disease and Distinct Vulnerability Profiles: A Nationwide 16-Year Cohort Study with Supporting Evidence from iPSC-Derived Neurons

Presenteur : Hee Jin Kim

Daeun Shin¹, Suna Kang², Hyo Jin Son¹, Danbee Kang¹, Hee Jin Kim¹

¹Samsung Medical Center, Seoul, Korea, Republic of, ²Korea Environment Institute, Sejong, Korea, Republic of

P163 — Remote From Diuresis to Dementia Prevention: How Carbonic Anhydrase Inhibitors May Modulate Dementia Risk in Glaucoma Patients

Presenteur : Rachel Dolan

Rachel Dolan¹, Reagan McGinley², Estevao Ribeiro³, Andrew Melson⁴, Claire Delpirou Nouh⁵

¹University of Oklahoma College of Medicine, University of Oklahoma Health Campus, Oklahoma City, United States, ²Baylor College of Medicine, Houston, United States, ³Department of Neurology, University of Oklahoma Health Campus - Oklahoma City (United States), Oklahoma City, United States, ⁴Dean McGee Department of Ophthalmology, University of Oklahoma Health Campus, Oklahoma City, United States, ⁵Department of Neurology, University of Oklahoma Health Campus, Oklahoma City, United States

P164 Distinct Temporal Profiles of ARIA Subtypes During Donanemab Treatment: Real-World Experience from a Japanese Single-Center Cohort

Presenteur : Taro Bannai

Taro Bannai¹, Ryoko Ihara^{1,2}, Masanori Kurihara^{1,2}, Ryosuke Shimasaki^{1,2,3}, Keiko Hatano¹, Fumio Suzuki⁴, Aya Midori Tokumaru⁴, Toshiaki Akashi⁴, Kenji Ishii^{2,5}, Atsushi Iwata^{1,2}

¹Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ²Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ³Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁴Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁵Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P166 Sex matters in Alzheimer's disease: Gaps and recommendations for clinical trials

Presenteur : Gillian Coughlan

Gillian Coughlan^{1,2}, Jill M. Goldstein^{3,4}, Roberta D. Brinton⁵, Kristine Yaffe⁶, Emily G. Jacobs^{7,8}, Roberta Marongiu⁹, Kathryn G. Schubert¹⁰, Heather Snyder¹¹, Jessica Z. K. Caldwell¹², Anna Chodos⁶, Michelle Mielke¹³, Lindsay R. Chura¹⁴, Diana Slowiejko¹⁵, Rachel Buckley^{1,2,16}

¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States, ²Brigham and Women's Hospital, Boston, Massachusetts, United States, ³Massachusetts General Hospital (MGH), Mass General Brigham Healthcare, and Harvard Medical School, Boston, Massachusetts, United States, ⁴Innovation Center on Sex Differences in Medicine (ICON-X), Massachusetts General Hospital (MGH), Boston, Massachusetts, United States, ⁵Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, United States, ⁶University of California San Francisco, San Francisco, California, United States, ⁷UC Santa Barbara, Santa Barbara, California, United States, ⁸Ann S. Bowers Women's Brain Health Initiative, Santa Barbara, California, United States, ⁹Weill Cornell Medicine, New York, New York, United States, ¹⁰Society for Women's Health Research, Washington, Dc, United States, ¹¹Alzheimer's Association, Chicago, Illinois, United States, ¹²University of Wisconsin-Madison, Madison, Wisconsin, United States, ¹³Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States, ¹⁴AARP, Washington, Dc, United States, ¹⁵Genentech, Inc., South San Francisco, California, United States, ¹⁶University of Melbourne, Melbourne, Victoria, Australia, Australia

P167 A common Alzheimer's disease-linked HLA-DRB1 genetic variant potentiates tau-associated microglial reactivity

Presenteur : João Pedro Ferrari-Souza

João Pedro Ferrari-Souza¹, Celia Bianco¹, Marco Antônio De Bastiani², Huan Li¹, Methasit Jaisa-aad¹, Giovanna Carello-Collar², Swarnali Dasgupta¹, Akhila Gundavelli¹, Srinija Alla¹, Jordan Marks¹, Bradley Hyman¹, Eduardo Zimmer², Sudeshna Das¹, Alberto Serrano-Pozo¹

¹Massachusetts General Hospital, Boston, United States, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

P168 APP-CTF accumulation: a key factor of APP dyshomeostasis in Alzheimer's disease

Presenteur : Alberto Lleo

Alberto Lleo, Sánchez-Aced Erika, Moya Borja, Sonia Siriri
Hospital Sant Pau, Barcelona, Spain

P169 Real-World Effects of Therapeutic Plasma Exchange With Albumin Replacement on Inflammatory Biomarkers Across the Alzheimer's Disease Continuum

Presenteur : Xavier Morato

Xavier Morato¹, Catherine Demos², Yahveth Cantero-Fortiz¹, Federico Casales¹, Emilio Alarcón-Martin¹, Oscar Bascuñana¹, Victoria Fernandez¹, Amanda Cano¹, Jordi Klamburg¹, Antonio Páez³, Basilio Hernandez³, Natalia Lopez Del Hoyo³, Anu Mathew³, Xavier Montalban¹, Mercè Boada¹

¹Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya (UIC), Barcelona, Spain, ²Meso Scale Diagnostics, LLC., Rockville, United States, ³Neuro-Innovation Hub, Grifols, Barcelona, Spain

P170 Computerized Olfactory Adaptive Training (COAT) Improves Hyperconnectivity in the Medial Temporal Lobe Networks in Patients with Mild Cognitive Impairments: a Randomized Clinical Trial

Presenteur : Evaristus A. Nwulia

Opeyemi Mercy Awofeso¹, Maria Hipolito², Ashley Vanmeter³, Narayan Rai², Tamal Sadhukhan², Claudia Ivonne Mejía Mondragón², Haroon S Popal¹, Van Hecke Kinney³, Rebecca Aitken³, Adedoyin Kalejaiye², Vamsi Reddy¹, Jamal Monger¹, Charles Nwaokobia¹, Thomas Obisesan², Evaristus A. Nwulia¹

¹Evon Medics, Ellicott City, United States, ²Howard University, Washington Dc, United States, ³Georgetown University Medical Center Evon Medics, Washington Dc, United States

P171 Topline results of a Phase IV trial of EGb761 in patients with Mild Cognitive Impairment: ACE-2020-EGb761

Presenteur : Xavier Morato Arus

Xavier Morato Arus¹, Marta Marquié¹, Juan Pablo Tartari¹, Asunción Lafuente¹, Marai Eugenia Sáez², Sara Jofresa¹, Laia Montoliu-Gayà³, Marta Ibarria⁴, Susana Diego⁴, Mar Buendia⁴, Nuria Aguilera⁴, Natalia Tantinya⁴, Laia Cañada⁴, Pilar Sanz⁴, Mercè Boada⁴

¹Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, ²3CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain, ³University of gothenburg, Mölndal, Sweden, ⁴Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Sweden

P172 Modulation of Fibronectin-1 Restores Blood-Brain Barrier Integrity and Gliovascular Signaling in APOEε4-Associated Alzheimer's Disease

Presenteur : Caghan Kizil

Prabesh Bhattarai¹, Elanur Yilmaz¹, Tal Nuriel², Badri Vardarajan¹, Richard Mayeux¹, Caghan Kizil¹

¹Department of Neurology, Columbia University Irving Medical Center, New York City, United States, ²Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York City, United States

P173 Neurogenesis Hypothesis: Evidence from Phase 2 Clinical Trials of NA-831 for the Treatment of Alzheimer's Disease

Presenteur : Lloyd Tran

Lloyd Tran, Fern Vu, Zung Tran
Biomed Industries, Inc., San Jose, United States

P174 Unified Theory of Neurodegenerative, Metabolic and Cardiovascular Diseases: Clinical Evidence from NA-831 for Alzheimer's Disease, NA-931 for Obesity, and NA-911 for Ischemic Stroke

Presenteur : Lloyd Tran

Lloyd Tran, Fern Vu, Zung Tran
Biomed Industries, Inc., San Jose, United States

P175 Outpatient therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world safety and feasibility in a single-center cohort from ACE Alzheimer Center Barcelona

Presenteur : Mercè Boada

Mercè Boada^{1,2}, Yahveth Cantero-Fortiz^{1,2}, Federico Casales¹, Sergi Valero¹, Genis Carrasco¹, Oscar Bascuñana¹, Berta Calm¹, Adrián Hinojosa¹, Emilio Alarcón-Martín¹, Amanda Cano¹, Victoria Fernández¹, Xavier Morató¹, Antonio Paéz³, Basilio Hernández³, Xavier Montalban^{1,4}

¹Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, ²Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, ³Neuro-Innovation Hub, Grifols, Barcelona, Spain, ⁴Universitat de Vic-central de Catalunya (UVic-UCC)4, Barcelona, Spain

P176 Therapeutic plasma exchange with albumin replacement via peripheral access in Alzheimer's disease: real-world evidence on cognitive outcomes in a single-center cohort from ACE Alzheimer Center Barcelona

Presenteur : Mercè Boada

Mercè Boada^{1,2}, Yahveth Cantero-Fortiz^{1,3}, Federico Casales¹, Sergi Valero¹, Genis Carrasco¹, Oscar Bascuñana¹, Berta Calm¹, Adrián Hinojosa¹, Emilio Alarcón-Martín¹, Amanda Cano¹, Victoria Fernández¹, Xavier Morató¹, Antonio Paéz⁴, Natalia López Del Hoyo¹, Xavier Montalban^{1,5}

¹Ace Alzheimer Center Barcelona- Universitat Internacional de Catalunya (UIC), Barcelona, Spain, ²Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, ³Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain, ⁴Neuro-Innovation Hub, Grifols, Barcelona, Spain, ⁵Universitat de Vic-central de Catalunya (UVic-UCC), Barcelona, Spain

P177 Concept for a Trial of Immunomodulatory Therapy with BCG to Prevent Progression of Preclinical Alzheimer's Disease

Presenteur : Pierre Tariot

Pierre Tariot¹, Inga Antonsdottir², Steven Arnold³, Nicholas Ashton⁴, William Bishai², Corey Casper⁵, Marisa Denkinge⁶, Denise Faustman³, Pascal Geldsetzer⁷, Tiffany Hensley-McBain⁸, Joe Jiang⁹, Jennifer Knox¹, Donald Lamm¹⁰, Jeremy Pruzin¹

¹Banner Alzheimer's Institute, Phoenix, United States, ²Johns Hopkins Medicine, Baltimore, United States, ³Mass General Brigham, Boston, United States, ⁴Banner Sun Health Research Institute, Phoenix, United States, ⁵Banner Health, Phoenix, United States, ⁶Banner Sun Health Research Institute's Institute, Phoenix, United States, ⁷Stanford Medicine, Palo Alto, United States, ⁸McLaughlin Research Institute, Great Falls, United States, ⁹DFnet, Seattle, United States, ¹⁰University of Arizona, Phoenix, United States

P178 Dissociated MAS1 Receptor and Effector Expression Identifies a Failed Compensatory State in Human Vascular Cognitive Impairment: Implications for Therapeutic Strategy

Presenteur : Meredith Hay

Meredith Hay
University of Arizona, Tucson, United States

P179 Site Engagement Within a Centralized Recruitment, Engagement, and Retention Framework: The Alzheimer's Clinical Trials Consortium Experience

Presenteur : Taylor Clanton

Taylor Clanton¹, Marina Ritchie¹, Doris Molina-Henry¹, Crystal Glover², Paul Aisen¹, Reisa Sperling^{3,4}, Joshua Grill², Rema Raman¹

¹Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²University of California, Irvine, Irvine, United States, ³Department of Neurology, Harvard Medical School, Boston, United States, ⁴Brigham and Women's Hospital, Boston, United States

P180 Feasibility of a multidomain intervention combining Reduced carbohydrate intake, Omega-3 fatty acids, MCT supplementation, and EXercise in older adults at risk of Alzheimer's disease: the ROMEX-AD trial.

Presenteur : Melanie Fortier

Melanie Fortier¹, Christian Bocti¹, Mark Espeland², Matthew Phillips³, Karl Fernandes¹, Stephen Cunnane¹

¹Research Center on Aging and Department of Medicine, Université de Sherbrooke, Sherbrooke, Canada, ²Wake Forest University School of Medicine, Winston-Salem, United States, ³Department of Neurology, Waikato Hospital, Hamilton, New Zealand

P182 Phase 1 Clinical Development Strategy for PNA5 in VCID: Translational Biomarkers, Neurovascular Mechanisms, and SAD/MAD Design

Presenteur : Meredith Hay

Meredith Hay, Tamara Crockett
ProNeurogen. Inc. Tucson. United States

P183 — Remote Is cerebral A β 42-amyloidosis (CAB42-A) a more appropriate labelling for asymptomatic patients than Alzheimer's disease?

Presenteur : Michaela Defrancesco

Michaela Defrancesco

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P184 — Remote Treatment of age-related upstream bioenergetic and redox impairment promotes clearance of A β and tau aggregates, lowers oxidative nitration and promotes synapse formation in isolated neurons from AD mouse models

Presenteur : Gregory Brewer

Gregory Brewer¹, Svara Shah¹, Ricardo Santana²

¹UC Irvine, Irvine, United States, ²UNAM, Mexico City, Mexico

P185 Pipeline Diversification and Emerging Therapeutic Hypotheses in Alzheimer's Disease

Presenteur : Laurentiu Gutiu

Laurentiu Gutiu¹, Abby Fuller², Antoniya Todorova³

¹Fortrea Germanv GmbH, Munich, Germany. ²Fortrea Inc., Durham, United States. ³Fortrea Belgium SRL, Brussels, Belgium

NEW HYPOTHESES – NON-PHARMACOLOGIC INTERVENTIONS

P186 Cognitive Benefits of a Multidomain Lifestyle Intervention Across Baseline Physical Function Levels in Older Adults with Mild Cognitive Impairment: A Secondary Analysis of the SUPERBRAIN-MEET Randomized Controlled Trial

Presenteur : [So Young Moon](#)

So Young Moon¹, Da Ae Kim¹, Seong Hye Choi²

¹Ajou university school of medicine, Suwon, Korea, Republic of, ²Inha University Hospital, Incheon, Korea, Republic of

P187 Personalized digital intervention is associated with greater adherence to brain-healthy lifestyle recommendations, with additional benefit from motivational coaching

Presenteur : [Javier Solana-Sánchez](#)

Javier Solana-Sánchez¹, Maria Ortuño-Saavedra¹, Simon Fankhauser¹, David Bartres-Faz², Paloma Chausa³, Diego Moreno-Blanco³, Gemma Albi-Villuendas¹, Marta Alvarez-Ambrosio³, Ignacio Oropesa³, Patricia Sánchez-González³, Enrique Gómez³, Gabriele Cattaneo¹

¹Guttmann Hospital de Neurorehabilitació, Institut Universitari adscrit a la UAB, Barcelona, Spain, ²Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain, ³Biomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain

P188 Primary endpoint evaluation of ultra-high frequency visual stimulation intervention on episodic memory impairment in Alzheimer's disease

Presenteur : [Julian Keil](#)

Julian Keil¹, Maria Buthut², Ravit Hadar¹, Jana Fass³, Liam Doherty¹, Jakob Litsch¹, Victor Hernandez-Urbina¹, Fabian Queisner¹, Markus Müschenich¹, Surjo Soekadar²

¹Nuuron GmbH, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Medical School Berlin, Berlin, Germany

P189 Lifestyle change and relationship of modifiable factors with cognition in women at risk for Alzheimer's disease

Presenteur : [Jessica Kirkland Caldwell](#)

Jessica Kirkland Caldwell¹, Taylor Levine², Nikki Kaplan², Emily Post², Zhi Baker², Sandra Darling³, Shehroo Pudumjee²

¹University of Wisconsin Madison, Madison, United States, ²Cleveland Clinic Nevada, Las Vegas, United States, ³Cleveland Clinic, Cleveland, United States

P190 Mind-Body Interventions for Individuals with Subjective Cognitive Decline: Feasibility, Acceptability, and Preliminary Effects on Blood Based Biomarkers of Amyloid and Tau Pathology

Presenteur : [Ruchika Prakash](#)

Ruchika Prakash¹, Quinn Meyerson¹, Madhura Phansikar^{1,2}, Elise Grant^{1,3}, Megan Fisher^{1,4}, A. Cordova¹, Sarah Dove¹, Rond Malhas⁵, James Teng¹, Nevyana Todorova¹, Ninette Simonian¹, Elizabeth Head⁵, Rebecca Andridge¹, Kathy Wright¹, Doug Scharre¹

¹The Ohio State University, Columbus, United States, ²Eastern Illinois University, Charleston, United States, ³Ohio University, Athens, United States, ⁴University of California at Los Angeles, Los Angeles, United States, ⁵University of California at Irvine, Irvine, United States

P192 Digital Cognitive Behavioral Therapy for Insomnia in Older Adults with Mild Cognitive Impairment: Results from the SHUTi MIND Phase IIb Randomized Controlled Trial

Presenteur : [Meghan Mattos](#)

Meghan Mattos¹, Wen You¹, Carol Manning¹, Jennifer Lingler², Kirsten Macdonnell¹, Naveen Abedin¹, Lee Ritterband¹

¹University of Virginia, Charlottesville, United States, ²University of California- Davis, Sacramento, United States

P193 Psychosocial outcomes after learning APOE and pTau-217 results: Findings from the eSMARTER trial

Presenteur : [Claire Erickson](#)

Claire Erickson¹, Angela Bradbury², Brian Egleston³, Carolyn Langlois¹, Elisabeth McCarty Wood², Kristin Harkins², Emily Largent², J. Scott Roberts⁴, Eric Reiman¹, Marisa Denninger¹, Nicholas Ashton¹, Jason Karlawish², Jessica Langbaum¹

¹BAI, Phoenix, United States, ²UPenn, Philadelphia, United States, ³Temple, Philadelphia, United States, ⁴UMich, Ann Arbor, United States

P194 Plasma Proteomics Identifies a Two-Signal Synaptic Preservation Signature Associated with Cognitive Benefit in the FINGER Trial

Presenteur : [Adrian Noriega De La Colina](#)

Adrian Noriega De La Colina^{1,2,3}, Arvid Gollwitzer^{1,4}, Anna Matton⁵, Francesca Mangialasche⁵, Li-Huei Tsai⁶, Alina Salomon^{5,7,8}, Tiia Ngandu^{5,7}, Giovanni Traverso^{9,2,10,11}, Miia Kivipelto^{12,13}

¹Broad Institute of MIT and Harvard, Cambridge, United States, ²Massachusetts Institute of Technology, Cambridge, United States, ³Brigham and Women's Hospital, Boston, United States, ⁴Massachusetts Institute of Technology, Cambridge, United States, ⁵Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden, ⁶The Picower Institute for Learning and Memory, MIT, Cambridge, United States, ⁷Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland, ⁸FINGERS Brain Health Institute, Stockholm, Sweden, ⁹Broad Institute of MIT and Harvard, Solna, Sweden, ¹⁰Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Cambridge, United States, ¹¹Koch Institute for Integrative Cancer Research, MIT, Cambridge, United States, ¹²Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, ¹³FINGERS Brain Health Institute, Stockholm, United States

P195 BRIGHT-Mind Study: A Prospective, Randomized Trial of Digital Cognitive Training Effects on Cognitive, Functional and Imaging Outcomes

Presenteur : Robert John Schafer

Robert John Schafer¹, Kevin Madore¹, Kelly Hennigan Macniven², John G. Nadra³, Preston P. Thakral⁴, P. Murali Doraiswamy⁵

¹Lumos Labs, Inc., San Francisco, United States, ²Independent, San Francisco, United States, ³Michigan State University, East Lansing, United States, ⁴Department of Psychology, Smith College, Northampton, United States, ⁵Duke University School of Medicine, Durham, United States

P196 Non-Pharmacological Interventions for Dementia Prevention in Cognitively Unimpaired Adults at Elevated Risk: A Scoping Review

Presenteur : Julie Oomens

Julie Oomens¹, Dandi Chen¹, Samira Maboudian¹, Mai Abdelmoaty², Joyce Chong¹, Jessica Kirkland Caldwell¹

¹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States, ²Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P197 Mood and Cognitive Outcomes of a Mindfulness Based Intervention in Veterans with Mild Cognitive Impairment: A Pilot Randomized Trial

Presenteur : Heera Kamaraj

Heera Kamaraj^{1, 2}, Kathy Xie^{1, 2}, Sarah Harer^{1, 2}, Brenna Hagan², Meltem Karaca³, Sofia Angelini¹, Brandon Frank^{1, 4}, Andrew Budson^{1, 4}, Katherine Turk^{1, 4}

¹Center for Translational Cognitive Neuroscience, VA Boston Healthcare System, Boston, United States, ²Alzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States, ³Assumption University, Worcester, United States, ⁴Alzheimer's Disease Research Center, Department of Neurology, Boston University School of Medicine, Boston, United States

P198 Faster is Better: Modifiable Risk Factors for Alzheimer's Disease & Dementia in the ACTIVE Study

Presenteur : Hyunkyu Lee

Hyunkyu Lee¹, Karlene Ball², Henry Mahncke¹

¹Posit Science, ²UNIVERSITY OF ALABAMA AT BIRMINGHAM

P199 Early Detection of cognitive Decline and Dementia prevention in women: the 3D study protocol

Presenteur : Salvatore Mazzeo

Salvatore Mazzeo^{1, 2}, Federico Emanuele Pozzi¹, Elisa Bortolin^{1, 2}, Giulia Bruschi^{1, 2}, Arianna Frijio¹, Alessandro Bombaci^{1, 2}, Gianni Cutillo^{1, 2}, Eleonora Ferrante¹, Laura Renna³, Rosanna Cardani³, Massimo Filippi⁴, Maria Salsone^{1, 2}

¹Neurology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³BioCor Biobank, IRCCS Policlinico San Donato, San Donato Milanese, Italy, ⁴Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Milan, Italy

P200 PodCaring: Investigating the Feasibility and Efficacy of the Dementia Untangled Podcast for Caregivers and Patients with Early-Stage Cognitive Impairment

Presenteur : Jasmine Zhang

Jasmine Zhang¹, Heather L. Mulder², Nellie M. High², Robert J. Bauer², Jennifer C. Knox², Yinghua Chen², Lori Nisson², Jessica B. Langbaum², Amber D. Ayers³, Matthew J. Huentelman⁴, David Coon⁵, Jeremy J. Pruzin²

¹University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, United States, ²Banner Alzheimer's Institute, Phoenix, Arizona, United States, ³Banner Alzheimer's Institute, Tucson, Arizona, United States, ⁴Translational Genomics Research Institute, Phoenix, Arizona, United States, ⁵Arizona State University Edson College of Nursing and Health Innovation, Phoenix, Arizona, United States

P201 – Remote VR&R Trial: Interim Results on the Use of Virtual Reality to Support Caregiver Respite in Dementia Care

Presenteur : Sahil Patel

Vanessa Geitz¹, Samantha Lewis-Fung¹, Sahil Patel², Mattaya Pallett^{1, 3}, Essete Tesfaye¹, Lora Appel^{1, 2}

¹University Health Network, Toronto, Canada, ²York University, Toronto, Canada, ³Humber Polytechnic, Toronto, Canada

P202 Can Menopausal Status Moderate the Effects of Aerobic Exercise on Executive Functions? Evidence from a Randomized Controlled Trial

Presenteur : Michal S. Beeri

Sharon Sanz Simon¹, Maya Gal², Seonjoo Lee³, Marcella D. Walker³, Michal S. Beeri¹, Gloria Bachman¹, Vincenzo Lauriola³, Richard Sloan³, Yunglin Gazes⁴

¹Rutgers University, New Jersey, United States, ²Albert Einstein College of Medicine, New York, United States, ³Columbia University, New York, United States, ⁴The Nathan Kline Institute for Psychiatric Research, New York, United States

P203 A Care Coach protocol for caregivers of persons with dementia (PWD) to help manage behavioral and psychological symptoms of dementia (BPSD).

Presenteur : Miriam Jocelyn Rodriguez

Miriam Jocelyn Rodriguez, Jacqueline Burnell, Sonia Cerezo, Vanessa Kercher, Jordan Hill, Richard Holden, Malaz Boustani

Indiana University, Bloomington, United States

P204 Factors contributing to retention in a mobile telehealth intervention trial for dementia caregivers.

Presenteur : Miriam Jocelyn Rodriguez

Miriam Jocelyn Rodriguez¹, Jordan Hill¹, Mariana Stavig¹, Roger Zoh¹, Anna Macagno¹, Agnis Duah¹, Malaz Boustani², Richard Holden¹

¹Indiana University, Bloomington, United States, ²Indiana University, Indianapolis, United States

P205 — Remote Cognitive Effects, Adherence, and Acceptability of a 12-Week Mobile Cognitive Training Program in Mild Cognitive Impairment

Presenteur : Seungwon Chung

Seungwon Chung¹, Bori R. Kim², Geonha Kim¹

¹Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea, Republic of, ²Ewha Medical Research Institute, Ewha Womans University, Seoul, Korea, Republic of

P206 — Remote Perceived Usefulness Mediates the Association Between Concern About Brain Health and Engagement in Brain Health Activities

Presenteur : Raymond L Ownby

Raymond L Ownby¹, Joshua Caballero²

¹Nova Southeastern University, Fort Lauderdale, FL, United States, ²University of Georgia, Athens, GA, United States

P209 Augmented Exercise Interventions: Optimizing Response to Exercise Modalities for Cognitive Enhancement in Early AD

Presenteur : Krista Lancot

Krista Lancot¹, Julian Schecter¹, Yejin Kang¹, Sandra Black¹, Nathan Herrmann², Sara Mitchell¹, Susan Marzolini³, Paul Oh³, Jennifer Rabin¹, Tarek Rajji⁴, Mark Rapoport¹, Walter Swardfager¹, Mehreen Siddiqui¹, Kate Survilla¹, Damien Gallagher¹

¹Sunnybrook Research Institute, Toronto, Canada, ²Department of Psychiatry, University of Toronto, Toronto, Canada, ³KITE Research Institute, Toronto Rehabilitation Institute – University Health Network, Toronto, Canada,

⁴Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States

P210 Neural substrates generating a gamma frequency response to 40Hz GENUS light and sound stimulation

Presenteur : Diane Chan

Diane Chan^{1,2}, Ute Geigenmuller¹, Monica Zheng¹, Andrew Becker¹, Erika Ruiz¹, Remi Philips¹, Natalie Hahn¹, Aaron Boes^{3,4}, Matthew Howard^{3,4}, Eleonora Marcantoni⁵, Simon Hanslmayr⁵, Diego Vidaurre Henche^{6,7,8}, Emery Brown^{1,9}, Edward Boyden¹, Li-Huei Tsai¹

¹MIT, Cambridge, United States, ²Alnylam, Cambridge, United States, ³University of Iowa, Iowa City, United States, ⁴Iowa Neuroscience Institute, Iowa City, United States, ⁵Centre for Neurotechnology, Glasgow, United Kingdom,

⁶Centre de Recerca Matemàtica, Barcelona, Spain, ⁷University of Oxford, Oxford, United Kingdom, ⁸Aarhus University, Aarhus, Denmark, ⁹Massachusetts General Hospital, Boston, United States

P211 Differential Cognitive Responses to Active and Sham rTMS Combined with Cognitive Training in Early Alzheimer's Disease

Presenteur : Juyoun Lee

Juyoun Lee¹, Inho Lee², Kun Ho Kim³, Ae Young Lee¹

¹Department of Neurology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, ²Department of Radiology, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of, ³Department of Nuclear Medicine, School of Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of

P212 Impact of a Multidomain Lifestyle Intervention on Gut Microbiota: An Exploratory Sub-study of the SUPERBRAIN Trial

Presenteur : Seong Hye Choi

Seong Hye Choi¹, Jee Hyang Jeong², Yangki Minn³, Woorim Kang⁴, So Young Moon⁵, Yoo Kyoung Park⁶

¹Inha University College of Medicine, Incheon, Korea, Republic of, ²Ewha Womans University School of Medicine, Seoul, Korea, Republic of, ³Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea, Republic of, ⁴Kangwon National University, Chuncheon, Korea, Republic of, ⁵Ajou University School of Medicine, Suwon, Korea, Republic of, ⁶Graduate School of East-West Medical Nutrition, Kyung Hee University, Yongin, Korea, Republic of

BIOMARKERS (CSF & PLASMA)

P213 An ultrasensitive immunoassay for cryptic HDGFL2 expression in CSF as a biomarker for TDP-43 nuclear loss of function

Presenteur : Sarah Shahub

Sarah Shahub¹, Alpna Singh¹, Marisa Denkinger¹, Antonia Demleitner², Laura Tzeplaeff², Kathryn Citrano³, Vidhya Bharathi Maheswari Jawahar⁴, Kari Dieckhoff¹, James Liu¹, Taina Marques¹, Kathryn Ghisays¹, Paul Lingor², Leonard Petrucelli⁴, Nicholas Ashton¹

¹Banner Sun Health Research Institute, Sun City, United States, ²Technical University of Munich, Munich, Germany, ³Mayo Clinic, Jacksonville, United States, ⁴University of Miami Miller School of Medicine, Miami, United States

P214 Quantitative Predicted Effects of Chronic Kidney Disease on Alzheimer's Disease Plasma Biomarkers and Biomarker Ratios

Presenteur : Joshua Bornhorst

Joshua Bornhorst¹, Chelsea Swartchick¹, Daniel Figdore¹, Susan Ashrafzadeh-Kian¹, Prashanthi Vemuri¹, Jonathan Graff-Radford¹, David Knopman¹, Micheal Griswold², Petrice Cogswell¹, Jack Jr CLIFFORD¹, Ronald Petersen¹, Stephen Weigand¹, Alicia Algeciras-Schimmich¹

¹Mayo Clinic, Rochester, United States, ²University of Mississippi Medical Center, Jackson, United States

P215 Clinical Verification of the Lumipulse Phosphorylated Tau 217/Amyloid Beta 42 Ratio Assay

Presenteur : Anna Mammel

Anna Mammel¹, Kelsey Hallett¹, Donald Biehl¹, Hans Frykman^{1,2,3}

¹Neurocode USA Inc., Bellingham, United States, ²BC Neuroimmunology, Vancouver, Canada, ³University of British Columbia, Vancouver, Canada

P216 Glycocalyx Blood Markers Predict and Monitor ARIA in Anti-Amyloid-Treated Patients: Convergent Evidence from BBB Imaging and Clinical Data

Presenteur : Brian DellaValle

Brian Dellavalle^{1,2,3}, Jeremy Ford⁴, Mathias Lindh Jørgensen^{1,3}, Luisa Knecht^{1,3}, Rikke Brønnum Nielsen^{1,5}, Tove Persson^{1,3}, Richard Frank⁶, Behnaz Khazai⁴, Vlad V Senatorov Jr⁷, Aaron R Friedman⁷, Nicholas Schwartz^{8,9}, Sarah Kremen¹⁰, Oleg Yerstein^{11,12,13}, Lawren Vandevrede⁹, Andreas Jeromin⁶

¹GLX Analytix ApS, Copenhagen, Denmark, ²GLX Analytix, Menlo Park, United States, ³Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁴Mass General Brigham, Harvard Medical School, Boston, United States, ⁵Copenhagen Center for Translational Research, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, ⁶GLX Analytix, Menlo Park, United States, ⁷Reservoir Neuroscience, Emeryville, United States, ⁸University of Maryland Baltimore, Baltimore, United States, ⁹Memory and Aging Center, Department of Neurology, University of California, San Francisco, United States, ¹⁰Goldrich Center for Alzheimer's and Memory Disorders, Department of Neurology, Cedars-Sinai Health Sciences University, Los Angeles, United States, ¹¹Synaptique, Chicago, United States, ¹²UMass Chan Medical School, Worcester, United States, ¹³Tufts University School of Medicine, Boston, United States

P217 Age, APOE Status, Renal Function, Glycemia, and Prior Ischemic Stroke Associate With Baseline Plasma p-tau217 in BROADWAY.

Presenteur : Akash Patel

Akash Patel¹, Andrew Hsieh², Adam Johnson², Michael Davidson²

¹University of Chicago, , United States, ²NewAmsterdam Pharma, , United States

P218 Plasma Proteomics in APOE ε4 Homozygotes Identifies a Central Role of the Immune System in Resilience and Susceptibility to Alzheimer's Disease

Presenteur : Erik Johnson

Eric Dammer, Shiva Afshar, Isabel Petrescu, Allan Levey, Erik Johnson

Emory University, Atlanta, United States

P219 Plasma p-tau217 above and below validated Alzheimer cutoffs in cardiovascular disease: between-range versus within-range determinants in BROADWAY.

Presenteur : Akash Patel

Akash Patel¹, Andrew Hsieh², Adam Johnson², Michael Davidson²

¹University of Chicago, , United States, ²NewAmsterdam Pharma, , United States

P220 Brain-Derived Plasma p-tau217 Lacks the HbA1c Association Observed With Conventional p-tau217 in American Indian Tribal Elders

Presenteur : William Mantyh

Rene Labounek¹, Matti Matheson¹, Annamarie Hill¹, Adam Block¹, Ashley Petersen¹, Adam Hansen¹, Meghan Kremer¹, Annie Roberston¹, Breton Asken², Danni Li¹, Igor Nestrasil¹, Christophe Lenglet¹, Corey Strong³, Joseph Henderson⁴, William Mantyh¹

¹University of Minnesota, Minneapolis, United States, ²University of Florida, Gainesville, United States, ³Bois Forte Band of Chippewa Health Services, Nett Lake, United States, ⁴University of Minnesota Duluth, Duluth, United States

P221 Selective detection of BD-tau species improves the specificity of blood AD biomarkers and reduces confounding from peripheral tau sources

Presenteur : Markus Otto

Samir Abu-Rumeileh¹, Henning Grosskopf¹, Arthur Guthknecht¹, Alexander Mensch¹, Patrick Oeckl², Hans Klafki³, Jens Wiltfang³, Lutz Froelich⁴, Lucrezia Hausner⁴, Vincenzo Silani⁵, Dietmar Thal⁶, Jochen Weishaupt², Ingolf Lachmann⁷, Federico Verde⁵, Markus Otto¹

¹Martin Luther University, Department of Neurology, Halle (Saale), Germany, ²University of Ulm, Ulm, Germany, ³University of Goettingen, Goettingen, Germany, ⁴ZI Mannheim, Mannheim, Germany, ⁵IRCCS Istituto Auxologico Italiano, Milano, Italy, ⁶Laboratory for Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, Leuven, Belgium, ⁷Roboscreen, Leipzig, Germany

P222 NPTX2-Centered Interaction-State Proteomics in Cerebrospinal Fluid and Plasma Reveals Biofluid-Specific Signatures of Alzheimer's Disease

Presenteur : Paul Worley

Paul Worley¹, Chan Hyun Na¹, Kyungdo Kim¹, Meifang Xiao¹, Taekyung Ryu¹, Carol Barnes², Douglas Galasko³, Jin Hyeok Kim¹

¹Johns Hopkins, Baltimore, United States, ²University of Arizona, Tucson, United States, ³UCSD, San Diego, United States

P223 Spectris treatment is associated with a coordinated plasma proteomic response: Module-level analysis from the OVERTURE feasibility study in mild-to-moderate Alzheimer's disease

Presenteur : Mihály Hajós

Mihály Hajós^{1, 2}, Saima Rathore³, Allan Levey³, Nicholas Seyfried³, Duc Duong^{3, 4}, Anantharaman Shantaraman³, Brennan Jackson¹, Miguel Hernandez¹, Nina Khera¹, Evan Hempel¹, Chandran Seshagiri¹, Ralph Kern¹

¹Cognito Therapeutics Inc., Cambridge, United States, ²Yale University Medical School, New Haven, CT, USA, New Haven, United States, ³Emory University, Atlanta, United States, ⁴Emtherapro Inc, Systems Biology, Atlanta, United States

P224 BEACON: A Future-Proof Neuropathological Validation Platform for Emerging Biomarkers of Proteinopathy

Presenteur : Colin Groot

Colin Groot, Ilse Bader, Rik Ossenkoppele, Coomans Emma

Amsterdam UMC, Amsterdam, The Netherlands

P225 Multimodal evaluation of a 5-plex blood-based biomarker panel for Alzheimer's disease

Presenteur : Andrea L. Benedet

Burak Arslan¹, Tevy Chan², Kubra Tan¹, Nesrine Rahmouni², Joseph Therriault², Tharick A. Pascoal³, Nicholas J. Ashton⁴, Henrik Zetterberg¹, Pedro Rosa-Neto⁵, Andrea L. Benedet¹

¹University of Gothenburg, Gothenburg, Sweden, ²McGill University, Montreal, Canada, ³University of Pittsburgh, Pittsburgh, United States, ⁴Banner Health Institute, Phoenix, United States, ⁵UT Southwestern, Texas, United States

P226 – Remote Diagnostic accuracy of the automated Elecsys CSF Aβ42/Aβ40 ratio and Aβ42 in a population reflective of clinical practice

Presenteur : Myrto Andreadou

Myrto Andreadou¹, Cornelia Fuetterer², David Caley³, Marc Suárez-Calvet^{4, 5}, Mercè Boada^{6, 7}, Kristian Steen Frederiksen^{8, 9}, David Watson¹⁰

¹Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ²Roche Diagnostics GmbH, Penzberg, Germany, ³Roche Diagnostics Ltd, Burgess Hill, United Kingdom, ⁴BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, ⁵Servei de Neurologia, Hospital del Mar, Barcelona, Spain, ⁶Ace Alzheimer Center Barcelona, International University of Catalunya, Barcelona, Spain, ⁷Center for Biomedical Research Network on Neurodegenerative Diseases (CIBERNED), Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain, ⁸Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark, ⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁰Alzheimer's Research and Treatment Center, Wellington, FL, United States

P227 Temporal plasma proteomic responses to lecanemab and their associations with amyloid clearance and cognitive change: a multicentre, real-world cohort study

Presenteur : Sang Won Seo

Jun Pyo Kim¹, Bo Hyun Kim¹, Jungah Lee¹, Hee Jin Kim¹, Eun-Joo Kim², Henrik Zetterberg³, Sang Won Seo¹

¹Samsung Medical Center, Seoul, Korea, Republic of, ²Pusan National University Hospital, Busan, Korea, Republic of, ³University of Gothenburg, Mölndal, Sweden

P228 Comparator Choice and Handling of Indeterminate Results in Reported Agreement and Confirmatory Testing for Plasma Amyloid Biomarkers: A Paired PET–CSF Study with PET-Anchored Thresholds

Presenteur : Khushboo Verma

Khushboo Verma¹, Satwant Kumar²

¹University of Texas at Tyler, TYLER, United States, ²Alzheimer Alliance of Smith County, TYLER, United States

P229 SLIM (Single-Arm Lead-In with Multiple Assessments): Optimizing Repeated Biomarker Assessments to Improve Statistical Power in Clinical Trials

Presenteur : Hiroko Dodge

Hiroko Dodge¹, Liu Chen¹, Chao-Yi Wu¹, Yan Gao¹, Gene Bowman², Howard Feldman³, Steven Arnold¹

¹Department of Neurology, Interdisciplinary Brain Center, Massachusetts General Brigham, Harvard Medical School, Boston, United States, ²Department of Neurology, McCance Center for Brain Health, Massachusetts General Brigham, Harvard Medical School, Somerville, United States, ³San Diego School of Medicine, Alzheimer's Disease Cooperative Study at the University of California, La Jolla, United States

P230 Nasal Fluid Biomarkers from the Brain-Nose Interface as a Novel Minimally Invasive Tool for Alzheimer's Disease Research and Diagnosis

Presenteur : Matthias Langhorst

Xiao Feng¹, Mohammad Bashiri¹, Philipp E. Geyer², Sebastian Virreira Winter², Oliver Peters³, Lutz Froelich⁴, Jens Wiltfang⁵, Timo J. Oberstein⁶, Stefan Kotschote¹, Maria Babu¹, Marion San Nicoló¹, Matthias Langhorst¹, Sabine Mertzig¹, Mareike Albert¹

¹Noselab GmbH, Widenmayerstrasse 27, 80538, Munich, Germany, ²ions.bio GmbH, Am Klopferspitz 19, 82152, Planegg, Germany, ³Charité-Universitätsmedizin Berlin, Department of Psychiatry, Berlin, Germany, ⁴Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ⁵Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold Strasse 5, 37075, Goettingen, Germany, ⁶Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany

P231 Treatment response biomarkers in early Alzheimer's disease: longitudinal trajectories, sample size estimates, and the impact of progression variability

Presenteur : Charlotte Teunissen

Marlies Oosthoek¹, Alida Leistra¹, Yanaika Hok-A-Hin¹, Michael Tanck¹, Tomohiro Okuda², Lisanne In 'T Veld¹, Azzam Aladdin¹, Pieter Van Bokhoven¹, Betty Tijms¹, Roos Jutten¹, Philip Scheltens³, Everard Vijverberg¹, Charlotte Teunissen¹, Lisa Vermunt¹

¹Amsterdam UMC, Amsterdam, The Netherlands, ²Toyama, Tokyo, Japan, ³EQT Life Sciences, Amsterdam, The Netherlands

P232 Native cfDNA Methylation Profiling Identifies Cortical Neuron-Associated Signals in Alzheimer's Disease and Mild Cognitive Impairment

Presenteur : Isaac Stirland

Isaac Stirland

Renew Biotechnologies, Pleasant Grove, United States

P233 Minimizing false positive and indeterminate plasma pTau-217 results caused by impaired renal clearance with myelin oligodendrocyte glycoprotein

Presenteur : Hyun Kook Lim

Hyun Kook Lim¹, Yoo Hyun Um¹, Li Wang², Adheesha Danthanarayana², Sasi Mudumba², Henry Huang², Irene B Meier³, Vaibhav A Narayan³, Menghan Liu⁴, Carlos Cruchaga⁴, Sterling Johnson⁵, Henrik Zetterberg⁵, Steve Williams², Yuling Luo², Xiao-Jun Ma²

¹The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, ²Alamar Biosciences., Fremont, United States, ³Davos Alzheimer's Collaborative, Geneva, Switzerland, ⁴Washington University, St. Louis, United States, ⁵The University of Wisconsin, Madison, United States

P234 Head-to-Head Comparison of Plasma pTau217 and pTau217/Aβ42 Across Key Immunoassay platforms in an Asian Cohort with High Cerebrovascular Disease Burden

Presenteur : Joyce Ruifen Chong

Joyce Ruifen Chong¹, Amelia Ting Yu Yam², Anqi Toh², Ng Chiew Yong², Gandan Jiang³, Temmei Ito³, Chizuru Kobayashi³, Amitabh Dash⁴, Pallavi Sachdev⁵, Christopher Chen², Mitchell Kim Peng Lai²

¹Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Wisconsin, United States, ²Memory, Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Eisai Co. Ltd., Tokyo, Japan, ⁴Eisai (Singapore) Pte Ltd., Singapore, Singapore, ⁵Eisai Inc., New Jersey, United States

P236 Neuron-Derived Extracellular Vesicles from Plasma Stratify APOE ε4 Carriers with TBI History

Presenteur : Michaela Cullum-Doyle

Michaela Cullum-Doyle^{1,2}, Matthew S. Panizzon¹, Victoria B. Risbrough¹, Robert A. Rissman²

¹University of California San Diego, La Jolla, United States, ²Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States

P238 VeraBIND Tau, a Novel Plasma Assay Reflecting Pathological Tau Binding Activity, Predicts Longitudinal Cognitive Decline Independently of Plasma pTau217

Presenteur : Bernard Hanseeuw

Bernard Hanseeuw¹, Lisa Quenon², Jean-Louis Bayart², Winnie Pak³, Josh Soldo³, Khalid Iqbal⁴

¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²UCLouvain, Brussels, Belgium, ³Veravus, Austin, United States, ⁴New York State Institute for Basic Research, New York, United States

P239 Influence of Pre-analytical Transport Conditions, Routine Blood Biomarkers, and Comorbidities on the performance of Elecsys plasma p-Tau181 (TAPOREWORLD study)

Presenteur : Peter Körtvelyessy

Peter Körtvelyessy^{1,2,3}, Falko Böhringer⁴, Luca Keller⁴, Julie Bitzer⁴, Ersin Ersözülü⁵, Julian Hellmann-Regen⁵, Laura Göschel¹

¹Charité – Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany, ²Labor Berlin, Divisions Innovation and Neurodegeneration, Berlin, Germany, ³German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, ⁴Labor Berlin, Division Studies and Cooperation, Berlin, Germany, ⁵Charité-Universitätsmedizin Berlin, Department of Psychiatry, Berlin, Germany

P240 Clinical Impact of Introducing Blood-Based pTau217 Testing in Canadian Alzheimer's Disease Diagnostic Pathways: Initial Results from a Localized Clinical Simulation Model

Presenteur : Alonso Montoya

Sophie Roth¹, Alonso Montoya², Aleina Spigelman², Ronald A. Booth³, Sharon Cohen⁴, Andrew Frank⁵, Linda Lee⁶

¹Roche Diagnostics International Ltd., Rotkreuz, Switzerland, ²Roche Diagnostics, Laval, Qc, Canada, ³University of Ottawa, Ottawa Hospital & Eastern Ontario Regional Laboratory Association (EORLA), Ottawa, On, Canada, ⁴Toronto Memory Program, Toronto, On, Canada, ⁵Bravere Health Research Institute, Ottawa, On, Canada, ⁶McMaster University, Hamilton, Schlegel-UW Research Institute for Aging, Hamilton, Waterloo, On, Canada

P242 Plasma Interleukin-6 Is Associated With Cognitive Impairment Independent of Ethnoracial Group in a Diverse Cohort of Older Adults

Presenteur : Maria Misiura

Maria Misiura¹, Tammy Joseph², Jessica Cooper³, Gabi Champion², Alex Bartlett², Jennalyn Burnette², Kyle Thatcher², Nadine Ciera Austin², Vonetta M. Dotson²

¹Center for Translational Research in Neuroimaging & Data Science | Georgia State University, Atlanta, United States, ²Georgia State University, Atlanta, United States, ³Emory University, Atlanta, United States

P243 pTau-217 in Clinical Practice: Utilization Patterns and APOE-Driven Variability in Real-World Data

Presenteur : David Alfego

David Alfego¹, Joseph Volpe²

¹Labcorp, San Diego, United States, ²Labcorp, Durham, United States

P244 Ratio-Based Plasma p-Tau217 Biomarkers Outperform Single Measures for Detecting Early Amyloid Pathology in Preclinical AD

Presenteur : James D Doecke

James D Doecke^{1,2}, Azadeh Feizpour^{3,4}, Rodrigo Canovas¹, Christopher J Fowler³, Simon Laws², Larry Ward³, Colin L Masters⁵, Ruth Pfeiffer⁶, Corey Carlson⁶, Jeremiah S Hinson⁷, Charbel Abou-Diwan⁶, Ruth Pfeiffer⁶, Christopher C Rowe^{3,4}, Vincent Dore^{8,4}

¹Australian E-Health Research Centre, CSIRO, Herston, Australia, ²Centre for Precision Health, Edith Cowan University, Joondalup, Australia, ³The Florey Institute of Neuroscience and Mental Health, Parkville, Australia,

⁴Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, ⁵Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, ⁶Beckman Coulter Diagnostics, Brea, United States,

⁷Danaher Diagnostics, Washington, United States, ⁸Australian E-Health Research Centre, CSIRO, Parkville, Australia

P245 Not a Substitute for Confirmation: The Performance of Commercial Plasma Biomarkers in a Real-World Anti-Amyloid Treatment Pathway

Presenteur : Aaron Ritter

Aaron Ritter¹, Stephanie Martins¹, Erica Welch¹, Junko Hara¹, Jefferson Kinney²

¹Hoag Neuroscience Institute, Newport Beach, United States, ²UNLV, Las Vegas, United States

P246 Foundation model-enabled multi-omic profiling for differential diagnosis of Alzheimer's disease and related dementias: discovery across AD, FTD and LBD with validation in a real-world NHS memory clinic cohort

Presenteur : Hayley Holt

Hayley Holt¹, Carolina Machado¹, Anjeet Jhutti¹, Christoforos Nalmpantis¹, Pouya Niki¹, Ravi Solanki², Georgia Ross¹, Ivan Koychev¹

¹Prima Mente, London, United Kingdom, ²Prima Mente, San Francisco, United States

P247 BD-p-Tau217/BD-p-Tau181 Tasso+ Capillary Plasma Ratio Best Correlates with Venous Plasma p-Tau217

Presenteur : Taraneh Atri

Taraneh Atri¹, Marisa N. Denkinger¹, James Liu¹, Alpana Singh¹, Michelle Surdyn¹, Victoria Brown¹, Guadalupe Martinez¹, Angela Kuramoto¹, Taina M. Marques¹, Jessica B. Langbaum², Alireza Atri¹, Nicholas J. Ashton¹

¹Banner Sun Health Research Institute, Sun City, United States, ²Banner Alzheimer's Institute, Phoenix, United States

P248 Impact of Blood-Based Biomarkers (BBMs) on Time to Treatment Initiation with Anti-Amyloid Therapies (AATs): A Retrospective Analysis Using the Optum Market Clarity Alzheimer's Enriched Data

Presenteur : Rifky Tkatch

Rifky Tkatch¹, Courtney Adams¹, Bryan Cobb¹, Feride Frech¹, Bonnie Bui², Jamie Tucker², Brady Dehart², Julia Certa², Hideki Toyosaki², Yosuke Nakamura², Rhonna Shatz³

¹Eisai Inc., Nutley, United States, ²Optum Life Science, Eden Prairie, United States, ³University of Cincinnati, Cincinnati, United States

P249 Brain Mass Spectrometry-Guided Development of Novel Plasma Immunoassays for Early Tau Pathology

Presenteur : Xuemei Zeng

Xuemei Zeng¹, Marissa Farinas¹, Lamia T Choity¹, Eric E Abrahamson¹, Milos D Ikonovic¹, Alexandra J Gilsrud¹, Monika R Sanotra¹, Julia K Kofler¹, Beth E Snitz¹, Annie D Cohen¹, Oscar L Lopez², Lei Liu², Jasmeer P Chhatwal², Thomas K Karikari¹

¹University of Pittsburgh, Pittsburgh, Pa. United States. ²Harvard University, Cambridge, Ma. United States

P250 Plasma and Tau-PET Reflect Distinct Biological Processes Underlying Cognitive Decline in Alzheimer's Disease

Presenteur : James D Doecke

James D Doecke^{1,2}, Azadeh Feizpour^{3,4}, Rodrigo Canovas⁵, Christopher J Fowler³, Jurgen Fripp¹, Simon Laws^{2,6}, Larry Ward³, Colin L Masters⁷, Paul Maruff⁸, Corey M Carlson⁹, Jeremiah S Hinson¹⁰, Charbel Abou-Diwan⁹, Ruth Pfeiffer⁹, Christopher C Rowe^{3,4}, Vincent Dore⁵

¹The Australian e-Health Research Centre, CSIRO, Herston, Australia, ²Centre for Precision Health, Edith Cowan University, Joondalup, Australia, ³The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, ⁴Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Australia, ⁵The Australian e-Health Research Centre, CSIRO, Parkville, Australia, ⁶Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁷Alzheimer's Research Australia, University of Western Australia, Nedlands, Australia, ⁸Cogstate, Ltd, Parkville, Australia, ⁹Beckman Coulter Diagnostics, Chaska, United States, ¹⁰Danaher Diagnostics, Washington, United States

P251 From Bench to Bedside: Presynaptic Complexins as Synaptic Endpoints for Alzheimer's Disease Trials

Presenteur : Ted Wilson

Justin H. Mendiola¹, Sophie Jones¹, Masood Manoochehri¹, Bess Frost¹, Edward Huey², Ted Wilson¹

¹Brown University, Providence, United States, ²Butler Hospital, Providence, United States

P252 Performance of Plasma and CSF biomarkers for tauPET staging in Alzheimer's Disease: evidence from mass spectrometry and immunoassays in Autonomy

Presenteur : Shannon Leslie

Tina Wang¹, Shannon Leslie¹, Setareh Moughadam¹, Fatma Ayhan², Stephanie Slania², Kristof Van Kolen³, Ziad Saad¹, Gallen Triana-Baltzer¹

¹Johnson & Johnson, San Diego, United States, ²Johnson & Johnson, Springhouse, United States, ³Johnson & Johnson, Beerse, Belgium

P253 — Remote Apolipoprotein E4 quantification by NULISA in cognitively unimpaired cohorts for screening for APOE ε4 carriership and homozygosity

Presenteur : Ashvini Keshavan

Ashvini Keshavan^{1,2}, Katharine Wiltshire^{1,2}, Amanda Heslegrave², Henrik Zetterberg^{2,3}, Jonathan Schott^{1,2}

¹Dementia Resarch Centre, UCL Queen Square Institute of Neurology, London, United Kingdom, ²UK Dementia Research Institute at University College London, London, United Kingdom, ³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

P254 A Clinically Tractable Five-protein Plasma Panel Improves Alzheimer's Disease Diagnosis Beyond p-Tau217

Presenteur : Johannes Eichner

Johannes Eichner¹, Scott Levin², Muhammad Ali³, Carlos Cruchaga³, Timo Wittenberger¹, Jeremiah Hinson²

¹Genedata, Basel, Switzerland, ²Danaher Diagnostics, Washington, Dc, United States, ³Washington University, Saint Louis, Mo, United States

P255 Plasma brain-derived p-tau217/total-tau ratio outperforms plasma p-tau217 for detecting autopsy-confirmed Alzheimer's neuropathology, including in early-disease and mixed-pathology cases

Presenteur : Denis Smirnov

Denis Smirnov^{1,2}, Xuemei Zeng³, Marissa Farinas³, Michel Nafash³, Victor Villemagne³, Sarah Berman³, Henrik Zetterberg⁴, Tharick Pascoal³, Beth Snitz³, Ann Cohen³, Oscar Lopez³, M. Ilyas Kamboh³, Milos Ikonomic³, Julia Kofler³, Thomas Karikari³

¹Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States, ³University of Pittsburgh, Pittsburgh, United States, ⁴University College London, London, United States

P256 Blood-Based and Digital Biomarker Strategies Are Reshaping Alzheimer's Clinical Trial Recruitment, Cohort Readiness, and Site Operations

Presenteur : Sean Stanton

Sean Stanton, Candice Espinoza, Sameer Siddiqui, Taylor Rice, Brandon Lenox, Briana Stanton

K2 Medical Research, Maitland, Fl, United States

P257 Quantum Capacitance Electrochemical Biosensor for the Rapid and Ultrasensitive Detection of p-tau217 and MTBR-tau243

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra¹, Keyao Song¹, Spondita Goswami², Rajan K. Chakrabarty¹

¹Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, United States, ²Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, United States

P258 Single-aggregate detection of misfolded neurodegenerative disease proteins

Presenteur : Andrew Stern

Andrew Stern¹, Chungmin Han², Borberg Ella², Lily Wickland Shearer¹, Tal Gilboa², Zoe Swank², Arek Melkonian², Justin Rolando², David Walt²

¹Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital Department of Neurology, Boston, United States, ²Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, United States

P259 US Real-World Patterns of Amyloid Testing and Anti-Amyloid Therapy Initiation in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI)

Presenteur : Kinyee Fong

Kinyee Fong¹, Ameer M. Manceur², Nick Belviso¹, Eli Shobin¹, Boyang Bian¹, Akash Bhushan³, Lisa Leung³, Adyasha Das³, Sonick Suri³, Vamsi Chandra Kasivajjala³, Lydia Wood¹

¹Biogen MA Inc., Cambridge, United States, ²Cytel, Cambridge, United States, ³NeuroDiscovery AI, Alpharetta, United States

P260 Needle-free biomarker detection platform using the olfactory neuroepithelium: superiority to blood-based assays in Alzheimer's disease

Presenteur : Koko Ishizuka

Koko Ishizuka, Guanqun Shang, Akira Sawa

Johns Hopkins University, Baltimore, United States

P261 Validation of Elecsys pTau217 plasma assay cutoffs for detection of amyloid pathology across care settings

Presenteur : Annunziata Di Domenico

Annunziata Di Domenico¹, Sayuri Hortsch², David Caley³, Niels Borlinghaus², Kaj Blennow^{4,5}, Oskar Hansson^{5,6}, Marc Suárez-Calvet^{7,8}, Craig Ritchie⁹, Nicholas Ashton^{10,11}, Marisa Denkinger¹¹, Christopher Rowe^{12,13}, Ming Lu¹⁴, Sameera Wijayawardana¹⁵, Sebastian Palmqvist^{6,16}

¹Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ²Roche Diagnostics GmbH, Penzberg, Germany, ³Roche Diagnostics Ltd, Burgess Hill, United Kingdom, ⁴Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ⁵Eli Lilly and Company, Stockholm, Sweden, ⁶Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, ⁷BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, ⁸Servei de Neurologia, Hospital del Mar, Barcelona, Spain, ⁹Scottish Brain Sciences, Edinburgh, United Kingdom, ¹⁰Banner Alzheimer's Institute and University of Arizona, Phoenix, United States, ¹¹Banner Sun Health Research Institute, Sun City, United States, ¹²Australian Dementia Network Ltd, Melbourne, Australia, ¹³University of Melbourne, Melbourne, Australia, ¹⁴Eli Lilly and Company, Philadelphia, United States, ¹⁵Eli Lilly and Company, Indianapolis, United States, ¹⁶Memory Clinic, Skåne University Hospital, Malmö, Sweden

P262 Mitigating amyloid endpoint heterogeneity to establish robust cutoffs and clinical performance of Elecsys pTau217 and pTau181 plasma immunoassays

Presenteur : Sayuri Hortsch

Sayuri Hortsch¹, Annunziata Di Domenico², Myrto Andreadou², Imke Kirste³, Michael Weiner⁴, Christopher Rowe^{5,6}, James Doecke^{7,8}, Niklas Mattsson-Carlgrén^{9,10}, Sebastian Palmqvist^{9,10}, Gregory Klein¹¹, Tobias Bittner^{11,12}

¹Roche Diagnostics GmbH, Penzberg, Germany, ²Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ³Roche Molecular Systems Inc, Tucson, United States, ⁴University of California San Francisco, San Francisco, United States, ⁵Australian Dementia Network, University of Melbourne, Melbourne, Australia, ⁶Austin Health, Melbourne, Australia, ⁷Australian E-Health Research Centre, CSIRO, Brisbane, Australia, ⁸Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, ¹⁰Memory Clinic, Skåne University Hospital, Malmö, Sweden, ¹¹F. Hoffmann-La Roche Ltd, Basel, Switzerland, ¹²Genentech, Inc., San Francisco, United States

P263 The associations between plasma-based synaptic, neurodegeneration, vascular, and inflammatory biomarkers with synaptic density in neurodegeneration measured using [18F]SynVesT-1 PET.

Presenteur : Koen Poesen

Koen Poesen¹, Soha Alali¹, Charles Carron¹, Amir Ghodrati¹, Susanne Schmidt², Koen Van Laere¹

¹KU Leuven, Leuven, Belgium, ²UBonn, Bonn, Germany

P264 Inflammatory Biomarkers in Alzheimer's Disease Immunomodulatory Trials: A Systematic Review of Biomarker–Clinical Concordance and Translational Context-of-Use

Presenteur : Myuri Ruthirakuhan

Myuri Ruthirakuhan¹, Nicole Owsicki¹, Sofia Perfetto¹, Kiran Shocker¹, Amanda Leisgang Osse², Yadi Zhou³, Min Su Kang¹, Feixiong Cheng³, Walter Swardfager¹, Jeffrey Cummings², Julie Ottroy^{1,4}

¹Sunnybrook Research Institute, Toronto, On, Canada, ²Department of Brain Health, University of Nevada Las Vegas, Las Vegas, United States, ³Cleveland Clinic, Las Vegas, United States, ⁴Department of Medicine (Neurology), University of Toronto, Toronto, On, Canada

P265 Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry

Presenteur : Jun Pyo Kim

Jun Pyo Kim¹, Gwendlyn Kollmorgen², Christian Kuffer², Annunziata Di Domenico³, Myrto Andreadou³, Tobias Bittner^{4,5}, Sayuri Hortsch², Sang Won Seo¹

¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, ²Roche Diagnostics GmbH, Penzberg, Germany, ³Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Genentech, Inc., South San Francisco, United States

P266 Inflection-based ordering of plasma and PET biomarkers along an Alzheimer's disease progression axis in two independent cohorts

Presenteur : Jeon So Yeon

Lee Kyungsung¹, Yi Dahyun², Ham Hyunsun³, Byun Min Soo^{4,5}, Kim Yu Kyeong^{6,7}, Lee Jun-Young^{3,4}, Lee Dong Young^{4,5}, Jeon So Yeon^{3,4}

¹Emocog, Seoul, Korea, Republic of, ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea, Republic of, ³Department of Psychiatry, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of, ⁴Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁵Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea, Republic of, ⁶Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁷Department of Nuclear Medicine, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of

P267 From Stackers to Streamliners: Alzheimer's Disease Work-up Archetypes and the Impact of AD BBM Ratio Test Results on Diagnostic Escalation

Presenteur : Trever Burgon

Trever Burgon¹, David Paculdo¹, Lopamudra Das²

¹QJURE Healthcare, St. Louis, United States, ²Beckman Coulter Diagnostics, Brea, United States

P268 A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment

Presenteur : Ser Mien Chia

Ser Mien Chia¹, Yumi Kawamura¹, Geetha Chilla¹, Nicholas Ho¹, Charlene Ong¹, Matthew Choo¹, Ryan Clark², Dean Lee¹, Asad Abu Bakar Ali¹, Matthew Kennedy²

¹Quantitative Biosciences, MSD International GmbH, Singapore, Singapore, Singapore, ²Discovery Neuroscience, Merck & Co., Inc., Boston, MA, USA, Boston, United States

P269 A 5-Plex Plasma Biomarker Panel for Amyloid PET Status Classification Beyond pTau-217 Alone: A Pilot Study

Presenteur : Noah Elder

Noah Elder, Hien Nguyen, Jason Wan, Robert Lin

Taudia, Inc., San Carlos, United States

P270 Development of a plasma biomarker signature for Alzheimer's disease using the Roche NTK; what do we gain by adding to pTau217?

Presenteur : James D. Doecke

Rodrigo Canovás¹, Azadeh Feizpour^{2,3}, Christopher J. Fowler², Vincent Dóré^{1,3}, Gwendlyn Kollmorgen⁴, Clara Quijano-Rubio⁵, Christopher M. Rank⁴, Simon M. Laws^{6,7,8}, Larry Ward², Colin L. Masters⁹, Christopher C. Rowe^{2,3}, James D. Doecke^{6,10}

¹The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia, ²The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Melbourne, Victoria, Australia, ³Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia, ⁴Roche Diagnostics GmbH, Penzberg, Germany, ⁵Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ⁶Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia, ⁷Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western Australia, Australia, ⁸Curtin Medical School, Curtin University, Bentley, Western Australia, Australia, ⁹Alzheimer's Research Australia, The University of Western Australia, Western Australia, Australia, ¹⁰The Australian e-Health Research Centre, CSIRO, Brisbane, Australia

P271 Use of the VeraBIND Tau Functional Plasma Assay to Detect Active Tau Pathology in Preclinical Mouse Models

Presenteur : Nicole M Maphis

Nicole M Maphis^{1,2}, Joshua Soldo³, Kavya Shamsundar³, Winnie Pak³, Khalid Iqbal^{4,5}, Ali Riazi², Kiran Bhaskar^{1,2}

¹Department of Molecular Genetics & Microbiology/Neurology, University of New Mexico, Albuquerque, United States, ²TheraVac Biologics, Albuquerque, United States, ³Veravas, Inc, Austin, United States, ⁴New York State Institute for Basic Research in Developmental Disabilities, Staten Island, United States, ⁵Phanes Biotech, Inc, Malvern, United States

P272 — Remote Real-World Plasma Alzheimer Biomarkers, Amyloid PET, and Functional–Cognitive Burden in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenteur : Hanan Sheikh Ibrahim.md, facp

Hanan Sheikh Ibrahim, Md, Facp

¹Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates ²Center for Continuing Medical Learning (CCLM), Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P273 Toward an inflammation axis for the ATN(V)I framework in dementia: CSF outperforms plasma and MRI biomarkers using the albumin index as a standard for inflammation

Presenteur : Gary Rosenberg

Azadeh Golduzian, Erik Erhardt, Atvind Caprihan, John Adair, Jsnice Knoefel, Jill Prestopnick, Sasha Hobson, Gary Rosenberg

University of New Mexico, Albuquerque, United States

P274 Brain-enriched Circular RNAs as blood-based biomarkers for detection of Alzheimer's disease-related biology across the disease continuum

Presenteur : Nikolaos Mellios

Nikolaos Mellios¹, Bridget Phillips², Jessie Sanford², Vaibhav Janve³, Nikolaos Mellios¹, Grigorios Papageorgiou¹, John Morris², Joel Perlmutter², Paul Kotzbauer², Richard Perrin², Timothy Hohman³, Laura Ibanez², Carlos Cruchaga²

¹Circular Genomics, San Diego, United States, ²Washington University School of Medicine, St Louis, United States, ³Vanderbilt University Medical Center, Nashville, United States

P275 A diagnostic blood omics-biomarker for Alzheimer's disease informed by microglial single-cell transcriptomics: A pilot study

Presenteur : Ornit Chiba-Falek

Michael Lutz, Ornit Chiba-Falek

Duke University, Durham, United States

P277 Elecsys pTau217 plasma assay cutoff determination and validation for the detection of amyloid pathology in a Chinese population

Presenteur : Jiawei Xin

Jiawei Xin¹, Yuyuan Huang², Xuhui Chen³, Ming Guan², Chuantao Zuo², Yingping Cao¹, Zhongyou Ji¹, Mengjie Dong³, Jun Hu³, Guoyu Lan⁴, Qiman Yin⁵, Yim Yung⁵, Xiaochun Chen¹, Jintai Yu², Tengfei Guo⁴

¹Fujian Medical University Union Hospital, Fuzhou, Fujian, China, ²Huashan Hospital affiliated to Fudan University, Shanghai, China, ³Peking University Shenzhen Hospital, Shenzhen, Guangdong, China, ⁴Shenzhen Bay Laboratory, Shenzhen, Guangdong, China, ⁵Roche Diagnostics (Shanghai) Ltd, Beijing, China

P278 Evaluation of Alzheimer's Blood Based Biomarkers in Race, Sex, Education, FAST and APOE ε4 Carrier Status Evaluation of Alzheimer's Blood based biomarkers in race, sex, education, FAST and APOE ε4 Carrier Status

Presenteur : Ruhaan Shah

Maya Ibrahim¹, Ruhaan Shah², Ira Katigbak², Lee Watson², Omar Almashharawi², Isabella Principe², Eduardo Chacon², Kevin Aimua², Rory Roberts², Monica Crane²

¹Tennessee Memory Disorders Foundation, Knoxville, United States, ²Tennessee Memory Disorders Foundation - Knoxville (United States), Knoxville, United States

P279 Comparative and Incremental Value of Plasma p-tau217, GFAP, NfL, and Aβ42/40 Across Amyloid, Tau, and Clinical Progression

Presenteur : Sunghwan (Andy) Kim

Sunghwan (Andy) Kim¹, Jun-Young Lee^{2,3}, So Yeon Jeon⁴, Jeong-Mi Moon¹

¹Emocog Inc., Gwacheon, Korea, Republic of, ²Seou National University, Gwacheon, Korea, Republic of, ³Emocog Inc. - Seoul (Korea, Republic of), Seoul, Korea, Republic of, ⁴Seou National University, Seoul, Korea, Republic of

P280 Short-term reproducibility and clinical risk categorization of commercial plasma biomarkers for Alzheimer's disease in a real-world US hospital setting

Presenteur : Lighwa Ncube

Lighwa Ncube, Joseph Morales, Briella Smaw, Elita Farahdel, Tafadzwa Nyikadzino, Danielle Jacobstein, Claudia Kunney, Anna Torten Rabinowitz, Ophir Keret, George Naasan, Fanny Elahi

Icahn School of Medicine at Mount Sinai, New York, United States

P281 — Remote Plasma Phosphorylated Tau in Alzheimer's Disease: The Translational Shift Toward Scalable Early Detection

Presenteur : Princess Obazee

Princess Obazee¹, Harita Dilip², Pranjal Arekar³, Alexander Nguyen⁴, Amelia Schenk⁵, Grace Lee⁶, Shreeya Kerthipati⁷, Shefali Bandla⁸, Saanvi Jain⁹, Sahana Saravana Kumar¹⁰, Aanya Veeranagoudar¹¹, Abel Biju¹², Peter Kucharczyk¹³

¹ThinkNeuro, Columbia, United States, ²ThinkNeuro, Cary, United States, ³ThinkNeuro, Little Rock, United States, ⁴ThinkNeuro, Houston, United States, ⁵ThinkNeuro, Bridgewater Township, United States, ⁶ThinkNeuro, Austin, United States, ⁷ThinkNeuro, Coppell, United States, ⁸ThinkNeuro, Denton, United States, ⁹ThinkNeuro, Livingston, United States, ¹⁰ThinkNeuro, Frisco, United States, ¹¹ThinkNeuro, Louisville, United States, ¹²ThinkNeuro, Toronto, Canada, ¹³ThinkNeuro, New York, United States

P282 AI-Based Retinal Hyperspectral Imaging for Detection of Brain Amyloid Pathology: Cohort Characterization and Blinded Validation Framework from the Bio-Hermes-002 Study

Presenteur : Eliav Shaked

Anthony Rinaldi¹, Justin Digregorio¹, Yanir Levy¹, Jared Westreich¹, Bar Mayo¹, Ahmad Omar Ahsan¹, Mailis Bietenhader¹, Rozana Naureen¹, Eliav Shaked¹, Doug Beauregard²

¹RetiSpec, Toronto, Canada, ²Global Alzheimer's Platform Foundation, Washington, United States

P283 Cost and Time Impact of LucentAD Complete as a Blood-Based Diagnostic Aid for Alzheimer's Disease: A Model-Based Analysis

Presenteur : Sam Dickson

Caleb Dayley¹, Lindsey Mette², David Wilson², Prince Agyapong¹, Mitch Wassom¹, Sam Dickson¹

¹Pentara Corporation, Salt Lake City, United States, ²Quanterix Corporation, Billerica, United States

P284 Utility of plasma pTau217 for cohort enrichment and outcome measurement in prevention trials

Presenteur : Pia Kivisäkk

Pia Kivisäkk, Hadia Fatima, Chao-Yi Wu, Hiroko H Dodge, David H Salat, Steven E Arnold

Massachusetts General Hospital, Harvard Medical School, Boston, United States

P285 Macrostructural brain changes associated with baseline Alzheimer's disease pathology: A longitudinal MRI study with CSF biomarkers from BIOCARD

Presenteur : [Dishaa Sinha](#)

Dishaa Sinha¹, Ishan Durve², Harshita Sinha³, Ahmet Begde¹, Yi Yang¹, Elijah Mak⁴, Nemanja Vaci⁵, Vanessa Raymont¹, Alejo Nevado-Holgado¹, Ivan Koychev⁶

¹University of Oxford, Oxford, United Kingdom, ²Independent Researcher, Mumbai, India, ³Queen Mary University of London, London, United Kingdom, ⁴Mayo Clinic, Rochester, United States, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Imperial College London, London, United Kingdom

P286 Racial and Ethnic Differences in Blood-Based Biomarkers of Alzheimer's Disease Risk

Presenteur : [Alexis Cieluch](#)

Alexis Cieluch, Mark Rapp, Avigayil Rapp, Thomas Fomin

Basil Clinical, Queens, United States

P287 Predicting Progression to Mild Cognitive Impairment Using a Machine Learning Model

Presenteur : [Alexa Pichet Binette](#)

Sebastian Rodriguez Marquez¹, Yara Yakoub², Jany Lehouillier¹, Clémence Peyrot¹, Alexa Pichet Binette¹

¹Université de Montréal, Montreal, Canada, ²Douglas Mental Health University Institute, Montreal, Canada

P288 Development and Analytical Validation of a High-Sensitivity Automated Immunoassay for p-tau205

Presenteur : [Masashi Mori](#)

Hiroimi Miyazaki¹, Masashi Mori¹, Nanako Doi¹, Yuta Imai², Aoi Tanaka², Kengo Ishiki², Mayu Fujita¹, Yoshifumi Shima¹, Masahiro Miura², Shinichiro Oguni¹

¹Reagent Development Division, Sysmex Corporation, Kobe, Japan, ²Central Research Laboratories, Sysmex Corporation, Kobe, Japan

P289 Therapeutic antibody interference with CSF tau assays in a gosuranemab basket trial across four primary tauopathies

Presenteur : [Connor Dietz](#)

Connor Dietz^{1,2}, Molly Olzinski², Yann Cobigo², Amy Wolf², Argentina Lario Lago², Nicholas Ashton^{3,4}, Rowan Saloner², Howie Rosen², Richard Tsai^{2,5}, Julio Rojas², Lawren Vandevrede², Danielle Graham⁶, Tien Dam⁷, Peter Ljubenkov², Adam Boxer²

¹Department of Medicine (Neurology), University of British Columbia, Vancouver, Canada, ²Edward and Pearl Fein Memory and Aging Center, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, United States, ³Banner Alzheimer's Institute and University of Arizona, Arizona, United States, ⁴Banner Sun Health Research Institute, Sun City, United States, ⁵Denali Therapeutics, South San Francisco, United States, ⁶Biogen, Cambridge, United States, ⁷Brenig Therapeutics, Somerville, United States

P290 Plasma Biomarkers of ARIA identified through NULISaseq Multiplex Profiling

Presenteur : [Gloria Xie](#)

Murali Doraiswamy, Laura Wang, Amber Navarra, Gloria Xie, Jeffrey Petrella, Andy Liu

Duke University, Durham, United States

P291 — Remote Re-evaluating TDP-43 assays: Hemolysis interference limits clinical utility

Presenteur : [Myrto Andreadou](#)

Myrto Andreadou¹, Anna Bayfield², Laura Effert², Nicholas J. Ashton³, Sterling Johnson⁴

¹Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ²Roche Diagnostics GmbH, Penzberg, Germany, ³Banner Sun Health Research Institute, Sun City, Az, United States, ⁴University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States

P292 Optimizing the Alzheimer's disease diagnostic pathway: An economic evaluation of a pTau217 blood-based biomarker in primary and specialist care in the US

Presenteur : [Matthew De Nave](#)

Sophie Roth¹, Matthew De Nave², Jared R. Brosch³, Jeffrey M. Burns⁴, Soeren Mattke⁵, Lawren Vande Vrede⁶, Maria-Magdalena Patru²

¹Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ²Roche Diagnostics Corporation, Indianapolis, United States, ³Indiana University School of Medicine, Indianapolis, United States, ⁴University of Kansas Medical Center, Kansas City, United States, ⁵University of Southern California, Los Angeles, United States, ⁶University of California, San Francisco, United States

P293 Novel High-Throughput, Fully Automated Immunoassay for Cerebrospinal Fluid Phosphorylated Tau-205

Presenteur : [Ben Schlichtmann](#)

Ben Schlichtmann¹, Laia Montoliu-Gaya², Andrew Becker¹, Miklos Szabo¹, Juan Lantero-Rodriguez², Marnie Wallin¹, Jean-Sebastien Blanchet³, Henrik Zetterberg², Mikaela Nickkova-Doseva¹

¹Beckman Coulter, Inc., Chaska, Minnesota, United States, ²University of Gothenburg, Gothenburg, Sweden, ³Beckman Coulter, Inc., Villepinte, France

P294 Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid-β pathology in early Alzheimer's disease: a 12-country survey

Presenteur : [Amitabh Dash](#)

Amitabh Dash¹, Temmei Ito², Gandan Jiang²

¹Eisai (Singapore) Pte Ltd., Singapore, Singapore, ²Eisai Co. Ltd., Tokyo, Japan

P295 Development and Analytical Validation of APOE Genotyping with Dried Blood Spots on FTA cards

Presenteur : Kumar Gyanendra

Emily Bogden, Abiordepey Kenny, Alidad Mireskandari, Finkelstein Sydney, Kumar Gyanendra
Diamir BioSciences, New Haven, United States

P296 BD pTau-217 and eMTBR-tau243 plasma biomarkers for Amyloid and Tau PET Classification in Alzheimer's Disease

Presenteur : Noah Elder

Noah Elder, Hien Nguyen, Robert Lin, Jason Wan
Taudia, Inc., San Carlos, United States

P297 Association of CSF p-tau217 with PET-Derived Individualized Amyloid Chronicity in PSEN1-E280A Mutation Carriers

Presenteur : V Ghisays

V Ghisays¹, Y Su², L Shan², M.N Denking¹, H.D Protas², D Aguillon³, T Bittner⁴, J.B Langbaum², P.N Tariot², S.C Johnson⁵, E.M Reiman², R.C Alexander², N.J Ashton¹

¹Banner Sun Health Research Institute, Sun City, United States, ²Banner Alzheimer's Institute, Phoenix, United States, ³Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia, ⁴F. Hoffmann-LaRoche Ltd, Basel Switzerland and Genentech Inc. a member of the Roche Group, South San Francisco, United States, ⁵University of Wisconsin School of Medicine and Public Health, Madison, United States

P298 Identifying circulating biomarkers for amyloid conversion and early cognitive decline in matched CSF and plasma through unbiased proteomics

Presenteur : Matthijs De Geus

Matthijs De Geus¹, Shichkova Polina², Jan Muntel¹, Aida Kamalian³, Alan Shomo¹, Nicole Barlow¹, Yuehan Feng², Abhay Moghekar³

¹Biogen Inc., Boston, United States, ²Biogen Inc., Schlieren, Switzerland, ³Johns Hopkins University, Baltimore, United States

P299 Baseline CSF p-tau181/Ab42 ratio predicts ARIA risk in lecanemab patients

Presenteur : Bethany Curd

Bethany Curd, Lin-Na Chou, Camilla Zubrick, Christine Cliatt Brown, Michelle Sorweid, Yoshimi Anzai, Satoshi Minoshima, Nicholas Frost
University of Utah, Salt Lake City, United States

P300 Astroglial Activation and Neurodegeneration as Kinetic Switches for p-Tau 217 Progression: A Longitudinal Multi-Analyte Stratification Analysis

Presenteur : David Wilson

David Wilson, Lindsey Mette, Meenakshi Khare, Matt Polack, Jorge Marques
Quantex, Billerica, United States

P301 Establishing a Biobank Registry for Limbic-predominant Age-related TDP-43 Encephalopathy at Sutter Health

Presenteur : Shawn Kile

Shawn Kile, Armen Moughamian, Kimberly Christensen, Tammy Donnel, Sarah Robinson, Katherine Gillespie, Gregory Tranah
Sutter Health Research Institute, San Francisco, United States

P303 Distribution of Biomarkers Among Patients Meeting Clinical Criteria for Alzheimer's Disease Psychosis Who Are Biomarker Negative for Amyloid Proteinopathy and p-Tau217

Presenteur : Samantha Friend

Samantha Friend¹, Bryan Dirks², Becky Howell², Xiaoshu Feng², Sanjeev Pathak²

¹Acadia Pharmaceuticals Inc., San Diego, United States, ²Acadia Pharmaceuticals Inc., Princeton, United States

P304 A Novel 5-Plex SPEAR Assay Targeting BD-pTau 217, eMTBR-Tau, BD-Tau, NF-L and GFAP Enables Comprehensive Assessment of Alzheimer's Disease Pathology and Neurodegeneration

Presenteur : Tracy Liu

Ahsan Ausaf Ali, Jiachong Chu, Pengyu Hao, Xi Chen, Arian Pushka, Chi Tang, Zidong Wang, Tracy Liu, Feng Xuan
Spear Bio, Woburn, United States

P305 Improved Stratification of Parkinson's Disease Using a Novel Ratio Analysis of Total and pS129- α -Synuclein Enabled by the SPEAR Platform

Presenteur : Tracy Liu

Jeremy Tan, Emma Tordoff, Erden Eren, Tucker Fontana, Tsz Wing Fan, Tracy Liu, Xue Feng
Spear Bio, Woburn, United States

P306 Enhanced Discrimination of Parkinson's Disease Using a Novel α -Synuclein Signature Assay on the SPEAR Platform

Presenteur : **Tracy Liu**

Erden Eren, Jeremy Tan, Emma Tordoff, Tucker Fontana, Tsz Wing Fan, Feng Xuan, Tracy Liu

Spear Bio, Woburn, United States

P307 — Remote Longitudinal Analysis of Circulating microRNA Expression Patterns During Alzheimer's Disease Progression in the 3xTg-AD Mouse Model

Presenteur : **Simran Yadav**

Simran Yadav¹, Aida Muntsant-Soria², Lydia Giménez-Llort², Urszula Wojda¹

¹Laboratory of Preclinical Testing of Higher Standard, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland, Warszawa, Poland, ²Institut de Neurociències, Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain., Spain, Poland

P308 Comparing results from three Alzheimer's Disease plasma biomarker tests in a prescreen study in healthy elderly participants

Presenteur : **Lydia Morris**

Lydia Morris¹, Lev Gertsik¹, Svetlana Semenova², Gary Walker³, Aaron Koenig³

¹California Clinical Trials Medical Group, Glendale, United States, ²Parexel International, Glendale, United States, ³Syndeio Biosciences, Indianapolis, United States

P309 — Remote Development and Analytical Validation of a Plasma ELISA for Glial Fibrillary Acidic Protein (GFAP) and Exploratory Analysis in a Clinical Cohort of Patients with Alzheimer's disease

Presenteur : **Maria Pascual-Lucas**

Noelia Fandos¹, Raquel Rodríguez¹, Judith Romero¹, María Pascual-Lucas¹, José Antonio Allué¹, Leticia Sarasa¹, Jesús Canudas¹, Ignacio Martínez¹, María Montañés¹, Jose Terencio^{2,1}, Jorge Loscos¹

¹Araclon Biotech, Zaragoza, Spain, ²Grifols, Sant Cugat Del Vallès, Barcelona, Spain

P310 Blood CD8 T cell recognition of APP and derivative non-A β peptides as screenable biomarkers for Alzheimer's and related MCI

Presenteur : **Christopher Wheeler**

Christopher Wheeler^{1,2,3,4}, Pénélope Bourgoin⁵, Debby Van Dam^{6,7}, Yannick Vermeiren^{8,9}, Hans De Reu⁹, Peter Paul De Deyn^{6,7}, Jean-Marc Busnel⁵

¹T-NeuroDx, Ortega NeuroTherapeutics, Albuquerque, Aptos, United States, ²Society for Brain Mapping & Therapeutics, World Brain Mapping Foundation., Los Angeles, United States, ³StemVax LLC, a wholly owned subsidiary of NovAccess Global, Cleveland, United States, ⁴Dept of Chemistry & Biochemistry, University of California, Santa Cruz, Santa Cruz, United States, ⁵Beckman-Coulter Life Sciences, Marseille, France, ⁶Dept of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, ⁷Dept of Neurology and Alzheimer Research Center, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands, ⁸Department of Biomedical Sciences, Institute Born-Bunge, Laboratory of Neurochemistry and Behavior, University of Antwerp, Antwerp, Belgium, ⁹Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Antwerp, Belgium

P311 Blood-Based Circular RNA Biomarkers for Alzheimer's Disease: Analytical Performance Using circRNA-specific quantitative and digital droplet PCR

Presenteur : **Nikolaos Mellios**

Grigorios Papageorgiou¹, Bridget Phillips², Carlos Cruchaga², Nikolaos Mellios¹

¹Circular Genomics, San Diego, United States, ²Washington University School of Medicine, St. Louis, United States

P312 Circular RNA Biomarkers for Alzheimer's Disease are Associated with Multi-Lineage Pathological Pathways and significantly enriched in the brain

Presenteur : **Nikolaos Mellios**

Grigorios Papageorgiou¹, Bridget Phillips², Carlos Cruchaga², Nikolaos Mellios¹

¹Circular Genomics, San Diego, United States, ²Washington University School of Medicine, St. Louis, United States

P313 Alzheimer's Disease specificity and consistent performance of a Circular RNA Blood-Based Biomarker Model Across Diverse Populations

Presenteur : **Jessica Dehart**

Bridget Phillips¹, Jessie Sanford¹, Vaibhav Janve², Nikolaos Mellios³, Grigorios Papageorgiou³, Jessica Dehart³, John Morris¹, Joel Perlmutter¹, Paul Kotzbauer¹, Richard Perrin¹, Timothy Hohman², Laura Ibanez², Carlos Cruchaga¹

¹Washington University School of Medicine, St. Louis, United States, ²Vanderbilt University Medical Center, Nashville, United States, ³Circular Genomics, San Diego, United States

P314 Circular RNA Blood-Based Biomarkers Reliably Predict Progression of Asymptomatic Individuals to Alzheimer's Disease: ADRC and A4/LEARN Cohort Replication

Presenteur : **Jessica Dehart**

Bridget Phillips¹, Jessie Sanford¹, Vaibhav Janve², Nikolaos Mellios³, Grigorios Papageorgiou³, Jessica Dehart³, John Morris¹, Joel Perlmutter¹, Paul Kotzbauer¹, Richard Perrin¹, Timothy Hohman², Laura Ibanez², Carlos Cruchaga¹

¹Washington University School of Medicine, St. Louis, United States, ²Vanderbilt University Medical Center, Nashville, United States, ³Circular Genomics, San Diego, United States

P315 Domain-Specific CSF Proteomic Signatures of Cognitive Function in the ALBION Cohort

Presenteur : Sokratis Charisis

Vasiliki Amaryllis Skyfa^{1,2}, Christopher Papandreou¹, Martina Samiotaki³, Georgios Hadjigeorgiou⁴, Efthimios Dardiotis⁵, Mary H. Kosmidis⁶, Mary Yannakoulia⁷, Paraskevi Sakka⁸, Archontoula Drouka⁷, Dora Brikou⁷, Eirini Mamalaki⁷, Eva Ntansi², Nikolaos Scarmeas², Sokratis Charisis⁹, George Manias¹⁰

¹Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, ²First Department of Neurology, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece, ⁴Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, ⁵Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, ⁶Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁷Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, ⁸Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, ⁹Harvard Medical School & Massachusetts General Hospital, Boston, United States, ¹⁰Department of Digital Systems, University of Piraeus, Piraeus, Greece

P316 Amyloid Pathology Modulates the Proteomic Architecture of Global Cognition

Presenteur : Sokratis Charisis

Vasiliki Amaryllis Skyfa^{1,2}, Christopher Papandreou¹, Martina Samiotaki³, Georgios Hadjigeorgiou⁴, Efthimios Dardiotis⁵, Mary H. Kosmidis⁶, Mary Yannakoulia⁷, Paraskevi Sakka⁸, Archontoula Drouka⁷, Dora Brikou⁷, Eirini Mamalaki⁷, Eva Ntansi², Nikolaos Scarmeas², Sokratis Charisis⁹, Athos Antoniadis¹⁰

¹Department of Nutrition and Dietetics, School of Health Sciences, Hellenic Mediterranean University, Crete, Greece, ²First Department of Neurology, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Vari, Greece, ⁴Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus, ⁵Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece, ⁶Laboratory of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, Thessaloniki, Greece, ⁷Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, ⁸Athens Association of Alzheimer's Disease and Related Disorders, Athens, Greece, ⁹Harvard Medical School & Massachusetts General Hospital, Boston, United States, ¹⁰Stremble Ventures LTD, Limassol, Cyprus

P317 – Remote Reducing the P-tau217 Diagnostic Grey Zone Through Multimarker and Sequential Strategies Incorporating Plasma A β in Mild Cognitive Impairment

Presenteur : María Pascual-Lucas

María Pascual-Lucas¹, Leticia Sarasa¹, Noelia Fandos¹, Jorge Loscos¹, Judith Romero¹, Adrián Sánchez¹, Jose Terencio^{2,1}, Isabel Ortega-Madueño³, María Cruz Cárdenas³, Fernando Cava-Valenciano³, María José Gil-Moreno⁴, Jordi A Matías-Guiu⁴, Jose Antonio Allué¹

¹Araclon Biotech-Grifols, Zaragoza, Spain, ²Grifols, Barcelona, Spain, ³Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain, ⁴Department of Neurology, Hospital Clínico San Carlos, Madrid, Spain

P318 – Remote Factors influencing longitudinal plasma phospho-tau 217 and 181 changes in Alzheimer's dementia – a memory clinic follow-up study.

Presenteur : Michaela Defrancesco

Michaela Defrancesco, Christian Humpel

Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria, Innsbruck, Austria

P319 Estimating the durability of residual effects on biomarkers after discontinuation of lecanemab

Presenteur : Jie Janice Pan

Simon Rothwell¹, Jie Janice Pan², Daniela Rossi¹, Jo Vandercappellen³, Cianne Park⁴, Indeg Sly⁴

¹Eisai Europe LTD, Hatfield, United Kingdom, ²Eisai Inc, Nutley, New Jersey, United States, ³Eisai Pharma AG, Zurich, Switzerland, ⁴Acumetis, London, United Kingdom

P320 – Remote Real-World Plasma Neurofilament Light Chain, Functional Staging Severity, and Amyloid PET Non-Concordance in an Underrepresented Multimorbid Gulf/MENA Memory-Clinic Cohort

Presenteur : Hanan Sheikh Ibrahim,md,facp

Hanan Sheikh Ibrahim, Md, Facp

Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates ¹ Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA, Abu Dhabi, United Arab Emirates

P321 Healthcare Provider Perspectives and Confidence in Using Alzheimer's Blood Biomarkers in Clinical Practice

Presenteur : Amy Deckert

Monica Zigman Suchsland, Karen Weyrauch, Katherine Selzler, Tim Macleod, Alissa Kurzman, Amy Deckert

Davos Alzheimer's Collaborative, Wayne, United States

P322 – Remote Baseline Biomarker Profiles in the Diverse Vascular Contributions to Cognitive Impairment and Dementia (DVCID) Study

Presenteur : Sitong (Agnes) Zhou

Sitong (Agnes) Zhou¹, Jacopo Di Lucente¹, Jacob Conston¹, Danielle Harvey¹, Myriam Fornage², Charles Decarli¹, Lee-Way Jin¹

¹University of California, Davis, Sacramento, United States, ²UTHealth Houston School of Public Health, Houston, United States

P323 Optimization of a Rapid, Cost-Effective qPCR Assay for Apolipoprotein E Genotyping

Presenteur : Lauren Johnson

Lauren Johnson¹, Sarah Auguste McCaulley¹, Isabelle Philipp¹, Zuguang Wang¹, Matthew Sticco², Logan Vero², Kavita Jain², Ganesan Anthony², Arejas Uzgis¹

¹Siemens Healthcare Diagnostics, East Walpole, United States, ²Siemens Healthcare Diagnostics, Tarrytown, United States

P324 Real-World Adoption of Blood Biomarkers to Support Timely Diagnosis of Alzheimer's Disease: Ongoing Multinational Implementation Study

Presenteur : **Amy Deckert**

Monica Zigman Suchsland, Karen Weyrauch, Tim Macleod, Katherine J. Selzler, Alissa Kurzman, Amy Deckert
Davos Alzheimer's Collaborative, Wayne, United States

P325 Association of HDL Cholesterol With Longitudinal Brain Tau Deposition: A Cross-Ethnic Cohort Study

Presenteur : **Jee Wook Kim**

Jee Wook Kim¹, Hye Ji I Cho¹, Shin Gyeom Kim², Dong Young Lee³

¹Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, ²Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of, ³Seoul National University Hospital, Seoul, Korea, Republic of

P326 Temporal and Dose-Dependent Modulation of the Endocannabinoid System by Dual FAAH/MAGL Inhibition in Humans: Implications for Alzheimer's Disease

Presenteur : **Jie Li**

Jie Li¹, Sumit Bansal², Rui Zhao², Joel Schwartz², Rosa Miceli², Marc Gleichmann², Yongjun Xue², Mary Coffey², Yi Luo², Sarah Harris²

¹BMS, San Diego, United States, ²BMS, Princeton, United States

P327 Latent Cognitive Processes Exhibit Compensatory Behavior for Neurodegeneration

Presenteur : Jason Bock

Jason Bock^{1,2}, Jared Roach³, Joseph Kemnitz⁴, Christopher Logan¹, John Alden¹, William Shankle¹

¹Shankle Clinic for Memory and Cognition, Newport Beach, United States, ²Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States, ³Institute for Systems Biology, Seattle, United States, ⁴University of Wisconsin-Madison, Madison, United States

P328 STX-03, an Orally Bioavailable Small-Molecule Tau Aggregation Disruptor, Reduces Pathological Tau in the rTg4510 Mouse Model

Presenteur : Per Nilsson

Per Nilsson¹, Lovisa Johansson¹, Paul Tempest², Laurent Martarello², Evgenia Krekoulia¹, Nicki Jennings², Nancy Stratman², Vasco Sousa³, Martins Katkevics⁴, Wen-Chieh Wang⁵, Thierry Bussiere², Karl Schmidt², John Beaver²

¹Karolinska Institutet, Dept of Neurobiology, Care, Stockholm, Sweden, ²Sentonix, Arlington, United States, ³Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden, ⁴Latvian Institute of Organic Synthesis, Riga, Latvia, ⁵National Health Research Institute, Taipei, Taiwan

P329 Blocking C1q binding to murine anti-amyloid antibody, 3D6, strongly reduces complement activation, BBB leakage, microhemorrhages in amyloid mice

Presenteur : Cynthia Lemere

Cynthia Lemere¹, Praveen Bathini¹, Brianna Colletti¹, Mathias Schenk², Jens-Ulrich Rahfeld², David Holtzman³, Stephan Schilling³

¹Brigham and Women's Hospital, Harvard Medical School, Boston, United States, ²Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany, ³Washington University School of Medicine St. Louis, St. Louis, United States

P330 Impact of epitope location on Tau antibody efficacy in inhibiting Tau-seeded aggregation

Presenteur : Bruno Vasconcelos

Bruno Vasconcelos¹, Bart Hermans¹, Wim Van Der Elst², Matthias Bruckner², Bianca Van Broeck¹, Clara Theunis¹, Kristof Van Kolen¹

¹Neuroscience Department, Johnson & Johnson, Beerse, Belgium, ²Discovery Statistics, Johnson & Johnson, Beerse, Belgium

P333 An 'all-human' monoclonal screen for neutralizing tau neuritic dystrophy in human neurons exposed to diffusible oligomers from AD cortex yields B28, a next-gen anti-A β antibody

Presenteur : Dennis J. Selkoe

Dennis J. Selkoe¹, Yi Ran Xu¹, Shaomin Li¹, Jean-Pierre Bellier¹, Youqi Tao¹, Anna E. Francis¹, Andrew M. Stern¹, Shanxue Jin¹, Beth L. Ostaszewski¹, Trebor L. Lawton², Laurent Pradier³, David Reczek⁴, Cynthia A. Lemere¹, Dominic M. Walsh¹, Ting Yang¹

¹Brigham and Women's Hospital, Boston, United States, ²Abyssinia Biologics, Inc., Boston, United States, ³Sanofi, Chilly Mazarin, France, ⁴Sanofi, Cambridge, United States

P334 ALC919 employs neurotrophic, glymphatic and anti-inflammatory mechanisms to arrest amyloid- β oligomer toxicity and restore brain mitochondrial complex I function

Presenteur : Sam Gandy

Sam Gandy¹, Mary Sano¹, Keiko Honda², Yuhki Saito², Haruka Saito², Koichi Kinoshita², Ayano Kimura², Ruriko Abe², Koichi Moteki², Takashi Sato³, Takaomi Saido⁴, Yasuomi Ouchi⁵, Saori Hata⁶, Kanae Ando³, Toshiharu Suzuki³

¹Icahn School of Medicine at Mount Sinai, New York, United States, ²Hokkaido University, Sapporo, Japan, ³Tokyo Metropolitan University, Tokyo, Japan, ⁴RIKEN Center for Brain Sciences, Wako, Japan, ⁵Hamamatsu University, Hamamatsu, Japan, ⁶Natl Institute of Advanced Industrial Science and Technology, Sapporo, Japan

P335 Exclusive Detection of U-p53AZ in Alzheimer's Disease Compared to Other Neurodegenerative Diseases

Presenteur : David Lynch

David Lynch^{1,2}, Sam Agus³, Rakez Kayed^{1,2}, Madison Samples^{1,2}, Yu-Hsiu Wang⁴, Rasche Michael³, Kinnon Paul³, Simona Piccirella⁵

¹Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, United States, ²Department of Neurology and Neurobiology, University of Texas Medical Branch, ³Diadem Inc, Palo Alto, United States, ⁴Department of Biochemistry and Molecular Biology, UTMB, Galveston, United States, ⁵Diadem SpA, Milano, Italy

P336 MPS-AD: Human iPSC-Derived Microphysiological Systems Capture Molecular Heterogeneity and Enable Therapeutic Screening in Alzheimer's Disease

Presenteur : Annabel Curle

Annabel Curle^{1,2}, Anna Cramer¹, Kellianne Alexander¹, Fasih Ahsan¹, Garrett Fogo¹, Courtney Benoit¹, Richard Pearse¹, Christina Muratore¹, Duc Duong³, Nicholas Seyfried³, David Bennett⁴, Tracy Young-Pearse⁴

¹Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States, ³Emory School of Medicine, Atlanta, United States, ⁴Rush University Medical Center, Chicago, United States

P337 AI-guided protein design combined with multiplexed in vivo screening identifies novel shuttles that efficiently deliver Alzheimer's therapeutics into the CNS with improved pharmacokinetics, biodistribution and target engagement

Presenteur : Kimberly Searce-Levie

Kimberly Searce-Levie, Alvaro Garcia, Isabel Albuja, Alex Gerew, John Avera, Glenn Hauk, Noa Liberman-Isakov, Marshall Case, Sharon McGonigle, Brianna Unda, Fabliha Anam, Hala Haddad, Gleb Kuznetsov, Pierce Ogden

Manifold Bio, Boston, United States

P338 Design and characterization of KRSA-028, a novel bispecific antibody targeting amyloid beta and transferrin receptor with selective effector function modulation

Presenteur : Maribel Reyes

Maribel Reyes¹, Bernard Liu², Melissa Conerly², Kevin J. Kramer², Kalyan Pande², Erin Clark³, Alexander A. Mitkas², Russell Sanderson³, Joana Vidal², Byron H. Kwan², Ghassan N. Fayad², Jennifer Sager¹, Jason Oh², Michael Meehl², Angela She¹

¹Korsana Biosciences, Waltham, Ma, United States, ²Paragon Therapeutics, Waltham, Ma, United States, ³Formerly of Paragon Therapeutics, Waltham, Ma, United States

P339 Next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenteur : Sylvain Lehmann

Sylvain Lehmann¹, Nicolas Pradeilles¹, Nadia Anceriz², Bruno Daubeuf², Pauline Lloveras², Laurence Chatel², Alizée Viandier², Adeline Lesnier², Eric Hatterer², Roman Rösemann³, Oleg Demin Jr⁴, Dmitry Shchelokov⁴, Galina Saynukova⁴, Jean-Philippe Courade⁵

¹Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Hôpital St Eloi, IRMB, Montpellier, France, Montpellier, France, ²Light Chain Bioscience - Novimmune SA, Geneva, Switzerland, Geneva, Switzerland, ³Granger Regulatory Consulting & Services, Muenchen, Germany, Muenchen, Germany, ⁴InSysBio CY, Paphos, Cyprus, Paphos, Cyprus, ⁵Discoveric bio alpha Ltd., Pfäffikon, Schwyz, Switzerland, Schwyz, Switzerland

P340 Exercise Training-Mediated Mitochondrial Modulation in the Alzheimer's Disease Hippocampus

Presenteur : Sean Kao

Sean Kao^{1,2}, Farhan Yousaf³, Shahid Ishaq³, Iqbal-Ali Shah³, Bor-Tsang Wu⁴, Shin-Da Lee³

¹Boston Medical Center, Boston, United States, ²Johns Hopkins University, Baltimore, United States, ³China Medical University, Taichung, Taiwan, ⁴National Taichung University of Science and Technology, Taichung, Taiwan

P341 Alzheimer's Disease Patient Biology in a Dish

Presenteur : Marama Diaz-Asper

Tetsuya Tanaka, Yasaman Anzabi, Marama Diaz-Asper

Ricoh Biosciences, Baltimore, United States

P342 Translating single-cell multi-omics discoveries into APOE-targeted epigenome therapy for Alzheimer's Disease

Presenteur : Ornit Chiba-Falek

Bernadette O'Donovan¹, Keats Shwab¹, Boris Kantor², Ornit Chiba-Falek¹

¹Duke University, Durham, United States, ²FSU, Durham, United States

P343 A postmortem whole human brain platform for Alzheimer's disease drug discovery

Presenteur : Paul Wes

Paul Wes, Nghia Nguyen, Congwei Wang, Scott Pope, Josip Butkovic, Ivan Mumlek, Chunmin Ge, Leah Rosales, Lindsay Slupczewski, Lucija Barisic, Brad Parry, Sean Murphy, Zvonimir Vrselja

Bexorg, New Haven, United States

P344 Systemic administration of a cell-internalizing CYTOPE® targeting phospho-TDP-43 achieves higher brain drug levels than parent pTDP-43 mAb and reduces CNS intraneuronal pathology in a mouse model of TDP-43 proteinopathy

Presenteur : Philip Dolan

Stephen Tam, Ian Gallagher, Lauri Li, Kimberly Thomas, Heather Prill, Gang Zhang, Joshua Salmans, Erich Goldbach, Leeann Louie, Robert Brenda, Tarlochan Nijjar, Brian Campbell, Wagner Zago, Philip Dolan

Prothema Biosciences, Brisbane, United States

P345 Translational Efficacy, Vascular Safety, and IND-Enabling Development of GAIA-Aβ, a TAM Receptor-Engaging Amyloid-Beta Therapeutic

Presenteur : Jin Kyung Lee

Jin Kyung Lee¹, Soo Min Ji¹, Chanhyuk Kim², Wonsuk Chung³, Sanghoon Park¹

¹Illimix Therapeutics, Inc., Seoul, Korea, Republic of, ²Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea, Republic of, ³Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic of

P346 Mechanistic and Therapeutic Evaluation of Small Molecule Tau Disaggregases as a treatment for Alzheimer's Disease

Presenteur : Nader Mostowfi

Nader Mostowfi, Foreman Ryan, Paul Seidler, Syed Ahmed, Michael Jakowec, Giselle Petzinger
University of Southern California, Los Angeles, United States

P347 Caspase-1 inhibitor VX-765 restores cognition across early, intermediate, and advanced stages of Alzheimer disease pathology in the J20 APPSwe/Ind mouse model

Presenteur : Andrea Leblanc

Andrea Leblanc¹, Joseph Flores², Anastasia Noel², Marie-Lyne Fillion³
¹Casp-Aid Inc., Montreal, Canada, ²McGill U, Montreal, Canada, ³Lady Davis Institute, Montreal, Canada

P349 Trends in Episodic Memory and Cognitive Symptoms in Cognitively Normal APOE2 Homozygotes

Presenteur : Aimen Vanood

Aimen Vanood, Meredith Wicklund, Donna Locke, Blake Langlais, Richard Caselli, Bryan Woodruff
Mayo Clinic, Scottsdale, United States

P350 Binding profile of lecanemab in brain of patients with early Alzheimer's disease

Presenteur : Linda Söderberg

Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Karolina Minta, Olof Zachrisson, Gunilla Osswald, Lars Lannfelt, Christer Möller
BioArctic AB, Stockholm, Sweden

P351 Clearing Tau from the Inside Out: TRIM21-Mediated Immunotherapy Against Intracellular Tau Pathology

Presenteur : Nemil Bhatt

Nemil Bhatt, Nikita Shchankin, Twisha Chatterjee, Jia Yi Liew, Balci Ahmet, Dhvani Pansuriya, Rakez Kaye
University of Texas Medical Branch, Galveston, United States

P352 Neural crest-derived nasal turbinate stem cells enhance the therapeutic efficacy of FDA-approved anti-A β immunotherapy in patient-derived Alzheimer's disease cerebral organoids

Presenteur : Sung Won Kim

Jung Yeon Lim¹, Jung Eun Lee², Seung Ho Yang², Hyun Kook Lim³, Sung Won Kim¹

¹Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, ²Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of, ³Department of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul, Korea, Republic of

P353 Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer's Disease

Presenteur : Meenakshi Bose

Meenakshi Bose¹, Allen Pan¹, Gabriela Farias-Quipildor^{2,3}, Yong Huang^{1,3}, Minghui Wang⁴, Michelle Ehrlich³, Stephen Salton¹

¹Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, United States, ²Nash Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai Family Department of Neuroscience, Friedman Brain Institute, and Department of Geriatrics and Palliative Medicine, New York, United States, ³Departments of Neurology, Genetics and Genomic Sciences, and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, United States, ⁴Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States

P354 HET3 mice are a model of brain aging: evidence for dendritic spine loss, proteome perturbations, and spatial learning deficits during aging.

Presenteur : Josh Krivinko

Josh Krivinko¹, Susan Erickson¹, Akayla Lewin¹, Jiaqian Liu², Matthew Macdonald¹, Jason Newman¹, Stacey Rizzo³, Robert Sweet^{1,4}

¹Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, ²Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, United States, ³Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁴Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh

P355 Preclinical Evaluation of CATA-002, a Novel A β /TfR Bispecific Brain-Shuttled Catalytic Antibody for Enhanced Brain Penetration and Enzymatic A β Degradation in Alzheimer's Disease

Presenteur : Yue Liu

Wang Bo, Hoag Matthew, Shan Yuxi, Dong Jianbo, Fay Nathan, Spadoni Nicholas, Putrevu Saroja, Titong Allison, Yue Liu
Ab Studio Inc., Hayward, Ca, United States

P356 — Remote QSP platform of Alzheimer's Disease for exploring efficacy of anti-tau immunotherapy bepranemab

Presenteur : Tatiana Karelina

Tatiana Karelina, Dmitry Gordeev, Olga Ivanova, Polina Maliukova
InSysBio, Paphos, Cyprus

P357 next-generation tau immunotherapy: NIDB-3101 biparatopic antibody PK, PD and tolerability data in NHP

Presenteur : Jean-Philippe Courade

Jean-Philippe Courade¹, Nadia Anceriz², Roman Rösemann³, Pauline Lloveras², Laurence Chatel², Bruno Daubeuf², Alizée Viandier², Adeline Lesnier², Eric Hatterer², Oleg Demin Jr⁴, Dmitry Shchelokov⁴, Galina Saynukova⁴, Nicolas Pradeilles⁵, Sylvain Lehmann⁵

¹Discoveric Bio Alpha, Pfäffikon, Switzerland, ²Light Chain Biosciences, Plan Les Ouates, Switzerland, ³Grnzer, Muenchen, Germany, ⁴Insysbio, Paphos, Cyprus, ⁵Laboratoire de Biochimie Protéomique Clinique CHU Montpellier, Montpellier, France

P358 Polygenic risk score–based frailty index predicts conversion to tau-positivity in Alzheimer’s disease

Presenteur : Mi-Young Oh

Mi-Young Oh¹, Sang-Hyuk Jung²

¹Department of Neurology, Sejong General Hospital, Bucheon-Si, Korea, Republic of, ²Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Korea, Republic of

P359 How Re:Cognition Health (RCH) has Fast Tracked Patients to Receive Amyloid Targeted Treatment (ATT)

Presenteur : Emer MacSweeney

George Robinson^{1,2}, Penny Muir¹, Emer Macsweeney¹

¹Cognition Health, London, United Kingdom, ²Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

P360 Synergistic Effects of Mild Behavioral Impairment and APOE ε4 on Cognitive Function in a Community-Based Middle-Aged and Older Population

Presenteur : Cheng-Sheng Chen

Cheng-Sheng Chen, Yi-Chun Yeh, Hsiu-Fen Lin

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

P361 A harmonized multi-trial resource for understanding Alzheimer's disease progression, heterogeneity, and sex differences

Presenteur : Caitlin McHugh

Caitlin McHugh¹, Matthew Clement¹, Niranjan Bose¹, Caleb Daley², Suzanne Hendrix², Julie Wood³

¹Alzheimer's Disease Data Initiative, Kirkland, United States, ²Pentara, Millcreek, United States, ³Vivli, Cambridge, United States

P362 Design-Induced Circularity in Alzheimer's Biomarker Trials and Trial-Ready Cohorts: Enrichment, Data-Driven Selection, and Estimand Mismatch

Presenteur : Khushboo Verma

Khushboo Verma, Satwant Kumar

University of Texas at Tyler, TYLER, United States

P363 Disaggregating Asian Populations in a Global Preclinical Alzheimer's Disease Trial: Recruitment, Screening and Randomization in the AHEAD 3-45 Study

Presenteur : Marina Ritchie

Marina Ritchie¹, Kedir Hussen¹, Oliver Langford¹, Maddox S. Bray², Shobha Dhadda³, Michael Irizarry³, Yasumi Kitahara⁴, Reisa A. Sperling⁵, Joshua D. Grill⁶, Rema Raman¹

¹Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²University of California, Santa Barbara, Santa Barbara, United States, ³Eisai Inc., Nutley, United States, ⁴Eisai Co., Ltd., Tokyo, Japan, ⁵Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, ⁶University of California, Irvine, Irvine, United States

P364 Assessing Efficiency in Adaptive ADRD Trial Frameworks: A Systematic Comparison of Group Sequential and Promising Zone Designs

Presenteur : Sarah Schlund

Sarah Schlund¹, Joshua Grill^{2,3,4,5}, Daniel Gillen^{1,2}

¹Department of Statistics, University of California, Irvine, Irvine, United States, ²University of California, Irvine Institute for Memory Impairments and Neurological Disorders, Irvine, United States, ³Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States, ⁴Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, United States, ⁵Institute for Clinical and Translational Science, University of California Irvine, Irvine, United States

P365 Plasma p-tau217 In Early Alzheimer's Disease Trial Screening: Insights from START

Presenteur : Marina Ritchie

Marina Ritchie¹, Oliver Langford¹, Yixuan Liang¹, Daniel Burns², Charlene Flournoy¹, Joshua D. Grill³, Anthony Caggiano⁴, Michael Grundman⁵, Robert A. Rissman¹, Paul Aisen¹, Christopher H. Van Dyck⁶, Rema Raman¹

¹Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²The University of Kansas, Lawrence, United States, ³University of California, Irvine, Irvine, United States, ⁴Cognition Therapeutics, Inc., Purchase, United States, ⁵Global R&D Partners, LLC, San Diego, United States, ⁶Yale School of Medicine, New Haven, United States

P367 A Shiny-based Clinical Trial Power Simulator Leveraging 20+ Years of the ADNI as a Longitudinal Biomarker and Comorbidity Data

Presenteur : Isabella Hausle

Isabella Hausle

Northern California Institute for Research and Education, Los Angeles, United States

P368 Biological heterogeneity at clinical conversion to mild cognitive impairment: Implications for Alzheimer's disease clinical trials

Presenteur : Alison Myoraku

Alison Myoraku, Marta Mila-Aloma, Isabella Hausle, Pamela Thropp, Duygu Tosun

NCIRE/UCSF, San Francisco, United States

P370 Clinical Trials Should Run Multi-Omic Foundation Models in the Loop

Presenteur : Arvid Gollwitzer

Arvid Gollwitzer^{1,2}, Adrian Noriega De La Colina^{1,2,3}, Li-Huei Tsai^{1,4}, Miia Kivipelto^{5,6}, Giovanni Traverso^{1,2,7}

¹Broad Institute of MIT and Harvard, Cambridge, United States, ²Massachusetts Institute of Technology, Cambridge, United States, ³Brigham and Women's Hospital, Boston, United States, ⁴The Picower Institute for Learning and Memory, Cambridge, United States, ⁵FINGERS Brain Health Institute, Stockholm, Sweden, ⁶Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁷Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, United States

P371 Leveraging the NACC Data Platform and ADRC Network Infrastructure to Operationalize CLARiTI: A Model for Multimodal Data Coordination in AD/ADRD Research

Presenteur : Heather O'connell

Heather O'Connell¹, Erin Chin², Shilpa Allimatti¹, Hannah Koenig¹, Laura McLeod¹, Christine Mac Donald¹, Lindsay Clark², Tatiana Foroud³, Gil Rabinovici⁴, Elizabeth Mormino⁵, Sterling Johnson², Walter Kukull⁶, Sarah Biber^{6, 7}

¹National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, United States, ²Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, United States, ³Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States, ⁴Fein Memory & Aging Center, Departments of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, California, United States, ⁵Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, United States, ⁶Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States, ⁷Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States

P372 The Financial and Societal Impact of Compromised Data Integrity in AD Trials and the Importance of Early Detection and Monitoring

Presenteur : Maycee A. Robison

Maycee A. Robison, Garrett B. Duncan, John Whetten, Mitchell B. Wassom, Samuel P. Dickson, Suzanne B. Hendrix

Pentara Corporation, Millcreek, United States

P373 Power analyses for stepped wedge designs with multivariate continuous outcomes

Presenteur : Kendra Plourde

Kendra Plourde¹, Monica Taljaard², Fan Li³

¹Yale School of Public Health - New Haven (United States), New Haven, United States, ²Ottawa Hospital Research Institute, Ottawa, Canada, ³Yale School of Public Health, New Haven, United States

P374 MinDSet: Training to Support Clinical Research Sites to Help Individuals with Down Syndrome Thrive

Presenteur : Thomas Mahan

Kate O'Neill, Amy Shapley-Farrell, Lois Kelly, Thomas Mahan

NDSS,

P375 Leveraging Anti-Amyloid Clinical Trial Screening to Establish a Longitudinal Primary Prevention Cohort: APEX Recruitment Strategy and Baseline Findings

Presenteur : Oliver Langford

Doris Molina-Henry¹, Andy Liu¹, Oliver Langford¹, Rema Raman¹, Michael Donohue¹, Andrew Mellor¹, Gustavo Jimenez-Maggiora¹, Robert Rissman¹, Keith Johnson², Paul Aisen¹, Reisa Sperling²

¹Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, United States

P376 Improving efficiency of preclinical Alzheimer's disease anti-amyloid trial recruitment using a community-based recruitment registry (Dutch Brain Research Registry)

Presenteur : Marissa Zwan

Lisa Waterink^{1, 2, 3}, Elliz Scheijbeler^{1, 2, 4}, Sietske Sikkes^{1, 2, 4}, Inge Verberk^{1, 5}, Jurgen Claassen^{6, 7, 8}, Ondine Van De Rest⁹, Nynke Smidt¹⁰, Sebastian Köhler¹¹, Esther Aarts⁷, Everard Vijverberg^{1, 2}, Marissa Zwan^{1, 2}

¹Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ²Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, ³Precision Health Clinic, Amsterdam, The Netherlands, ⁴Faculty of Behavioural and Movement Sciences, Department of Clinical, Neuro and Developmental Psychology, Vrije Universiteit, Amsterdam, The Netherlands, ⁵Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ⁶Department of Geriatrics, Radboudumc Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands, ⁷Cognition and Behaviour, Donders Institute for Brain, Radboud University, Nijmegen, The Netherlands, ⁸Department of Cardiovascular Sciences, Leicester University, Leicester, United Kingdom, ⁹Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands, ¹⁰Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ¹¹Mental Health and Neuroscience Research Institute (MHeNs), Department of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, Maastricht University, Maastricht, The Netherlands

P377 Prognostic versus propensity-score covariates for trial efficiency across the Alzheimer's disease spectrum: an evaluation in dominantly-inherited and preclinical AD

Presenteur : Yuchen Cao

Yuchen Cao, Guoqiao Wang, Jorge Llibre-Guerra, Eric McDade, Randall Bateman

Washington University in St. Louis, St. Louis, United States

P378 Pragmatic Barriers to Inclusivity in Geriatric Clinical Trials

Presenteur : Saeed Hashem

Saeed Hashem

McLean Hospital, Belmont, United States

P380 2D or Not 2D: Transition from 2D to a 3D Analysis Model for Ioflupane I-123 SPECT

Presenteur : Victoria Hegedus

Victoria Hegedus¹, Nicole Hurley¹, Samuel Lockhart^{1, 2}, David Cash^{1, 3}, Elif Sikoglu¹, Joseph Petrulli¹

¹Perceptive, Burlington, United States, ²Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, United States, ³UCL Queen Square Institute of Neurology, London, United Kingdom

P381 Association of MAO-B Inhibitors with Cognitive Decline Over 10 Years in Parkinson's Disease: A Quasi-Experimental Study

Presenteur : Joao Pedro Ferrari-Souza

Joao Pedro Ferrari-Souza^{1,2}, Alberto Serrano-Pozo^{1,2,3}

¹Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States, ³Massachusetts Alzheimer's Disease Research Center, Charlestown, United States

P382 Improving efficiency of preclinical Alzheimer's disease anti-amyloid trial recruitment using memory clinic-based screening

Presenteur : Elliz P. Scheijbeler

Elliz P. Scheijbeler^{1,2}, Lisa Waterink^{1,2,3}, Sterre C. M. De Boer^{1,2}, Betty M. Tijms^{1,2}, Argonde C. Van Harten^{1,2}, Everard G. B. Vijverberg^{1,2}, Marissa D. Zwan^{1,2}

¹Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ²Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, ³Precision Health Clinic, Amsterdam, The Netherlands

P384 Expanded Access as a Dual-Mandate Model for Real-World Evidence Generation in Alzheimer's Disease: Lessons from a Decentralized ALS Program

Presenteur : Ildefonso Vicente-Suarez

Ildefonso Vicente-Suarez¹, Bjorn Oskarsson², Shona Allen¹, Ramana Sonty³, Jess Rabourn³

¹WideTrial, San Jose, United States, ²Mayo Clinic Florida, Jacksonville, United States, ³Strata Partners, San Jose, United States

P385 Portable, Low-field MRI Combined with Machine Learning Segmentation for Cognitively Impaired Individuals

Presenteur : Ava Farnan

Ava Farnan^{1,2}, Annabel J. Sorby-Adams^{1,2}, John R. Dickson¹, Liliana Ramirez Gomez¹, Arman Fesharaki-Zadeh³, Christopher Van Dyck⁴, Matthew S. Rosen⁵, Kevin N. Sheth⁴, J. Eugenio Iglesias⁶, Adam De Havenon⁴, Teresa Gomez-Isla¹, Alberto Serrano Pozo¹, W. Taylor Kimberly^{7,2}

¹Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States, ²Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States,

³Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA, New Haven, United States, ⁴Department of Neurology, Center for Brain & Mind Health, Yale

New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, New Haven, United States, ⁵Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical

School, Boston, MA, USA - United States, Boston, United States, ⁶Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, United States,

⁷Department of Neurology, Center for Brain & Mind Health, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, USA - United States, Boston, United States

P386 IMPACT-AD LATAM: A Regional Training Program to Strengthen ADRD Clinical Trial Capacity in Latin America

Presenteur : Lucia Crivelli

Ma. Florencia Clarens¹, Maria C. Carrillo², Joshua D. Grill³, Rema Raman⁴, Heather M. Snyder², Lucia Crivelli¹, Jorge Llibre-Guerra⁵

¹Department of Cognitive Neurology, Fleni, Buenos Aires, Argentina, ²Division of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, United States, ³Institute for Memory Impairments and

Neurological Disorders, Departments of Psychiatry and Human Behavior and Neurobiology and Behavior, University of California, Irvine, United States, ⁴Alzheimer's Therapeutic Research Institute, University of Southern

California, San Diego, United States, ⁵Department of Neurology, Washington University in St. Louis, St Louis, United States

P387 Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer's Research Engagement

Presenteur : Sonia Simons

Marilyn Wilson¹, B. Joy Snider¹, David Carr¹, Maryanna Milanez², Emily Dugan¹, Jordan Kulage¹, Sonia Simons¹

¹Washington University School of Medicine, St. Louis, United States, ²Global Alzheimer's Platform Foundation, Inc., Chicago, United States

P388 Design considerations of a phase II multi-site randomized controlled trial of Harmony Dementia Care: a sensory-based intervention for people with Alzheimer's disease and related dementias

Presenteur : Elizabeth K. Rhodus

Elizabeth K. Rhodus¹, David S. Geldmacher², Rema Raman³, Michael Donohue³, Laura Henley¹, Clarissa Benzarti¹, April Stauffer¹, Nancy Wolff¹, Kennedy Walcott-George¹, Susan Westneat¹, Carolyn Baum⁴, Paul Aisen³

¹University of Kentucky, Lexington, United States, ²University of Alabama at Birmingham, Birmingham, United States, ³Alzheimer's Therapeutic Research Institute, San Diego, United States, ⁴Washington University in St. Louis, St. Louis, United States

P389 Age-Dependent Sensitivity of the MMSE for Detecting Amyloid-Confirmed Alzheimer's Disease

Presenteur : Dorothy MacFarlane

Dorothy MacFarlane, Hale Hailie, Nolan Hadley, Vera Lukas, Poplyk Sophia, Namaky Nauder

Adams Clinical, Watertown, United States

P390 Advancing Alzheimer's Disease Clinical Trials Through the Critical Path for Alzheimer's Disease Consortium (CPAD)

Presenteur : Diane Stephenson

Yashmin Karten¹, Nicholas Henscheid¹, Colleen Jacobsen¹, Hartmuth Kolb², Klaus Romero¹, Gregory Klein³, Diane Stephenson¹

¹Critical Path Institute, Tucson, United States, ²Enigma Biomedical Group, Knoxville, United States, ³F. Hoffmann-La Roche Ltd., Basel, Switzerland

P391 Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials

Presenteur : [Richard Gallardo](#)

Richard Gallardo¹, Christian Navarro¹, Michael Donohue¹, Oliver Langford¹, Brenda Armenta-Copca¹, Hongmei Qiu¹, Paul Newhouse², Paul Aisen¹, Gustavo Jimenez-Maggiora¹

¹University of Southern California, San Diego, United States, ²Vanderbilt University, Nashville, United States

P392 Achieving Greater Generalizability in Alzheimer's Clinical Trials through a Multi-sector Committee

Presenteur : [Daphne Delgado](#)

Christine Lee¹, Christopher Miller², Michelle Bruno³, Daphne Delgado², Sam Dickson⁴, Martine Meyer⁵, Constantina Mizis⁶, Jonathan Tobin⁷, Charisse Winston⁸, Michael Weiner⁹

¹ACHIEVE Expertise, , United States, ²UsAgainstAlzheimer's, , United States, ³MB Insights, LLC, , United States, ⁴Pentara Corporation, , United States, ⁵The Janssen Pharmaceutical Companies of Johnson & Johnson, , United States, ⁶Latino Alzheimer's and Memory Disorders Alliance, , United States, ⁷Clinical Directors Network, , United States, ⁸University of Southern California, , United States, ⁹University of California, San Francisco, , United States

P393 From short-term data to long-term trajectories: Statistical modeling framework for predicting multidomain progression in Alzheimer's disease

Presenteur : [Ryoichi Hanazawa](#)

Ryoichi Hanazawa, Hiroyuki Sato, Shin Watanabe, Ryo Kitabayashi, Akihiro Hirakawa

Department of Clinical Biostatistics, Institute of Science Tokyo, Tokyo, Japan

P394 Clinical and operational determinants of amyloid-targeting therapies treatment initiation in early Alzheimer's Disease: A discrete choice experiment

Presenteur : [Elena Garcia Arcelay](#)

Juan Fortea¹, Elena Garcia Arcelay², Alberto Villarejo³, Raquel Sanchez Del Valle⁴, Neus Canal⁵, Monica Sarmiento⁵, Jorge Mauriño², Guillermo Garcia-Ribas⁶, Gustavo Saposnik⁷

¹Sant Pau Memory Unit, IR SANT PAU, Hospital Universitario de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ²Medical Department, Roche Farma, Madrid, Spain, ³Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Department of Neurology, Hospital Clinic, FRCB- IDIBAPS, Universidad de Barcelona, Barcelona, Spain, ⁵RWCS, IQVIA Information, Madrid, Spain, ⁶Department of Neurology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁷Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Canada. Clinical Outcomes and Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronto, Canada

P395 Most Screening-Baseline MMSE Variability Is Individual Noise: Pooled Analysis of 17 Alzheimer's Trials

Presenteur : [David Miller](#)

David Miller¹, Alan Kott², Xingmei Wang³

¹Signant Health, Philadelphia, United States, ²Signant Health, Prague, Czechia, ³Signant Health, Blue Bell, United States

P396 The Effects of Benzgalantamine (ZUNVEYL®) on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in the Treatment of Mild to Moderate Alzheimer's Dementia. RESOLVE: a Phase IV Open-label Study

Presenteur : [Denis Kay](#)

Michael McFadden, Denis Kay, Carson Harrod, Pavel Svintozelskiy, Andrew Wahlert, Kurt Grady

Alpha Cognition Inc., Grapevine, United States

P397 From Initial Enthusiasm to Routine Practice: Temporal Changes in Anti-Amyloid Therapy Uptake and Eligibility in Japan

Presenteur : [Ryoko Ihara](#)

Ryoko Ihara, Masanori Kurihara, Keiko Hatano, Taro Bannai, Ryosuke Shimasaki, Akira Hatakeyama, Ko Furuta, Fumio Suzuki, Aya Tokumaru, Kenji Ishii, Atsushi Iwata

Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

COGNITIVE AND FUNCTIONAL OUTCOMES

P399 Capturing clinically meaningful change in preclinical Alzheimer's disease using the Amsterdam IADL Questionnaire as outcome measure

Presenteur : Roos Jutten

Roos Jutten, Luise Wagner, Angela Van Der Putten - Toorenburg, Sophie Van Der Landen, Federica Anastasi, Charlotte Teunissen, Everard Vijverberg, Betty Tijms, Argonde Van Harten, Sietske Sikkes
Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands

P401 Financial Vulnerability as an Early Functional Marker of Alzheimer's Disease: From Neuroimaging to Plasma Biomarker Considerations

Presenteur : Duke Han

Duke Han, Jenna Axelrod, Aaron Lim, Belinda Zhang, Daisy Noriega-Makarskyy, Cassidy Molinare, Emma Oyen, Melanie Leguizamon, Camdyn Wu, Maanya Agarwal, Laura Mosqueda, Hussein Yassine
University of Southern California, Los Angeles, United States

P402 Virtual Reality Measures of Everyday Function and Cognition Characterizes the Risk of Early-Stage Alzheimer's Disease

Presenteur : James Galvin

James Galvin, Mustafa Shuqair
University of Miami Miller School of Medicine, Boca Raton, United States

P403 Increasing granularity in the Clinical Dementia Rating: Does a 0.25 Memory box score signal faster cognitive decline?

Presenteur : Mark A. Dubbelman

Mark A. Dubbelman^{1,2}, Vivienne Lubbat², Hairin Kim^{1,2}, Lex R. Minto^{1,2}, Dorene M. Rentz^{1,2}, Rachel F. Buckley^{1,2}, Reisa A. Sperling^{1,2}, Gad A. Marshall^{1,2}, Rebecca E. Amariglio^{1,2}, Kathryn V. Papp^{1,2}
¹Center for Alzheimer Research & Treatment, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, United States, ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

P404 Streamlining the Alzheimer's Disease Diagnostic Journey through Primary Care: Real-World Insights from the Better DX Study

Presenteur : Rhonna Shatz

Rhonna Shatz¹, Katherine Schmidt¹, Jinda Bowerman¹, Jackson Hearn¹, Feride Frech², Bryan Cobb², Courtney Adams², Yosuke Nakamura², Rifky Tkatch², Hideki Toyosaki²
¹University of Cincinnati, Cincinnati, United States, ²Eisai Inc., Nutley, United States

P405 Unawareness of medication self-administration errors as a clinical outcome and marker of cognitive decline.

Presenteur : A.M. Barrett

A.M. Barrett¹, Honghuang Lin¹, Joanne Murabito², Emily Muller¹
¹UMass Chan Medical School, Worcester, United States, ²UMass Chan Medical School, Boston, United States

P406 Lecanemab Treatment in a New England Alzheimer's Disease Center: Real-World Outcomes From a Single-Center, Retrospective Case Series

Presenteur : Salvatore Napoli

Salvatore Napoli, Rachel O' Donnell, Lauren Nassr, Emily Maize
Alzheimer's Neurology and Infusion Centers of New England, Foxboro, United States

P407 Real-World Effectiveness, Safety, and Patient Experience of Lecanemab in the United States: A Systematic Literature Review

Presenteur : Gregory Jicha

Gregory Jicha¹, Chenyue Zhao², Dominic Igbelina³, James Frampton³, Henry Ogden³, Feride Frech², Hideki Toyosaki², Joanna Campbell³, Liana Apostolova⁴
¹University of Kentucky College of Medicine, Lexington, United States, ²Eisai Inc., Nutley, United States, ³Thermo Fisher Scientific Inc., Waltham, United States, ⁴Indiana University School of Medicine, Indianapolis, United States

P408 A Harmonized Multi-Cohort Evaluation of SOMI Stages for Predicting Cognitive Impairment

Presenteur : Priyanka Kumari

Priyanka Kumari¹, Richard B. Lipton^{1,2,3}, Cuiling Wang³, Ellen Grober¹
¹Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States, ²Montefiore Medical Center, Bronx, NY, United States, ³Department of Epidemiology & Population Health, Bronx, NY, United States

P409 Measuring meaningful benefits across cultures in AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics

Presenteur : [Ali Jannati](#)

Stina Saunders^{1, 2}, Yuki Takeda³, Hisatomo Kowa⁴, Atsushi Iwata⁵, Norio Chihara⁶, Himanshi Malik¹, Ali Jannati^{1, 7}, Claudio Toro-Serey¹, Sean Tobyne¹, Ricky Kurzman⁸, Yosuke Nakamura⁹, Jo Vandercappellen¹⁰, Álvaro Pascual-Leone^{1, 7, 11}

¹Linus Health, Boston, United States, ²University of Edinburgh, Edinburgh, United Kingdom, ³Kobe University, Graduate School of Medicine, Division of Neurology, Kobe, Japan, ⁴Kobe University, Graduate School of Medicine, Department of Health Sciences, Suma-ku, Kobe, Japan, ⁵Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, ⁶Kobe University, Graduate School of Medicine, Division of Neurology, Tokyo, Japan, ⁷Department of Neurology, Harvard Medical School, Boston, United States, ⁸Eisai Inc., Nutley, United States, ⁹Eisai Co Ltd, Tokyo, Japan, ¹⁰Eisai Pharma AG, Zurich, Switzerland, ¹¹Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P410 Advancing Personalized Outcome Assessment in Frontotemporal Dementia: A Standardized Goal Inventory for Goal Attainment Scaling (GAS) in Clinical Trials

Presenteur : [Chere Chapman](#)

Gunes Sevinc¹, Chere Chapman², Kaitlin Casaletto³, Howie Rosen³, Kenneth Rockwood⁴

¹Ardea Outcomes, Vancouver, Canada, ²Ardea Outcomes, Halifax, Canada, ³University of California, San Francisco, San Francisco, Canada, ⁴University of California, San Francisco, Halifax, Canada

P411 Real-World Cognitive, Safety and Biomarker Outcomes Among Patients Receiving Anti-Amyloid Monoclonal Antibodies in ALZ-NET

Presenteur : [Gil Rabinovici](#)

Gil Rabinovici¹, Alireza Atri², Kirk Daffner³, Constantine Gatsonis⁴, Oscar Lopez⁵, Anton Porsteinsson⁶, Katherine Possin¹, Stephen Salloway⁷, Mary Sano⁸, Christopher Whitlow⁹, Charloes Windon¹, Michael Rafii¹⁰, Maria Carrillo¹¹

¹Fein Memory and Aging Center, Depts. of Neurology, Radiology & Biomedical Imaging, University of California, San Francisco, United States, ²Banner Alzheimer's & Research Institutes, Banner Research/Banner Health, Peoria, United States, ³Harvard School of Medicine, Boston, United States, ⁴Brown School of Public Health, Providence, United States, ⁵University of Pittsburgh School of Medicine, Pittsburgh, United States, ⁶University of Rochester School of Medicine, Rochester, United States, ⁷Butler Hospital / Warren Alpert Medical School of Brown University, Providence, United States, ⁸Mt Sinai School of Medicine, New York, United States, ⁹Yale University / American College of Radiology, New Haven, United States, ¹⁰Keck School of Medicine, University of Southern California, San Diego, United States, ¹¹Alzheimer's Association, Chicago, United States

P412 Estimating progression from MCI to dementia with a MoCA clock

Presenteur : [Willem Huijbers](#)

Willem Huijbers¹, Murray Gillies¹, Ziad Nasreddine¹, Suzanne Schindler², Kellen Petersen²

¹MoCA Cognition, Montreal, Canada, ²Department of Neurology, Washington University in St. Louis, St. Louis, United States

P413 Real-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer's Disease in the United States: A Case Series

Presenteur : [Victor Faradji](#)

Victor Faradji, Jaziel Rodriguez

First Choice Neurology and Visionary Investigators Network (VIN), Miami, United States

P414 Real-World Long-Term Persistence and Early Subcutaneous Maintenance Utilization of Lecanemab in the United States

Presenteur : [Michael Rosenbloom](#)

Diana Brixner¹, Chenyue Zhao², Hideki Toyosaki², Feride Frech², Michael Rosenbloom³

¹Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, United States, ²Eisai Inc., Nutley, United States, ³Memory and Brain Wellness Center, University of Washington, Seattle, United States

P415 Associations of frailty, cognition and amyloid status in preclinical Alzheimer's disease in prerandomization data from the AHEAD 3-45 study

Presenteur : [Paul Yates](#)

Andrew Huynh^{1, 2, 3}, David Ward⁴, Scott Wrigley¹, Courtney Shelton¹, Sanka Amadoru^{1, 2}, Michael Woodward^{1, 2}, Louise Burrell², Paul Yates^{1, 5}

¹Department of Geriatric Medicine, Austin Health, Melbourne, Australia, ²Department of Medicine, University of Melbourne, Melbourne, Australia, ³Alzheimer's Research Australia, Melbourne, Australia, ⁴Frazer Institute, Faculty of Health, Medicine & Behavioural Sciences, University of Queensland, Brisbane, Australia, ⁵Department of Medicine, Melbourne, Australia

P416 High-Frequency Monitoring of Cognitive and Biomarker Changes in Healthy Aging Over One Year

Presenteur : [Michelle Budman](#)

Michelle Budman¹, Phyllis Tameilau¹, Alexandra N. Trelle¹, S. Subbulakshmi², Jintao Sheng^{2, 3}, Tran T. Nguyen⁴, Divya Channappa¹, Gayle Deutsch², Holden T Maecker⁵, Sharon Sha¹, Tony Wyss-Coray^{1, 3}, Anthony D. Wagner², Christina B. Young^{6, 7}, Joseph R. Winer⁸, Elizabeth C. Mormino^{1, 9}

¹Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, United States, ²Department of Psychology, Stanford University, Palo Alto, United States, ³Phil and Penny Knight Initiative for Brain Resilience, Palo Alto, United States, ⁴Institute for Immunity, Transplantation, and Infection Operations, Stanford University, Palo Alto, United States, ⁵Department of Microbiology and Immunology, Stanford University, Palo Alto, United States, ⁶Department of Radiology, UC Davis, Davis, United States, ⁷Department of Neurology, UC Davis, Davis, United States, ⁸Sutter Health Research Institute, San Francisco, United States, ⁹Wu Tsai Neurosciences Institute, Palo Alto, United States

P417 A Retrospective, Case-Series Analysis of Lecanemab Treatment in Individuals with Early Alzheimer's at a Colorado Neurological Clinic

Presenteur : [Adam Wolff](#)

Adam Wolff

Porter Adventist Hospital, Colorado Neurological Clinic, Denver, United States

P418 Real-World Lecanemab Treatment in Early Alzheimer's Disease: A Retrospective Case Series from a Geriatric Medicine Clinical Practice

Presenteur : Margarita Reyes

Margarita Reyes, Mary Maxine Zapata Reyes

Office of Dr Reyes, Bristol, United States

P419 — Remote Repeated cognitive features for predicting clinical progression for preclinical Alzheimer's Disease

Presenteur : Shu Liu

Shu Liu¹, Yijing Xu², Chunming Xie³, Hualou Liang^{4,5,6}, Xiaochuan Li⁷, Qihong Lu¹

¹Department of Neuroscience, City University of Hong Kong, Hong Kong, China, ²Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China, ³Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Jiangsu Key Laboratory of Brain Science and Medicine, Southeast University, Nanjing, China, ⁴Division of Artificial Intelligence and the Humanities, The Hong Kong Polytechnic University, Hong Kong, China, ⁵Department of Language Science and Technology, The Hong Kong Polytechnic University, Hong Kong, China, ⁶Departments of Data Science and Artificial Intelligence, The Hong Kong Polytechnic University, Hong Kong, China, ⁷Hybridio Limited, Chaozhou, China

P420 Associations of episodic memory measures with Alzheimer's Disease biomarkers in clinically unimpaired participants: AHEAD3-45 screening data

Presenteur : MaryBeth Bailer

Marybeth Bailer, Karra Harrington, Jordan Barbone, Pam Ventola

Cogstate, New Haven, CT, United States

P421 Limitations of Cognitive Pre-screening for Amyloid Enrichment in Early Alzheimer's Disease Trials. Results from Evoke programme at Neuroclnx Glasgow

Presenteur : Jennifer Lynch

Kanwal Aadil, Lucy Frenz, Sophie Mitchell, Areej Shaukat, Jennifer Lynch

Neuroclnx, Glasgow, United Kingdom

P423 Development of performance criteria to identify test compliance on the Online Repeatable Cognitive Assessment (ORCA)

Presenteur : Karra Harrington

Karra Harrington¹, Gabriel Stellman¹, Pam Ventola¹, Paul Maruff²

¹Cogstate, New Haven, United States, ²Cogstate, Melbourne, Australia

P424 Linguistic Profiles Based on Bilingualism and Verbal Fluency Are Associated with Longitudinal Cognitive Outcomes in a Multilingual Ageing Cohort

Presenteur : Gabriele Cattaneo

Gabriele Cattaneo¹, Simon Fankhauser¹, Gemma Albi-Villuendas¹, Alvaro Pascual-Leone², David Bartrés-Faz³, Javier Solana-Sánchez¹

¹Guttmann Hospital de Neurorehabilitació, Badalona, Spain, ²Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife, Boston, Spain, ³Departament de Medicina, Facultat de Medicina i Ciències de la Salut, i Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain

P425 Experience, Not Education, Drives Rater Performance on the Clinical Dementia Rating Scale

Presenteur : Dorothee Schoemaker

Dorothee Schoemaker, Danielle Digregorio, Selam Negash, Cong Liu, Chris Randolph

Clario, part of Thermo Fisher Scientific, United States

P426 Effects of regional tau accumulation on visual discrimination behaviors in clinically unimpaired older adults

Presenteur : Dhruv Kapadia

Dhruv Kapadia¹, Luciah Guerra¹, Isha Sai¹, Tyler Bonnen², Anthony Wagner¹, Elizabeth Mormino¹, Alexandra Trelle¹

¹Stanford University, Stanford, United States, ²University of Pennsylvania, Philadelphia, United States

P427 Comparative analysis of lexical and acoustic speech biomarkers in mild cognitive impairment due to Lewy bodies and Alzheimer's disease

Presenteur : Min Seok Baek

Min Seok Baek^{1,2}, Sung-Woo Kim¹, Han-Kyeol Kim¹, Mark Liberman³, Sunghye Cho⁴

¹Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of, ²Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, United States, ³Linguistic Data Consortium & Linguistics Department, University of Pennsylvania, Philadelphia, Korea, Republic of, ⁴Department of Communication Sciences and Disorders, University of Cincinnati, Cincinnati, Korea, Republic of

P428 A Digital Clock and Recall (DCR)-First Clinical Workflow Substantially Increases Dementia Case-Finding in Primary Care

Presenteur : Ali Jannati

Ali Jannati¹, Claudio Toro-Serey¹, Connor Higgins¹, John Showalter¹, David Bates¹, Alvaro Pascual-Leone^{1,2}, Sean Tobyne¹

¹Linus Health, Boston, United States, ²Hebrew SeniorLife - Harvard Medical School

P429 Technical and Real-World Validation of the Digital Clock and Recall: A Scalable Cognitive Screener for Primary Care and Clinical Trial Enrichment

Presenteur : Ali Jannati

Claudio Toro-Serey¹, Karl Thompson¹, Daniel Schulman¹, Olivia Jacks¹, Connor Higgins¹, Alvaro Pascual-Leone^{1,2}, Ali Jannati¹, Sean Tobyne¹

¹Linus Health, Boston, United States, ²Hebrew SeniorLife - Harvard Medical School, Boston, United States

P430 Understanding NPI-C Rating Errors in AD Psychosis Trials: A Multi-Study Analysis of Hallucination and Delusion Domain Flags

Presenteur : Amanda Aedo

Amanda Aedo, Gila Barbaty, Andrei Iacob, Sayaka Machizawa, Erica Appleman

Signant Health, Coral Springs, United States

P431 ADAS-Cog 11 vs 13 in early Alzheimer's disease: sensitivity to longitudinal change

Presenteur : Danielle DiGregorio

Catarina Cunha¹, Matt Welch², Daema Pina Delgado², Zsolt Ternei³, Selam Negash², Chris Randolph², Danielle Digregorio²

¹Clario, part of Thermo Fisher Scientific, Coimbra, Portugal, ²Clario, part of Thermo Fisher Scientific, Philadelphia, United States, ³Clario, part of Thermo Fisher Scientific, Budapest, Hungary

P432 Comparison-Based Subjective Cognitive Decline Predicts Objective Cognition in APOE ε4 Non-Carriers

Presenteur : Jee Wook Kim

Hye Ji Choi¹, Shin Gyeom Kim², Jee Wook Kim¹

¹Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea, Republic of, ²Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of

P433 Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer's Disease

Presenteur : Casey Vanderlip

Casey Vanderlip^{1,2}, Karra Harrington², Paul Maruff², Pam Ventola²

¹UC Irvine, Irvine, United States, ²Coestate Ltd, Melbourne, Australia

P434 Performance on a Multiday Digital Cognitive Assessment Is Associated with Plasma p-tau217 and Subjective Cognitive Concerns in a Large Remote Registry Cohort

Presenteur : Lex Minto

Lex Minto^{1,2}, Cecily Jenkins³, Rema Raman³, Oliver Langford³, Kedir Hussen³, Reisa Sperling^{1,2}, Paul Aisen³, Daniel Soberanes¹, Gustavo Jimenez-Maggiora³, Rebecca Amariglio^{1,2}, Kathryn Papp^{1,2}

¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, ³Epstein Family Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, United States

P435 Remote Multiday Digital Cognitive Assessment Among Patients Evaluated for Anti-Amyloid Treatment: Feasibility and Clinical Correlates

Presenteur : Rebecca Amariglio

Rebecca Amariglio, Daniel Soberanes, Vivienne Lubbat, Claudia Suarez Rodriguez, Risal Ilisa, Alberto Serrano Pozo, John Dickson, Beata-Gabriela Simpson, Teresa Gomez-Isla, Kathryn Papp

Mass General Brigham, Boston, United States

P436 A Digital Memory Task Enables Efficient Identification of Cognitive Impairment in Alzheimer's Disease Trials

Presenteur : Casey Vanderlip

Casey Vanderlip^{1,2,3}, Karra Harrington², Johnathan Wagg³, Anahita Kyani³, Charmaine Demanuele³, Macarena Garcia Valdecasas Colell³, Arthur Simen³, Craig Stark¹, Paul Maruff², Pam Ventola²

¹UC Irvine, Irvine, United States, ²Cogstate Ltd, Melbourne, Australia, ³Johnson and Johnson, New Brunswick, United States

P437 REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer's disease

Presenteur : Alexandria Wise Brown

Alexandria Wise Brown¹, Frank Boess², Frank Perilli³, Ira Goodman³, Erin Beck³, Karra D. Harrington⁴, Nicklas Linz⁵, Alison Buick⁵, Nicola Maiorano², Ruth Croney⁶, Kelly Coultres⁷, Janice Smith⁶

¹Genentech, Inc., South San Francisco, California, United States, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³SiteRx, New York, New York, United States, ⁴CogState Ltd, New Haven, Connecticut, United States, ⁵Ki: Elements GmbH, Saarbrücken, Germany, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada

P438 Longitudinal Game-Based Monitoring in Older Adults With and Without Cognitive Impairment Using MIND GamePack

Presenteur : Anna Favaro

Anna Favaro^{1,2}, Jake Galler¹, Beata-Gabriela K. Simpson¹, Yingnan He¹, Cathrine Young¹, Steven E. Arnold^{1,2}, Mark Eldaief^{1,2}, Sudeshna Das^{1,2}

¹Massachusetts General Hospital, Boston, United States, ²Harvard Medical School, Boston, United States

P439 Changes in Occipital Alpha Frequency Precede Clinical Conversion from Mild Cognitive Impairment to Alzheimer's Disease

Presenteur : Julie Clarot

Julie Clarot¹, Emma Depuydt¹, Gert Vanhollenbeke¹, Velislava Zoteva¹, Lukas Gemein², Christoffer Hatlestad-Hall², Hanna Renvall^{3,4}, Fernando Maestù^{5,6,7}, Camillo Marra^{8,9}, Paolo Maria Rossini⁸, Ira Hebold Haraldsen², Pieter Van Mierlo¹

¹Clouds of Care, Ghent, Belgium, ²Department of Neurology, Oslo University Hospital, Oslo, Norway, ³BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, Helsinki, Finland, ⁴Department of Neuroscience and Biomedical Engineering, Aalto University, Helsinki, Finland, ⁵Center for Cognitive and Computational Neuroscience (C3N), Universidad Complutense de Madrid, Madrid, Spain, ⁶Department of Experimental Psychology, Cognitive Psychology and Speech & Language Therapy, Universidad Complutense de Madrid, Madrid, Spain, ⁷Health Research Institute of the Hospital Clínico San Carlos (IdiSSC), Madrid, Spain, ⁸Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁹Department of Psychology, Catholic University of the Sacred Heart, Rome, Italy

P440 Fully Remote Telehealth Evaluation and Delivery of Amyloid-Targeted Therapy in Early Symptomatic Alzheimer's Disease: Feasibility and Initial Experience

Presenteur : Oleg Yerstein

Oleg Yerstein¹, Jeremy Pruzin^{1,2}, Mayra Reyna¹, Mercedes Guevara¹, Meagan Gates¹, Sonia Bajwa¹, Abigail O'Connell¹, Benjamin Williams¹, Erin Leahy¹, Eric Anderson¹, Melissa Yu¹

¹Synapticure, Chicago, United States, ²Banner Health, Phoenix, United States

P441 Association of a Digital Speech Biomarker for Cognition (SB-C) with Functional Outcomes in Early Preclinical Alzheimer's Disease: Functional Equivalence to In-Clinic PACC Within the Beta AARC Cohort

Presenteur : Alexandra König

Alexandra König¹, Clàudia Porta-Mas^{2,3}, Andreea Rădoi², Elisa Malick¹, Johannes Tröger¹, Oriol Grau-Rivera^{2,4}, Gemma Salvadó^{2,5}, Gonzalo Sánchez-Benavides^{2,6}

¹Kielements, Saarbrücken, Germany, ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain, ³IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, ⁴Universitat Pompeu Fabra, Barcelona, Spain, ⁵Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain, ⁶IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

P442 Maximizing Signal in Early AD: How Digital Assessments Outperform the CDR-SB and ADAS-Cog

Presenteur : Katelyn Miller

Katelyn Miller, Samuel Dickson, Suzanne Hendrix

Pentara Corporation, Millcreek, Ut, United States

P443 SpeechDx: Advancing Prognostic Speech Markers for Alzheimer's Disease

Presenteur : Melissa Lee

Shirine Moukaled¹, Andréa Lessa Benedet², Henrik Zetterberg², Stephan Meylan^{1,3}, Jerica Reeder¹, Speech Dx The Speechdx Consortium¹, Aishwarya Sukumar⁴, Laura Nisenbaum¹, Lampros Kourtis^{1,4}, Melissa Lee¹

¹Alzheimer's Drug Discovery Foundation, New York, United States, ²University of Gothenburg, Mölndal, Sweden, ³Surprisal B.V., Amsterdam, The Netherlands, ⁴Gates Ventures, Kirkland, United States

P444 Associations between Alzheimer's disease biomarkers and multiday digital cognitive performance in older adults at elevated vascular risk

Presenteur : Lex Minto

Lex Minto^{1,2}, Hairin Kim^{1,2}, Mark Dubbelman^{1,2}, Daniel Soberanes¹, Vivienne Lubbat¹, Laura Baker³, Mark Espeland³, Susan Landau⁴, Rebecca Amariglio^{1,2}, Kathryn Papp^{1,2}

¹Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States, ³Wake Forest University School of Medicine, Winston-Salem, United States, ⁴University of California, Berkeley, Berkeley, United States

P445 Promoting dementia research participation in high-risk communities – co-creating a Research Ambassador Program.

Presenteur : Sarah Walter

Sarah Walter¹, Joe Costello², Cynthia Huling Hummel³, Paul Aisen¹, Colin Chandler⁴, Leah Macaden⁵

¹Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective - San Diego (United States), San Diego, United States, ³Alzheimer's Clinical Trials Consortium, Research Ambassador Community Collective, San Diego, United States, ⁴School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom, ⁵Nursing Studies, School of Health in Social Science, University of Edinburgh, Edinburgh, United Kingdom

P446 Noise-cancellation variability as a source of longitudinal drift in speech-based digital endpoints for Alzheimer's disease trials

Presenteur : Lisa Chiang

Adrian Ortiz, Lisa Chiang

Cephalgo, Strasbourg, France

P447 Cognitive Benefit from the Structured Lifestyle Intervention in U.S. POINTER Replicated and Extended with Digital Cognitive Outcomes

Presenteur : Kathryn Papp

Kathryn Papp¹, Sarah Farias², Sarah Evans³, Magdalene Harki⁴, Joni Evans³, Athene Lee⁵, Bonnie Sachs⁶, Christy Tangney⁷, Maria Carrillo⁸, Katie Garcia³, Amber Thro⁶, Iris Leng⁶, Kristin Ijeh⁹, Mark Espeland⁶, Laura Baker⁶

¹Mass General Brigham, Boston, United States, ²UCDavis, Davis, United States, ³Advocate Health, Charlotte, United States, ⁴AAH, Chicago, United States, ⁵Brown University, Providence, United States, ⁶Wake Forest, Winston-Salem, United States, ⁷Rush, Chicago, United States, ⁸Alzheimer Association, Chicago, United States, ⁹BCM, Houston, United States

P448 Refer-MCI: Enriching Referrals of Patients to Memory Clinics for Mild Cognitive Impairment (MCI)

Presenteur : Emrah Duezel

Emrah Duezel^{1,2,3}, Jochen René Thyrian⁴, Vanessa Kurth⁵, Nadine Diersch³, Anne Boehlen⁶, Hannes Vossfeldt³, David Berron^{1,3}, Frank Jessen^{6,7}, Annika Spottke⁶, Stefan Teipel⁸

¹German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, ²Otto-von-Guericke University, Institute of Cognitive Neurology and Dementia Research (IKND), Magdeburg, Germany, ³neotiv GmbH, Magdeburg, Germany, ⁴German Center for Neurodegenerative Diseases (DZNE), Greifswald, Germany, ⁵Lilly Germany, Bad Homburg, Germany, ⁶German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, ⁷University of Cologne, Cologne, Germany, ⁸German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany

P449 Understanding Cognitive Impairment Through Analysis of Process Metrics Derived from the Digital Assessment of Cognition

Presenteur : Tanya Talker

Tanya Talker¹, Connor Higgins¹, Ali Jannati¹, David Libon^{1,2,3}, Rod Swenson^{1,4}, Sean Tobyne¹

¹Linus Health, Boston, United States, ²Department of Geriatrics and Gerontology, New Jersey Institute for Successful Aging, Rowan University-School of Osteopathic Medicine, Glassboro, United States, ³Department of Psychology, Rowan University, Glassboro, United States, ⁴University of North Dakota School of Medicine and Health Sciences, Grand Forks, United States

P450 Tracking Cognitive Change in Mild Cognitive Impairment Using Repeated Speech-Based Digital Cognitive Assessments: Comparison with the Clinical Dementia Rating Scale

Presenteur : Alexandra König

Johannes Tröger¹, Elisa Mallick¹, Alexandra König¹, Alison Buick¹, Mathias Bähr², Emrah Düzel³, Björn Falkenburger⁴, Gabor Petzold⁵, Josef Pillar⁶, Annika Spottke⁵, Stefan Teipel⁷, Michael Wagner⁵, Jens Wiltfang², Inga Zerr², Stefanie Köhler⁷

¹Ki elements GmbH, Saarbrücken, Germany, ²German Center for Neurodegenerative Diseases DZNE, Göttingen, Germany, ³German Center for Neurodegenerative Diseases DZNE, Magdeburg, Germany, ⁴German Center for Neurodegenerative Diseases DZNE, Dresden, Germany, ⁵German Center for Neurodegenerative Diseases DZNE, Bonn, Germany, ⁶German Center for Neurodegenerative Diseases DZNE, Berlin, Germany, ⁷German Center for Neurodegenerative Diseases DZNE, Rostock, Germany

P451 Smartphone-based User-adaptive Assessment of Cognitive Functions in Patients with Mild Cognitive Impairment

Presenteur : Shibeshih Belachew

Antonio Rodríguez-Romero¹, Katarzyna Kita¹, Alexa Burk², Emmanuel Bartholomé¹, Claudia Mazzà¹, Carlos Luque¹, Óscar Reyes¹, Corrado Bernasconi¹, Shibeshih Belachew¹, Rhoda Au²

¹Indivi AG, Basel, Switzerland, ²Boston University Chobanian & Avedisian School of Medicine, Boston, United States

P452 A/B-test results of XpressO-Mix: a remote cognitive prescreener that mitigates practice effects

Presenteur : Willem Huijbers

Willem Huijbers¹, Hans-Aloys Wischmann², Murray Gillies¹, Ziad Nasreddine¹

¹MoCA Cognition, Montreal, Canada, ²Charité, Berlin, Germany

P453 The Person, Not the Device: Evidence from Ten Years of In-Home Remote Monitoring Research in Dementia

Presenteur : Ramin Nilforooshan

Ramin Nilforooshan^{1,2}, Chloe Walsh^{1,3}, Sai-Bo Cheung¹, Payam Barnaghi³

¹Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom, ²University of Surrey, Guildford, United Kingdom, ³Imperial College London, London, United Kingdom

P454 Digital cognitive assessments discriminate early tau pathology in cognitively unimpaired older adults

Presenteur : Karra D. Harrington

Karra D. Harrington¹, Casey R. Vanderlip¹, Charles O'Connor², Pam Ventola¹, Paul Maruff²

¹Cogstate, New Haven, United States, ²Cogstate, Melbourne, Australia

P455 Digital Phenotyping For Detecting Subtle Longitudinal Changes In Alzheimer's Treatment

Presenteur : Byun Andrew

Byun Andrew¹, Meaghan McKenna², Ko Woon Kim³, Margaret Yang¹, John Torous¹, Chun Lim¹

¹BIDMC, Boston, United States, ²University of Rochester, Rochester, United States, ³Jeonbuk National University Medical School & Hospital, Jeonju, Korea, Democratic people's republic of

P456 Prognostic enrichment of AD studies with a brief at-home digital assessment: predicting 12-month decline and projected reductions in trial sample size

Presenteur : Brian Murphy

Brian Murphy¹, Florentine Barbey¹, Hugh Nolan¹, George Stothart²

¹Cumulus Neuroscience, Dublin, Ireland, ²Cumulus Neuroscience, Belfast, United Kingdom

P458 Improving Early Detection of Cognitive Impairment with Cognivue Clarity Across Diverse Clinical Settings: Accounting for Age, Education and Race Differences in Performance

Presenteur : James Galvin

James Galvin¹, Paul Estes², Heather Harris², Lun-Ching Chang³

¹University of Miami Miller School of Medicine, Boca Raton, United States, ²Cognivue, Inc, Victor, United States, ³Florida Atlantic University, Boca Raton, United States

P459 Remote Odor Percept Identification as a Scalable Marker of Alzheimer's Disease

Presenteur : Benoît Jobin

Benoît Jobin, Colin Magdamo, Hengbin Zhang, Beyzanur Ergun, Sean Reineke, Alefiya Dhillal-Albers, Mark Albers

Mass General Brigham/Harvard Medical School, Boston, United States

P460 Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, Community Partners and Embedded Clinical Trial Recruitment

Presenteur : Gregory Sahagian

Gregory Sahagian

The Neurology Center of Southern California, Carlsbad, United States

P461 Longitudinal digital speech assessment in progressive supranuclear palsy

Presenteur : Charlie Weige Zhao

Kyurim Kang¹, Ilkay Potter², Ram Mishra², Rylee Cole², Tejas Pawar², Charlie Weige Zhao³, Antje Mefferd⁴, Michael De Riesthal⁵, Ashkan Vaziri², Anne-Marie Wills³, Alexander Pantelyat³

¹Johns Hopkins University, Baltimore, United States, ²Biosensics LLC, Newton, United States, ³Mass General Brigham, Boston, United States, ⁴Vanderbilt University Medical Center, Nashville, United States, ⁵Vanderbilt University, Nashville, United States

P462 Automated verbal fluency as a digital cognitive biomarker in progressive supranuclear palsy: a longitudinal study

Presenteur : Charlie Weige Zhao

Jesse Wang¹, Ilkay Potter², Charlie Weige Zhao¹, Ram Mishra², Kyurim Kang³, Tejas Pawar², Rylee Cole², Ashkan Vaziri², Alexander Pantelyat³, Anne-Marie Wills¹

¹Mass General Brigham, Boston, United States, ²Biosensics LLC, Newton, United States, ³Johns Hopkins University, Baltimore, United States

P463 Ensuring Demographic Equity: Evaluating the SB-C Speech-Based Cognitive Assessment Across Ethnic Groups in US

Presenteur : Alexandra König

Johannes Tröger, Louisa Schwed, Simona Schäfer, Alison Buick, Nicklas Linz, Alexandra König

ki elements GmbH, Saarbrücken, Germany

P464 Diagnosed Too Late to Treat: Nationwide Real-World Evidence on Diagnostic Delay, Treatment Coverage and Persistence in Dementia Care

Presenteur : Petra Marica Halmos

Petra Marica Halmos, Balázs Dobi, Dániel Bereczki, Tibor Kovács

Semmelweis University, Budapest, Hungary

P465 From readiness to real-world implementation: a national Community of Practice for novel Alzheimer's disease therapies in Australia

Presenteur : Paul Yates

Paul Yates^{1,2}, Christopher Belder³, Oneil Bhalala⁴, Antonia Clarke⁵, Emma Devenney⁶, Kathryn Goozee⁷, Colin Masters⁸, Christopher Rowe⁹, Cathy Short¹⁰, Ashwin Shukla¹¹, Stephanie Ward¹², Michael Woodward^{1,2}, Mark Yates¹³, Ranjeev Chrysanth Pulle¹⁴, Amy Brodtmann⁵

¹Department of Geriatric Medicine, Austin Health, Heidelberg, Australia, ²Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia, ³Royal Adelaide Hospital/Queen Elizabeth Hospital, Adelaide, Australia, ⁴Walter and Eliza Hall Institute, Parkville, Australia, ⁵Monash University, Clayton, Australia, ⁶NeuRA, Sydney, Australia, ⁷KaraMinds, Sydney, Australia, ⁸University of Western Australia, Perth, Australia, ⁹Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Australia, ¹⁰The Queen Elizabeth and Royal Adelaide Hospitals, Adelaide, Australia, ¹¹SA Geriatrics Pty Ltd, Adelaide, Australia, ¹²University of NSW, Sydney, Australia, ¹³Grampians Health, Ballarat, Australia, ¹⁴The Prince Charles Hospital, Brisbane, Australia

P466 National Real-World Use of Amyloid-Targeting Therapies in Australia: Early Experience from the ADNeT mAbs Registry

Presenteur : Paul Yates

Paul Yates^{1,2,3}, Robert Adam⁴, Susannah Ahern⁵, Rohit Bansal⁶, James Bice⁷, Bruce Brew⁸, Henry Brodaty⁹, Roger Clarnette¹⁰, Yun Tae Hwang¹¹, Penny King¹², Michael Leihy¹³, Karen Robinson¹⁴, Courtney Shelton^{3,1}, Paul Viray¹⁵, Stephanie Ward⁹

¹Department of Geriatric Medicine, Austin Health, Heidelberg, Australia, ²Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia, ³Warringal Private Hospital, Heidelberg, Australia, ⁴Robert Adam Neurology, Brisbane, Australia, ⁵Monash University, Clayton, Australia, ⁶Healthy Ageing Gold Coast, Tugun, Australia, ⁷Specialist Memory Services, Box Hill, Australia, ⁸St Vincent's Hospital, Sydney, Australia, ⁹University of NSW, Sydney, Australia, ¹⁰Cardiometabolic Services, Nedlands, Australia, ¹¹Central Coast Neurosciences, Erina, Australia, ¹²Aurora Health, Robina, Australia, ¹³The Healthy Brain and Memory Centre, Southport, Australia, ¹⁴Melbourne Cognitive Services, Melbourne, Australia, ¹⁵Cabrini Hospital, Malvern, Australia

P467 A Safety Comparison of Lecanemab and Donanemab Across Three Clinical Institutions

Presenteur : Michael Rosenbloom

Varun Mehta¹, Daniel Fisher¹, Andrea Schnee¹, David Weisman², Kala Zingle², Jordyn Kelman², Emily Kuhlmann³, Ryan Townley³, Faris Shaker³, Michael Rosenbloom¹

¹University of Washington, Seattle, United States, ²Abington Neurological Associates, Abington, United States, ³KUMC, Kansas City, United States

P468 Higher baseline mean arterial pressure predicts moderate-to-severe ARIA and ARIA-related treatment discontinuation in a real-world population

Presenteur : Elizabeth Moore

Elizabeth Moore^{1,2}, Era Laho¹, Sokratis Charisis^{1,2}, Ron Danziger^{1,2}, Jasmeer Chhatwal^{1,2}, Bradford Dickerson^{1,2}, Reisa Sperling^{1,2}, Sheena Baraton^{1,2}, John Dickson^{1,2}, Michael Erkinen³, Nathan Praschan^{4,2}, Liliana Ramirez-Gomez^{1,2}, Kirk Daffner^{1,2}, Teresa Gomez-Isla^{1,2}, Wai-Ying Wendy Yau^{1,2}

¹Department of Neurology, Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States, ³Department of Neurology, University of California Davis, Sacramento, United States, ⁴Department of Psychiatry, Mass General Brigham, Boston, United States

P470 Door-to-Needle Time for Anti-Amyloid Therapy in a Community Neurology Practice: A Retrospective Cohort Study of a Primary Care and Outpatient Neurology Partnership

Presenteur : Molly Budhiraja

Molly Budhiraja¹, Samar Quadri¹, Rohan Vallamshetla², Karan Vallamshetla³, Dominic Alamsjah⁴, Aarav Sabnekar⁵, Aashi Singhai⁶, Kinsey Gudenkauf⁷, Hemant Pandey⁸

¹Arizona State University, Tempe, United States, ²University of California, Berkeley, Berkeley, United States, ³Cornell University, Ithaca, United States, ⁴Arizona State University, Tempe, United States, ⁵Basis Chandler, Chandler, United States, ⁶Hamilton High School, Chandler, United States, ⁷Banner - University Medical Center Phoenix, Phoenix, United States, ⁸Brain and Spine Center, Chandler, United States

P471 Real-world Experience of Amyloid-Targeting Therapies at Sutter Health - a Large Integrated Healthcare System

Presenteur : Armen Moughamian

Armen Moughamian^{1,2}, Joe Winer³, Amanda Pickett³, Julian De La Cruz³, Jane Kim³, Aria Sengupta³, Avery Razavi³, Julinna Cheung³, Juliana Van Cleve³, Lisamarie La Vallee², Shawn Kile^{2,4}

¹Ray Dolby Brain Health Center, Sutter Health, San Francisco, United States, ²Sutter Health Neuroscience Service Line, Sacramento, United States, ³Sutter Health Research Institute, Sutter Health, Emeryville, United States, ⁴Sacramento Memory Center, Sutter Health, Sacramento, United States

P472 A Multidisciplinary Model to Facilitate Safe Access to Amyloid-Targeting Therapies in General Neurology Across the Sutter Health System

Presenteur : Armen Moughamian

Armen Moughamian^{1,2}, Lisamarie La Vallee², Shawn Kile^{2,3}, Travis Urban¹, Austin Momii¹, Michelle Manifield², Jean Minton²

¹Ray Dolby Brain Health Center, Sutter Health, San Francisco, United States, ²Sutter Health Neuroscience Service Line, Sacramento, United States, ³Sacramento Memory Center, Sutter Health, Sacramento, United States

P474 Cardiovascular changes during lecanemab treatment and subsequent amyloid-related imaging abnormalities

Presenteur : Park Hee Kyung

Park Hee Kyung¹, Sungjoo Lee², Heekyoung Kang³, Lee Jungah⁴, Lee Kyungbok⁴, Yim Sohyun⁵, Shin Daeun⁶, Kim Seonghyeon⁷, Kim Jun Pyo¹, Kim Hee Jin¹, Seo Sang Won¹

¹Department of Neurology, Samsung Medical Center, Sun, Seoul, Korea, Republic of, ²Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea, Republic of, ³Department of Neurology, Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of, ⁴Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Korea, Republic of, ⁵Department of Neurology, Inje University Haeundae Paik Hospital, Busan, Korea, Republic of, ⁶Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, ⁷Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of

P475 When willingness is not enough: participation fit and potentially modifiable person-study mismatches in dementia trial recruitment

Presenteur : Patricia Fuller

Patricia Fuller^{1,2}, Andrew Claxton³, Helen Pocock^{4,5}, Samantha Willaims³, Nicola Claxton³, Amanda Wollam⁶, Daniel Blackburn⁷, George Devitt⁸, Sarah Fearn^{1,2}, Christopher Kipps^{9,10}

¹University of Southampton, Southampton, United Kingdom, ²NIHR Applied Research Collaboration Wessex, Southampton, United Kingdom, ³South Central Ambulance Service NHS Foundation Trust, Bicester, England, UK, Bicester, United Kingdom, ⁴South Central Ambulance Service NHS Foundation Trust, Bicester, England, UK, Bicester, United Kingdom, ⁵University of Warwick, Warwick Clinical Trials Unit, Coventry, United Kingdom, ⁶Patient and Public Involvement and Engagement, NIHR Applied Research Collaboration Wessex, Southampton, England, UK, Southampton, United Kingdom, ⁷The University of Sheffield Institute for Translational Neuroscience, Sheffield, England, UK, Sheffield, United Kingdom, ⁸University Hospital Southampton NHS Foundation Trust, Neurodegenerative Research, Southampton, England, UK, Southampton, United Kingdom, ⁹University of Southampton, Southampton, UK, Southampton, United Kingdom, ¹⁰University Hospital Southampton NHS Foundation Trust, Neurodegenerative Research, Southampton, United Kingdom

P476 ALZEVIT: A Nationwide Digital Registry of APOE ε4/ε4 Carriers to Enable Prevention Trials in Alzheimer's Disease

Presenteur : Audrey Gabelle

Audrey Gabelle¹, Federica Zilli², Margaux Faurie², Miguel Casanova³, Stéphanie Boutillier³, Renaud David⁴, Gaël Nicolas⁵, David Wallon⁵, Eloi Magnin⁶, François Sellal⁷, Frédéric Blanc⁸, Hüseyin Firat²

¹CHU Montpellier, Montpellier, France, ²Firalis, Huningue, France, ³Amoneta Diagnostics, Huningue, France, ⁴CHU Nice, Nice, France, ⁵CHU Rouen, Rouen, France, ⁶CHU Besançon, Besançon, France, ⁷Hôpitaux Civils, Colmar, France, ⁸CHRU, Strasbourg, France

P477 iconsortium ad: A 10-Year, AI-Powered Longitudinal Real-World Data Registry to Advance Alzheimer's Disease Care and Standardize Neuroimaging Outcomes

Presenteur : Wim Van Hecke

Wim Van Hecke^{1,2}, Nuno Pedrosa De Barros^{1,2}, Dirk Smeets^{1,2}

¹icometrix, Leuven, Belgium, ²GEHC, Diegem, Belgium

P478 Real-World Biomarker Changes During Amyloid-Targeting Therapy in a Treatment Clinic

Presenteur : Nicholas Schwartz

Nicholas Schwartz^{1,2}, Tara Ellingson¹, Hong Nguyen¹, Connor Dietz¹, Nicholas Ashton³, Jeff Dage⁴, Rowan Saloner¹, Peter Ljubenkov¹, Julio Rojas¹, Marlene Lin¹, Renaud La Joie¹, Gil Rabinovici^{1,5}, Bruce Miller¹, Adam Boxer¹, Lawren Vandevrede¹

¹Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States, ²University of Maryland, Baltimore, Baltimore, MD, United States, ³Banner Sun Health Research Institute, Sun City, AZ, United States, ⁴Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, United States, ⁵Department of Radiology & Biomedical Imaging, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States

P479 Bridging the Gap from Real-World Data to Real-World Impact: A Roadmap for Common Data Element (CDE) Development and Adoption in AD/ADRD Research

Presenteur : Zoe Arvanitakis

Zoe Arvanitakis¹, Ronald Petersen², Licong Cui³, Yong Chen⁴, Hongfang Liu⁵, Guo-Qiang Zhang³

¹Rush University Med Ctr, Chicago, United States, ²Mayo Clinic, Rochester, United States, ³University of Texas Health Sciences, Houston, United States, ⁴University of Pennsylvania, Philadelphia, United States, ⁵University of Texas, Austin, United States

P482 Clinical and real-world experience with the synaptic regenerative drug, tazbentetol, in Alzheimer's patients

Presenteur : Sharron Gargosky

Lauren Priest¹, Bruce Brew², Allison Perrin³, Cazyer Aimee¹, Bramah Valerie², Peter Vanderklish⁴, Craig Erickson⁴, Ernest Pedapati⁵, Sharron Gargosky⁴, Stella Sarraf⁴

¹Flinders Medical Center, Adelaide, Australia, ²St Vincent's Hospital, Sydney, Australia, ³Banner Alzheimers Health, Scottsdale, United States, ⁴Spinogenix, Los Angeles, United States, ⁵Cincineuro, Cincinnati, United States

P483 — Remote Real-World Practice Patterns and Clinical Considerations in Lecanemab Administration: A Survey-Based Analysis of Dosing Strategies, Schedule Flexibility, and Economic Workarounds

Presenteur : Young Hee Jung

Young Hee Jung¹, Young Ho Park², Seong Hye Choi³, Kee Hyung Park⁴, Geon Ha Kim⁵, Hojin Choi⁶, Dong Won Yang⁷

¹Hallym Sacred Heart Hospital, Anyang, Korea, Republic of, ²Seoul National University Bundang Hospital, Bundang, Korea, Republic of, ³Inha University, Incheon, Korea, Republic of, ⁴Gachon University Gil Medical Center, Incheon, Korea, Republic of, ⁵Ewha Womans University, Seoul, Korea, Republic of, ⁶Hanyang University Guri Hospital, Guri, Korea, Republic of, ⁷Seoul St. Mary's Hospital, Seoul, Korea, Republic of

P484 Optimizing Recruitment Resources for Underrepresented Latino Older Adults in Alzheimer's Research: A Randomized Trial of Community-Based Recruitment

Presenteur : Yuhsuan (olivia) Wang

Yuhsuan (Olivia) Wang^{1,2}, Jonathan N Cloughesy^{1,3}, Tom Chang⁴, Doris P Molina-Henry⁵, Mireille Jacobson¹

¹Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, United States, ²Department of Gerontology and Long-term Care, Taipei Medical University, Taipei, Taiwan, ³Mann School of Pharmacy, University of Southern California, Los Angeles, United States, ⁴Department of Finance and Business Economics, University of Southern California, Los Angeles, United States, ⁵Epstein Family Alzheimer's Therapeutic Research Institute, San Diego, United States

P485 ROAD-US: An evaluation of the utilization and clinical utility of Alzheimer's disease blood biomarkers in US community practices, a pre-post time series study

Presenteur : Martin Guess

Martin Guess¹, Daniel Gautieri², Daniel Barulli², David Henley², Soeren Mattke³, Sophie Roth¹, Maria-Magdalena Patru⁴, Matthew Denave⁴, Bora Plaku⁵, Margaret K. Ogongo⁴, Pierre Tariot⁶

¹Roche Diagnostics International Ltd, Rotkreuz, Switzerland, ²SiteRx, New York, NY, United States, ³USC Brain Health Observatory, USC Dornsife, Los Angeles, CA, United States, ⁴Roche Diagnostics Corporation, Indianapolis, IN, United States, ⁵Roche Diagnostics GmbH, Penzberg, Germany, ⁶Banner Alzheimer's Institute, Phoenix, AZ, United States

P487 Real-world data analysis of post 12-months donanemab, amyloid targeting therapy, from a memory and cognitive disorders clinic

Presenteur : Maileen Ulep

Maileen Ulep, Charles Bernick

Cleveland Clinic Nevada Lou Ruvo Center for Brain Health, Las Vegas, United States

P488 Implementing Lecanemab at a Veteran Affairs Medical Center: Evaluation of Operational Challenges and Neurology Resident Knowledge

Presenteur : Neal Nathan

Neal Nathan

Brigham and Women's Hospital, Boston, MA, United States

P489 Clinical Effectiveness of Primary Care-Led Post-Diagnostic Dementia Management: One-Year Real-World Outcomes from a Nationwide Cohort in Korea

Presenteur : Sun Min Lee

Sun Min Lee^{1,2}, Kiyong Kim³, Kyoung Chang Kim³, Yungi Hwang³, Im Seok Koh^{1,2}, Choi Jisook³

¹Department of Neurology, National Medical Center, Seoul, Korea, Republic of, ²National Institute of Dementia, National Medical Center, Seoul, Korea, Republic of, ³Health Insurance Review and Assessment Research Department, Health Insurance Review & Assessment Service, Wonju, Korea, Republic of

P490 Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Donanemab

Presenteur : Maya Ibrahim

Ruhaan Shah, Maya Ibrahim, Ira Katigbak, Omar Almashharawi, Lee Watson, Eduardo Chacon, Kevin Aimua, Bella Principe, Rory Roberts, Monica Crane

Tennessee Memory Disorders Foundation, Knoxville, United States

P491 Patient Outcomes and Real-World Treatment Review and Assessment of Infusion Therapies with Lecanemab

Presenteur : Ira Katigbak

Ira Katigbak, Ruhaan Shah, Maya Ibrahim, Omar Almashharawi, Lee Watson, Eduardo Chacon, Isabella Principe, Kevin Aimua, Rory Roberts, Monica Crane

Tennessee Memory Disorders Foundation, Knoxville, United States

P492 Community Brain Health Network: A Web-Based Registry Platform for Engagement, Participation, and Retention in Dementia Research

Presenteur : Daniel Gautieri

Paula Aduen¹, Daniel Gautieri¹, Steven Smith², John Lucas¹, Angela Lunde², Maria Vassilaki², Elizabeth Boots², Nikki Stricker², Jonathan Graff-Radford², Gregory Day¹, Neill Graff-Radford¹, Bradley Boeve², Ronald Petersen²

¹Mavo Clinic, Jacksonville FL, United States, ²Mavo Clinic, Rochester MN, United States

P493 Door-to-Needle Time for Anti-Amyloid Therapy in a Community Neurology Practice: A Retrospective Cohort Study of a Primary Care and Outpatient Neurology Partnership

Presenteur : Molly Budhiraja

Molly Budhiraja¹, Samar Quadir¹, Karan Vallamshetla², Rohan Vallamshetla³, Dominic Alamsjah¹, Aarav Sabnekar⁴, Aashi Singhai⁵, Kinsey Gudenkauf⁶, Hemant Pandey⁷

¹Arizona State University, Tempe, United States, ²Cornell University, Ithaca, United States, ³University of California, Berkeley, Berkeley, United States, ⁴Basis Chandler, Chandler, United States, ⁵Hamilton High School, Chandler, United States, ⁶Banner - University Medical Center Phoenix, Phoenix, United States, ⁷Brain and Spine Center, Chandler, United States

P494 Evaluating Research Attitudes and Willingness to Participate in Alzheimer's Disease and Related Dementias Clinical Trials Across Disaggregated AANHPI Subgroups: Data from the CARE Registry

Presenteur : Kenny Li

Kenny Li¹, Muskan Jain², Thomas Hoffmann², Tsoh Janice³, Van Park², Joshua Grill¹

¹Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, United States, ²Department of Community Health Systems, University of California, San Francisco (UCSF), San Francisco, United States, ³Department of Psychiatry and Behavioral Sciences, UCSF, San Francisco, United States

P495 Utilization and reimbursement of blood-based pTau181 and pTau217 tests in Medicare Part B from January 2025 to April 2026

Presenteur : Lee Honigberg

Lee Honigberg¹, Theo Devos², Teodora Stoica¹, James Pistorino³, Soeren Mattke⁴

¹ALZpath, Inc., Carlsbad, CA, United States, ²Boudicca Dx, Seattle, WA, United States, ³Lumaclaims, LLC, Tampa, FL, United States, ⁴USC Brain Health Observatory, University of Southern California, Los Angeles, CA, United States

P496 Study partner availability and willingness to be contacted about clinical trials in a local recruitment registry

Presenteur : Eunji Russ

Eunji Russ^{1,2}, Dan Hoang², Joshua Grill^{1,3,2}, Dan Gillen^{4,2}

¹Department of Neurobiology and Behavior, University of California, Irvine, IRVINE, United States, ²Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, IRVINE, United States, ³Department of Psychiatry and Human Behavior, University of California, Irvine, IRVINE, United States, ⁴Department of Statistics, University of California, Irvine, IRVINE, United States

P497 Cognitive Testing as a Predictor of Anti-Amyloid Therapy Eligibility: An Exploratory Analysis of Real-World Memory Clinic Data

Presenteur : Wedgina Norelus

Wedgina Norelus¹, Katelyn Horan¹, Sokratis Charisis^{1,2}, Cinthya Agüero^{1,2}, Kathryn Papp^{1,2}, John Dickson^{1,2}, Teresa Gomez-Isla^{1,2}

¹Mass General Brigham, Boston, United States, ²Harvard Medical School, Boston, United States

P498 Evolving Real-World Diagnostic Pathways to Alzheimer's Disease-Modifying Treatment: Longitudinal EHR Evidence from the SiteRx Real-World Database

Presenteur : Daniel Gautieri

Matthew Qiao, Daniel Gautieri

SiteRx, New York, United States

P499 Smart Triage for Amyloid-Targeting Therapies (STATT)

Presenteur : William Powell

William Powell¹, Albert Lai¹, Suzanne Schindler², Barbara Snider^{2,3}, Zachary Posey², Carson Woodfin², Inez Oh¹, Abigail Lewis¹, Philip Payne¹, Mackenzie Hoffer^{1,4}, Aditi Gupta¹

¹Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St. Louis, United States, ²Department of Neurology, Washington University School of Medicine, St. Louis, United States, ³Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, United States, ⁴Division of General Medicine, Washington University School of Medicine in St. Louis, St. Louis, United States

P500 The Effect of Messaging on Research Enrollment

Presenteur : Megan Witbracht

Megan Witbracht¹, Sarah Schlund², Thuy Lu³, Dan Hoang¹, Amy Kind⁴, Daniel Gillen², Joshua Grill¹

¹Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, United States, ²Department of Statistics, University of California, Irvine, Irvine, United States, ³Arrowhead Pharmaceuticals, Inc, Pasadena, United States, ⁴Center for Health Disparities Research and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States

P501 Automated speech analysis of a semantic verbal fluency task for the detection of cognitive impairment

Presenteur : Ricardo Sainz-Fuertes

Ricardo Sainz-Fuertes^{1,2}, Patricia Laura Marañ^{1,3}, Sergi Valero^{4,5}, Berta Calm⁴, Brian Murphy², Carla Zaldua¹

¹Accesible Impacto s.l., Barcelona, Spain, ²Cumulus Neuroscience, Belfast, United Kingdom, ³Psychiatry, Mental Health and Addictions Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigaci' on Sanitaria Acreditado Instituto de Investigaci' on - Hospital Universitario Vall d'Hebron (IR-HUVH, Barcelona, Spain, ⁴Ace Alzheimer Center, Barcelona, Spain, ⁵Universitat Internacional de Catalunya, Barcelona, Spain

P502 Baseline Completion and Retention with a New Cognitive Assessment in an Online Alzheimer's Disease Trial Registry: Results from the APT Webstudy

Presenteur : Margaret D. Mastrolorenzo

Margaret D. Mastrolorenzo¹, Marina Ritchie¹, Kedir Hussen¹, Oliver Langford¹, Gustavo Jimenez-Maggiora¹, Paul Aisen¹, Kathryn V. Papp², Rebecca E. Amariglio², Reisa A. Sperling², Cecily Jenkins¹, Rema Raman¹

¹Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, ²Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, United States

P503 Infusion-Related Reactions Associated with Anti-Amyloid Monoclonal Antibodies: A Real-World Comparison of Lecanemab and Donanemab

Presenteur : Katelyn Horan

Katelyn Horan¹, Wedgina Norelus¹, Sokratis Charisis^{1,2}, Cinthya Agüero^{1,2}, Yingnan He¹, Sudeshna Das^{1,2}, John Dickson^{1,2}, Teresa Gomez-Isla^{1,2}

¹Massachusetts General Hospital, Boston, United States, ²Harvard Medical School, Boston, United States

P504 Temporal Relationship between pTau-217 and Beta-amyloid 42/40 Blood-based Biomarkers in Real-World Data

Presenteur : David Alfego

Kathleen Bailey¹, David Alfego², Joseph Volpe³

¹Labcorp, Los Angeles, Ca, United States, ²Labcorp, San Diego, Ca, United States, ³Labcorp, Durham, Nc, United States

P505 Digital cognitive assessments in primary care: Outcomes from a real-world implementation study

Presenteur : Kyra O'Brien

Louis McKinnon, Wheeler Maxwell, Stacy Iannone, Kyra O'Brien

University of Pennsylvania Perelman School of Medicine, Philadelphia, United States

P506 Real-world safety with Lecanemab: An initial experience from Singapore

Presenteur : Kim En Lee

Kim En Lee

Lee Kim En Neurology Pte Ltd, Mount Elizabeth Medical Centre, #11-14/15, Singapore, Singapore

P507 Divergent cognitive trajectories in patients with suspected co-pathology receiving lecanemab

Presenteur : Nick Frost

Nick Frost, Bethany Curd, Camilla Zubrick, Christine Cliatt Brown, Michelle Sorweid, Yoshimi Anzai, Satoshi Minoshima

University of Utah, Salt Lake City, United States

P508 Implementation of a Standardized, Digitally Enabled Memory Clinic Pathway Accelerates Diagnosis and Improves Early Alzheimer's Disease and Mild Cognitive Impairment Detection in Community Neurology

Presenteur : Gregory Sahagian

Gregory Sahagian

The Neurology Center of Southern California, Carlsbad, United States

P509 Frequency and Predictors of Non-Progression in Lecanemab-Treated Alzheimer's Disease: A Retrospective Cohort Study

Presenteur : David Weisman

David Weisman

Abington Neurological Associates, Elkins Park, United States

P510 — Remote — Remote Retrospective analysis of aducanumab and lecanemab treatment switches to donanemab in Alzheimer's disease (AD) patients with mild cognitive impairment (MCI) or mild dementia stage of disease[TS1] and presence of amyloid beta pathology

Presenteur : Christen Kutz

Christen Kutz

Rocky Mountain Research and Consulting, Colorado Springs, United States

P512 Optimizing Pre-Screening in Alzheimer's Disease Clinical Trials: Using SLUMS Delayed Memory Index to Minimize Screen Failures and Maximize Inclusion

Presenteur : Susan Nguyen

Susan Nguyen¹, Criselle Penamante¹, Alfreda Wright¹, Marissa Sandoval¹, Myoungin Bae¹, T. Richard Parenteau^{1,2}, Ralph Lee³

¹Irvine Clinical Research - Oakland Clinical, Oakland, United States, ²University of California, San Francisco, Division of Geriatrics, San Francisco, United States, ³Irvine Clinical Research, Irvine, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : **Zhihan Yang**

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : **Fred Kim**

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : **Dishit P. Ghumra**

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : **Amir Meghdadi**

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : **DaeKeun Kim**

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : **Gaurav Malik**

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : **Volker Herrmann**

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : **Shmuel (sam) Agus**

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : **James Galvin**

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : **Zhihan Yang**

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : **Fred Kim**

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : **Dishit P. Ghumra**

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : **Amir Meghdadi**

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : **DaeKeun Kim**

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : **Gaurav Malik**

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : **Volker Herrmann**

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : **Shmuel (sam) Agus**

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : **James Galvin**

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States

P514 Low Cost Plasma pTau217 Detection Using a Droplet Digital ELISA Platform

Presenteur : Zhihan Yang

Zhihan Yang, Qingyang Zhang, Chong Dai
Shenzhen Gate Biotech Co., Ltd., Shenzhen, China

P515 AriBio: Building an Oral Therapeutic Franchise Across Alzheimer's Disease and Related Dementia, with Phase 3 AR1001 and Phase 2 AR1005

Presenteur : Fred Kim

Tianyang Xi¹, Fred Kim¹, Vitella Fomenko¹, James Rock¹, Jai Jun Choung²
¹AriBio Co., Ltd., San Diego, United States, ²AriBio Co., Ltd., Seongnam-Si, Korea, Republic of

P516 Point-of-care Biosensor for Dual p-tau217 and MTBR-tau243 Screening in 30 Minutes: Solving the Trial Enrollment Bottleneck

Presenteur : Dishit P. Ghumra

Dishit P. Ghumra^{1,2}, Joshin Kumar^{1,2}, Spondita Goswami³, Robert C. Elliot¹, Rajan K. Chakrabarty^{1,2}
¹Agilus Neuro, St. Louis, MO, 63015, USA., St. Louis, United States, ²Department of Energy, Environmental, and Chemical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA., St. Louis, United States, ³Bioethics Research Center, Division of General Medicine & Geriatrics, John T. Milliken Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA., St. Louis, United States

P517 From Pathology to Function: Convergent Evidence for a Scalable EEG/ERP Biomarker Platform in Alzheimer's Disease

Presenteur : Amir Meghdadi

Amir Meghdadi, Chris Berka
Advanced Brain Monitoring, Carlsbad, United States

P519 Early Identification and Community-Based Intervention for Cognitive Impairment: Transcranial Photobiomodulation Evidence from Korea and Japan

Presenteur : DaeKeun Kim

Daekeun Kim¹, Morihiro Tsujishita², Seung Wan Kang¹, Jun Yeop Kim¹, Nam Heon Kim¹, Paolo Cassano³
¹MediSync Inc, Seoul, Korea, Republic of, ²Naragaku University, Nara, Japan, ³Harvard Medical School, Boston, United States

P520 IntelliXR: A Clinically Validated XR Oculomotor Platform Extending From Glaucoma Perimetry to Neurodegenerative Disease Biomarker Capture

Presenteur : Gaurav Malik

Gaurav Malik
Citrusbits, Pleasanton, United States

P521 Advancing Brain-Gut Modulation to a Next-Generation Home-Based Therapy for Alzheimer's Disease

Presenteur : Volker Herrmann

Volker Herrmann, Guillaume Blivet
REGENLIFE, Paris, France

P523 A Constrained-Disorder, AI-Guided Variability Regimen for Curcumin in Early-Symptomatic Alzheimer's Disease: A Biomarker-Endpoint Proof-of-Concept

Presenteur : Shmuel (sam) Agus

Shmuel (Sam) Agus¹, Oren Fuerst², Yaron Ilan²
¹Oberon Sciences, Boston, United States, ²Oberon Sciences, Herzliya, Israel

P524 Paving the Path in Digital Health: Cognivue's Adaptive Psychophysics Unlocks a Digital Cognitive Biomarker for Inherent Amyloid Risk and Optimized Two-Stage Screening

Presenteur : James Galvin

James Galvin, Heather Harris
CSO, Cognivue, Boca Raton, United States